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Some other trifling particulars 
might be mentioned, but they are all 
of slight importance and have 
nothing to do with the true relation 
of the history; and no history can be 
bad so long as it is true. 
 










The local administration of drugs into the intra-articular cavity is beneficial for the 
treatment of a number of joints pathologies. Unfortunately, despite this interest, the efficient 
intra-articular delivery of drugs represents a challenge, which is mainly associated to the fast 
drug elimination from the synovial cavity. Therefore, there is a clear need to develop 
advanced controlled release technologies that may overcome this limitation. At the same 
time, the discovery of novel immunotherapeutic targets has prompted the design and 
development of highly specific antagonists for effective therapies. This is the case of the 
extracellular protein galectin-3 (Gal-3), which has been recently identified as a primer trigger 
of the pro-inflammatory cascade in arthritis. The inhibition of Gal-3 could block the whole 
inflammatory cascade, prevent further joints degradation and alleviate the inflammatory joint 
diseases.  
In this work we have developed a novel drug delivery system (DDS) composed of an 
in situ forming hydrogel combined with hyaluronic acid (HA) nanocapsules (NCs). HA NCs 
consisting of an olive oil core surrounded by a HA shell were prepared by the solvent 
displacement technique. The NCs exhibited a particle size of 135 ± 9 nm, a negative surface 
charge and a modest capacity to encapsulate dexamethasone, which was used as a model 
drug. Thereafter, two injectable in situ hydrogels systems composed of HA-fibrin and 
fortified HA-fibrin (with crosslinker factor XIII and α2-antiplasmin) were developed. Both 
gels displayed easily adjustable gelation time and mechanical properties. These NCs-
containing hydrogels showed the capacity to control the release of dexamethasone in 
simulated synovial fluid for up to 72 h. 
On the other hand, an antagonist of Gal-3 was designed, synthesized and 
characterized. It was based on its natural ligand type II lactosamine [Gal(1→4)-GlcN] core, 
modified with aromatic substituents to greatly increase its affinity and specificity. Gal-3 
inhibitor revealed high affinity to Gal-3 (Kd = 0.59 µM at 4 °C) and selectivity among Gal-1/ 
Gal-3/Gal-7. This compound was further encapsulated within HA NCs (531 ± 5 µg/mL), 
dispersed within the in situ HA-fibrin hydrogel and tested in a carrageenan-induced acute 
knee joint synovitis rat model. Both, groups with drug-loaded NCs alone and in the gel, 
administrated intra-articularly at microgram scale doses (200 and 55 μg/kg), showed a 
remarkable suppression of inflammation compared with the non-treated control. These 
findings highlight the potential of Gal-3 inhibitor as a lead compound for the treatment of 
rheumatoid arthritis. In addition, the in vitro and in vivo experiments showed the interest of 














Otras algunas menudencias había 
que advertir, pero todas son de poca 
importancia y que no hacen al caso 
a la verdadera relación de la 
historia, que ninguna es mala como 
sea verdadera. 
 












La administración local de fármacos en la cavidad intra-articular puede ser 
beneficiosa para el tratamiento de ciertas patologías asociadas a las articulaciones. Sin 
embargo, a pesar de su interés, la liberación intra-articular de fármacos eficiente representa 
un desafío, principalmente debido a su rápida eliminación de la cavidad sinovial. Por lo tanto, 
hay una clara necesidad de desarrollar tecnologías de liberación controlada avanzadas que 
puedan superar estas dificultades. Al mismo tiempo, el descubrimiento de nuevas dianas 
inmunoterapéuticas ha suscitado el diseño y desarrollo de antagonistas altamente específicos 
con el fin de obtener terapias efectivas. Este es el caso de la proteína extracelular galectina-3 
(Gal-3), que ha sido identificada recientemente como un iniciador principal de la cascada pro-
inflamatoria en la artritis. La inhibición de Gal-3 podría bloquear toda la cascada 
inflamatoria, prevenir una mayor degradación de la articulación y aliviar las enfermedades 
inflamatorias de las articulaciones.  
En este trabajo hemos desarrollado un sistema de liberación de fármacos compuesto 
por un hidrogel, que se forma in situ, combinado con nanocápsulas (NCs) de ácido 
hialurónico (HA). Las NCs de HA consisten en un núcleo oleoso de aceite de oliva rodeado 
por una cubierta de HA y fueron preparadas por el método de desplazamiento de disolvente. 
Las NCs presentan un tamaño de 135 ± 9 nm, una carga superficial negativa y una capacidad 
modesta de encapsular dexametasona, usada en este estudio como fármaco modelo. 
Posteriormente, se desarrollaron dos sistemas tipo hidrogel formados por HA-fibrina y HA-
fibrina reforzado (con el entrecruzante factor XIII y α2-antiplasmina). Ambos geles muestran 
tiempos de gelificación y propiedades mecánicas fácilmente modulables. Los hidrogeles 
cargados de NCs permitieron la liberación controlada de dexametasona en fluido sinovial 
simulado durante 72 h. 
Por otro lado, se ha diseñado, sintetizado y caracterizado un antagonista de la Gal-3. 
Dicho antagonista se basa en su ligando natural, con un núcleo tipo II de lactosamina 
[Gal(1→4)-GlcN], modificado con sustituyentes aromáticos para incrementar en mayor 
medida su afinidad y especificidad. El inhibidor de Gal-3 mostró elevada afinidad por la Gal-
3 (Kd = 0.59 µM a 4 °C) y selectividad entre Gal-1/Gal-3/Gal-7. Posteriormente, este 
compuesto fue encapsulado en NCs de HA (531 ± 5 µg/mL), que a su vez fueron dispersadas 
en un hidrogel de HA-fibrina y el conjunto evaluado en ratas, en un modelo de sinovitis 
aguda de rodilla inducida por carragenano. Tanto el grupo tratado con las NCs cargadas de 






articularmente (200 and 55 μg/kg), dieron lugar a una reducción destacable de la inflamación, 
comparados con el grupo control no tratado. Estos resultados muestran el interés del  
inhibidor de Gal-3 como un compuesto lider a candidato a fármaco con potencial indicación 
en el tratamiento de la artritis reumatoide. Al mismo tiempo, los experimentos in vitro e in 
vivo muestran el potencial de las nanocapsulas dispersas en el gel como sistema de liberación 
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Nuevas terapias basadas en la 
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En general, las cavidades de las articulaciones diartrodiales son adecuadas para la 
inyección intraarticular (IA) de fármacos. Por ello, en las últimas décadas, esta modalidad de 
administración ha sido aceptada como una vía directa que puede mejorar la eficacia de los 
tratamientos de las enfermedades articulares.
1–4
 Los beneficios de la administración IA sobre 
la oral o intravenosa se reflejan en un aumento de la eficacia y en una reducción de la 
toxicidad del fármaco asociada a la exposición sistémica. Los principales fármacos 
actualmente disponibles en el mercado para el tratamiento de las artropatías y la mejora de la 
homeostasis de la rodilla son antagonistas de COX-2, TNF-α, IL-1 y IL-6, administrados de 
forma sistémica. Las principales limitaciones de estos fármacos son la falta de especificidad y 
la aparición de considerables efectos secundarios,
2,5–7
 haciendo de la administración IA una 
alternativa atractiva. 
Los avances en el área de biofarmacia durante las últimas décadas han permitido el 
desarrollo de sistemas de liberación controlada de fármacos, que disminuyen la toxicidad 
sistémica de los mismos y ofrecen un mayor tiempo de permanencia en el lugar de acción, 
con una liberación controlada y prolongada del fármaco directamente en el lugar requerido.
2,4
 
Sin embargo, la administración IA de fármacos sigue siendo un reto, principalmente debido a 
la eliminación prematura del fármaco de la cavidad sinovial junto con la rápida renovación 
del líquido sinovial, la internalización celular y la invasividad de la ruta.
2
 
Se han desarrollado distintos tipos de sistemas de liberación controlada de fármacos 
para el tratamiento local de artropatías, con énfasis en nano-/microsistemas e hidrogeles,
2,4,6,8
 
siendo las formulaciones más prometedoras y avanzadas una combinación de ambos 
sistemas.
9–14
 Dichos sistemas permiten una retención suficiente y una liberación prolongada 
de fármacos de bajo peso molecular (PM), cuyo tiempo de permanencia en las articulaciones 
es normalmente corto cuando se administran en disoluciones.
2,15
  
El cartílago articular tiene una capacidad limitada para su auto-regeneración.
16–18
 
Además, el líquido sinovial pierde en gran medida sus funciones intrínsecas en las patologías 
articulares.
19
 Teniendo esto en cuenta, los vehículos de administración de fármacos 
multifuncionales deben diseñarse para contribuir a la curación de la diartrosis. En este 
sentido, pueden no sólo permitir una liberación del fármaco controlada y prolongada, sino 
que también pueden estar compuestos de materiales resistentes a la deformación para 
permanecer en la cavidad articular y evitar una descomposición enzimática rápida. 





Simultáneamente, los sistemas de liberación controlada pueden tener una papel de 
viscosuplementación, para mejorar la homeostasis de la rodilla, y servir de andamiajes 
celulares  in situ para la regeneración del tejido del cartílago. 
 Al mismo tiempo, el descubrimiento de nuevas dianas terapéuticas ha suscitado 
grandes esfuerzos dirigidos hacia el diseño y desarrollo de pequeñas moléculas antagonistas 
altamente específicas para conseguir terapias eficaces (en particular para diferentes tipos de 
cáncer, enfermedades autoinmunes, diabetes, etcétera).
20–23
 Este es el caso de la proteína 
extracelular galectina-3 (Gal-3), que  ha sido recientemente identificada como 
desencadenante de la inflamación.
24,25
 Además, esta proteína favorece la secreción de 
citocinas pro-inflamatorias, quimiocinas
24
 y metaloproteinasas de la matriz extracelular,
26
 que 





2. Hipótesis  
 
1. El uso de nanocápsulas (NCs) cargadas con fármacos dispersas en hidrogeles puede 
aumentar sustancialmente el tiempo de retención intra-articular de dichos fármacos. 
Las NCs pueden actuar como reservorios de fármacos lipófilos, permitiendo su 
liberación controlada, mientras que el hidrogel formado in situ podría proteger a las 
NCs de una rápida descomposición, endocitosis y eliminación de la cavidad sinovial, 
modulando también la liberación del fármaco. Dicha formulación inyectable de NCs 
combinadas con un hidrogel también podría contribuir a la homeostasis de la rodilla, 
debido al núcleo de aceite de oliva de las NCs y al recubrimiento de ácido hialurónico 
(HA) de 700 kDa, ambos con propiedades antiinflamatorias.
28–31
 Además, el hidrogel 
3D de fibrina fortalecida con ácido hialurónico podría actuar como viscosuplemento, 
con propiedades elásticas adecuadas para su permanencia en la cavidad articular y 




2. Dado que el bloqueo tradicional de COX-2 y las citocinas pro-inflamatorias TNF-α,  
IL-1 e IL-6, ha demostrado una efectividad limitada en las enfermedades 
inflamatorias de las articulaciones,
2,4,35–37
 planteamos la hipótesis de que la inhibición 
de la diana galectina-3, podría bloquear toda la cascada inflamatoria y evitar la 
posterior degradación de las articulaciones.  







Basándonos en los antecedentes bibliográficos y en las hipótesis anteriormente 
expuestas, el objetivo de esta tesis ha sido doble, por un lado, el de desarrollar un nuevo 
hidrogel que se forma in situ tras la inyección y que posee nano-reservorios que permiten  la 
liberación prolongada de fármacos en la cavidad intraarticular; por otro lado, un objetivo 
adicional ha sido el de sintetizar un nuevo antagonista de la galactina-3 y su incorporación en 
el hidrogel antes mencionado para una evaluación in vivo. 
 
Con este propósito, los objetivos generales se dividen en los siguientes objetivos 
específicos: 
 
1) Desarrollo y evaluación in vitro de un nuevo sistema de liberación de fármacos 
destinado a la administración intra-articular  
En el desarrollo de este objetivo se han cubierto las siguientes fases de trabajo: 
1. Formulación de NCs de ácido hialurónico, cargadas con dexametasona (fármaco 
modelo), y posterior caracterización con respecto a sus propiedades fisicoquímicas, 
estabilidad en líquido sinovial simulado y estabilidad en almacenamiento. 
2. Diseño y desarrollo de un hidrogel destinado a gelificar in situ tras la administración 
intraarticular, y estudio de la influencia de los parámetros que pueden modificar su 
tiempo de gelificación, propiedades mecánicas y evaluar su capacidad de ser 
inyectado. 
3. Estudio de la formación del hidrogel en presencia de las NCs, análisis de su capacidad 
de carga y de la modificación de las propiedades reológicas del hidrogel en presencia 
de las NCs. Caracterización del comportamiento reológico tanto de los hidrogeles 
blancos como de los cargados con NCs, su estructura superficial y porosidad. 
4. Optimización y caracterización de dos hidrogeles cargados con NCs, que difieren en 
el grado de entrecruzamiento de la red del hidrogel, diseñados para tratar la 
inflamación aguda y crónica de las articulaciones usando modelos in vivo de rata. 
5. Evaluación del perfil de liberación in vitro de la dexametasona a partir del gel cargado 
con NCs. 





Los resultados correspondientes a estos objetivos se presentan en el Capítulo 1: 
“An injectable, in situ forming hydrogel containing nanocapsules for intra-articular 
drug delivery”. 
 
2) Síntesis de un nuevo compuesto anti-inflamatorio, incorporación en el sistema 
de liberación de fármacos desarrollado y evaluación de su actividad in vivo  
En el desarrollo de este objetivo se han cubierto las siguientes fases de trabajo: 
6. Diseño y síntesis un nuevo candidato a fármaco antiinflamatorio – un antagonista de 
la galectina-3 extracelular (Gal-3), usando como núcleo su ligando natural, la 
lactosamina de tipo II [Gal(1→4)-GlcN], modificado con sustituyentes aromáticos 
para aumentar en mayor medida su afinidad y especificidad. 
7. Caracterización del inhibidor de Gal-3 obtenido, a través de la valoración de su 
afinidad y selectividad entre Gal-1/Gal-3/Gal-7, comparación con el primer inhibidor 
de bajo peso molecular de la Gal-3 comercializado (TD139) y selección del inhibidor 
sintético más potente para su posterior evaluación in vivo. 
8. Incorporación del  inhibidor de Gal-3 en las NCs cargadas en el hidrogel, posterior 
caracterización de sus propiedades fisicoquímicas y evaluación de su actividad 
antiinflamatoria in vivo en un modelo en rata con sinovitis aguda de rodilla inducida 
por carragenano. 
 
Los resultados relacionados con este trabajo se presentan en el Capítulo 2: 
“New galectin-3 inhibitor as a lead compound for anti-inflammatory drug 
candidates”. 
 





4. Resultados y discusión 
 
1. Gal-3i como compuesto líder candidato a fármaco en el tratamiento de la artritis 
reumatoide 
Teniendo en cuenta su participación en la fisiopatología de la artritis reumatoide, la 
galectina-3 (Gal-3) se presenta como una nueva diana inmunoterapéutica,
24,27,38–40
 cuyo 
bloqueo podría prevenir toda la cascada inflamatoria y la posterior degradación de las 
articulaciones. Con este objetivo, se han diseñado, sintetizado y caracterizado antagonistas de 
bajo peso molecular de la Gal-3 extracelular. Los compuestos se basaron en el núcleo que 
posee el ligando natural de Gal-3: una lactosamina tipo II [Gal(1→4)-GlcN], modificado 
con sustituyentes aromáticos para aumentar de manera considerable su afinidad y 
especificidad. Sus estructuras, denominadas oxazolina y Gal-3i, se comparan en la Figura 1 
con otros inhibidores de la Gal-3 que han sido evaluados en ensayos clínicos para el 
tratamiento de diferentes patologías.
41–48
 
Gal-3i, oxazolina y TD139 (el primer antagonista de Gal-3 de bajo PM aprobado por 
la FDA), testados en un ensayo de polarización de fluorescencia directo y competitivo, 
revelaron selectividad entre Gal-1/Gal-3/Gal-7. Gal-3i demostró una afinidad 7,5 veces 
mayor a la Gal-3 (Kd = 0,59 μM a 4 °C y 2,99 μM a 25 °C) que la oxazolina (Kd = 4,4 μM a 
4 °C y 23 μM a 25 °C) y se seleccionó para su evaluación in vivo. 
 
 
Figura 1. Estructuras de dos inhibidores comerciales de Gal-3: GM-CT-01 (DAVANAT®) y 
TD139; junto a la oxazolina y el Gal-3i sintetizados en este trabajo. 





2. Desarrollo y caracterización de un sistema de liberación de controlada de fármacos 
para la aplicación intraarticular 
Para evitar los dos principales desafíos que afrontan los sistemas de administración IA 
de fármacos, la internalización celular y la rápida eliminación de la cavidad sinovial,
2,15
 se 
desarrolló un sistema compuesto de NCs dispersadas en un hidrogel formado in situ (Figura 
2). 
 
Figura 2. Ilustración esquemática de la estructura de una articulación sinovial y la inyección 
intraarticular de un hidrogel formado in situ combinado con nanocápsulas cargadas con un 
fármaco lipofílico. Adaptada y modificada con el permiso,
15
 Copyright© 2009, Taylor & 
Francis. 
 
Las NCs, preparadas mediante la técnica de desplazamiento de disolvente, están 
compuestas de aceite de oliva (OO), tensioactivos biodegradables y biocompatibles: lecitina 
de soja (Lec) y oleilamina (OAm) y, finalmente, HA de 700 kDa como polímero de cubierta. 
Nuestro objetivo era desarrollar NCs con un tamaño de ~130 nm, que no se espera que causen 
daño en el cartílago u otros daños mecánicos en la articulación
11
 y que permitan encapsular la 
cantidad suficiente de fármacos lipofílicos (un fármaco modelo – dexametasona [DXM] y el 
nuevo compuesto Gal-3i). En la Tabla 1 se resumen el tamaño de partícula, el potencial zeta y 
la eficacia de encapsulación de las formulaciones. 
Las NCs fueron estables en condiciones de almacenamiento a 4 °C durante un período 
de al menos 1 mes. Sin embargo, la estabilidad de las NCs se vio comprometida tanto en PBS 
como en líquido sinovial simulado. Por lo tanto, desarrollamos un hidrogel inyectable, 
formado en presencia de NCs, para mejorar su estabilidad y aumentar su retención en la 





cavidad articular (evitando la internalización celular y su rápida eliminación de la 
articulación). Al mismo tiempo, el hidrogel permitiría la liberación prolongada del fármaco. 
Para la preparación del gel se seleccionaron los biopolímeros HA y fibrina que 
forman una red 3D interpenetrante (IPN),
33,49–52
 debido a la afinidad del HA de alto PM por la 
fibrina.
32,53
 La formación del hidrogel se basa en la activación enzimática del fibrinógeno por 
la trombina (Thr), y permite diseñar por etapas una IPN en presencia de HA de diferentes 
PM, de agentes entrecruzantes de fibrina (el factor XIII y la α2-antiplasmina) y de NCs 
cargadas con el fármaco.  
 
Tabla 1. Propiedades fisicoquímicas de las NCs de HA de 700 kDa blancas y cargadas con 
fármaco (media ± SD, n = 6). OO = aceite de oliva, Lec = lecitina de soja, OAm = 
oleilamina, PDI = índice de polidispersión 
 




















s prototipo 1 15 3,75 0,75 128 ± 13 0,2 −27 ± 3 n/a 





















 prototipo 1 15 3,75 0,75 160 ± 12 0,2 −20 ± 4 0,75 ± 0,13 







 prototipo 2 22 5,625 1,125 122 ± 11 0,2 −29 ± 5 0,53 ± 0,05 
 
La formación de los geles se monitorizó mediante análisis de turbidez (λ = 350 nm) y 
estudios reológicos que permitieron identificar la fase de retardo, el punto de gelificación 
(Figura 3) y la evolución del gel en el tiempo. 
 







Figura 3. Resumen de la determinación del punto de gelificación mediante reología en los 
diferentes sistemas: geles blancos de "HA-fibrina" y de "HA-fibrina fortalecido" y estos geles 
con NCs al 30%. La línea de trazos y puntos refleja la fase de retardo requerida de 2 minutos. 
Las mediciones se llevaron a cabo a 37 ºC. Expresado como media ± SD; n = 3. 
 
La modificación de la concentración de distintos compuestos, como la Thr, HAs, 
NCs, Ca
2+
, factor XIII y α2-antiplasmina han permitido una modificación controlada de la 
microarquitectura del gel y de su tiempo de gelificación, obteniendo un tiempo de retardo de 
la gelificación adecuado para los estudios in vivo. Los geles permitieron albergar un 30% 
(v/v) de NCs en su estructura durante su autoensamblaje, con una distribución homogénea 
dentro del gel y con poros bien definidos (7,29 ± 1,23 μm y 4,88 ± 1,12 μm, respectivamente 
para los geles de HA-fibrina y HA-fibrina reforzado con 30% (v/v) de NCs). Los valores 
iniciales de viscosidad de la mezcla física HA-fibrina (sin adición la Thr) fueron 118,9 mPa·s 
y 81,3 mPa·s a 20 °C y 37 °C, respectivamente, significativamente más bajos que los 
viscosuplementos comerciales,
54,55
 por lo que se puede anticipar una fácil inyección, previa a 
la formación in situ del hidrogel, en los estudios in vivo. El hidrogel formado presentó 
características reológicas tanto de material elástico como de tipo sólido, adecuado para 
sostener las deformaciones intra-articulares. En resumen, hemos desarrollado dos sistemas de 
liberación controlada: "un gel de HA-fibrina con 30% de NCs" y "un gel reforzado de HA-
fibrina con 30% de NCs" (Figura 3), que podrían ser adecuados para tratar inflamaciones 
articulares agudas y crónicas, respectivamente. 





El perfil de liberación in vitro de la dexametasona desde el gel de HA-fibrina con 
30% de NCs se prolongó hasta 72 h en fluido sinovial simulado, lo que podría ser altamente 
ventajoso para la administración intraarticular del fármaco (Figura 4). 
 
 
Figura 4. Liberación de dexametasona (DXM) desde el hidrogel  de ácido hialurónico-fibrina 
con 30% de NCs en líquido sinovial simulado, 37 ºC, 72 h. 
 
3. Actividad antiinflamatoria in vivo del inhibidor de Gal-3  
Para evaluar la actividad biológica del Gal-3i, se empleó un modelo de inflamación 
aguda inducida por carragenano en ratas,
56




Los animales con sinovitis inducida se distribuyeron en tres grupos de acuerdo con el 
tratamiento recibido (100 μL, IA): NCs blancas utilizadas como vehículo control (grupo 1), 
NCs cargadas con Gal-3i a una dosis de 200 μg/kg (grupo 2) y NCs cargadas con Gal-3i 
dispersadas (30% v/v) en el gel de HA-fibrina reforzado a una dosis de 55 μg/kg (grupo 3). 
La actividad del fármaco se controló a las 4 horas después de la inducción de la sinovitis, 
cuando se observa el pico de la inflamación.
56
 Los datos de las mediciones de la hinchazón de 
la rodilla, los análisis de sangre, el análisis histopatológico y la cuantificación de los 
marcadores pro-inflamatorios del plasma sanguíneo, demostraron una actividad anti-
inflamatoria pronunciada del Gal-3i y la mejora del estado de las articulaciones. Los datos de 
hinchazón de la rodilla (Figura 5) mostraron una reducción del diámetro de la rodilla en: 1,6 










Figura 5. Efecto del tratamiento con el inhibidor de Gal-3 en el modelo de inflamación de la 
articulación inducido por carragenano usando las NCs y las NCs en gel comparado con NCs 
blancas y el control de carragenano (n = 5 para los grupos 1-3, n = 1 para el control de 
carragenano). Δ es la diferencia en el diámetro de la rodilla en diferentes momentos antes y 
después de la inyección de carragenano, expresada en mm. Datos expresados como media ± 
SEM. 
 
Este hallazgo resulta más notable si se considera que la dosis del grupo 3 (NCs 
cargadas con Gal-3i en el gel a una dosis de 55 μg/kg), es considerablemente más baja que en 
el grupo 2 (NCs cargadas con Gal-3i a una dosis de 200 µg/kg). Posiblemente, el hidrogel de 
HA-Fibrina mantiene de manera efectiva las NCs dentro de la cavidad articular, modula la 
liberación y, por sí mismo, tiene un efecto beneficioso en la curación de las articulaciones, 
incluso en el modelo de inflamación aguda en ratas. 
Los resultados obtenidos en este ensayo preliminar in vivo demostraron una notable 
supresión de la inflamación debida al Gal-3i encapsulado en el hidrogel y administrado de 
manera intraarticular en dosis de microgramos. Los resultados presentan al Gal-3i como un 
compuesto líder candidato a fármaco inmunoterapéutico para las enfermedades de la rodilla, 
en particular para la artritis reumatoide. Es de destacar, que el hidrogel con NCs sin fármaco 
también demostró una tendencia a contribuir a la curación de las articulaciones y a reducir la 
inflamación sinovial, gracias, probablemente, al núcleo de aceite de oliva y al ácido 
hialurónico presente en su composición.
28,29,58
 Al mismo tiempo, el hidrogel de ácido 
hialurónico-fibrina podría, potencialmente, funcionar como un viscosuplemento, con 





propiedades elásticas adecuadas para la permanencia intra-articular y como una estructura 




El objetivo de esta tesis ha sido el diseño y desarrollo de un nuevo sistema inyectable 
destinado a prolongar el tiempo de residencia intraarticular y lograr una liberación controlada 
de fármacos. El sistema consiste en un hidrogel con nanocápsulas dispersas en él, sirviendo 
como multireservorio para diferentes fármacos antiinflamatorios y lipófilos, tales como i) la 
dexametasona, empleada en este estudio como fármaco modelo y ii) un nuevo candidato a 
fármaco – un antagonista de la galectina-3 (Gal-3). Los resultados experimentales obtenidos 
condujeron a las siguientes conclusiones: 
 
1) En este estudio, se desarrolló y sintetizó un nuevo inhibidor monovalente altamente 
afín, potente y selectivo de la Gal-3, formado por dos restos diferentes ensamblados a un 
núcleo de lactosamina modificado. Su Kd hacia la Gal-3, medido en un ensayo de 
polarización de fluorescencia directo y competitivo, fue de 0,59 μM a 4 °C (2,99 μM a 
25 °C), mientras que el inhibidor de Gal-3 marcado con fluoresceína mostró una afinidad 
muy alta hacia la Gal-3, Kd = 14 nM a 4 °C (82 nM a 25 °C), ciertamente más alta que la del 
inhibidor comercial de Gal-3 DAVANAT®. Una característica importante de este compuesto 
es la capacidad de discriminar entre Gal-1/Gal-3/Gal-7, mientras que DAVANAT® 
difícilmente discrimina entre Gal-1 y Gal-3. Por otro lado, se ha confirmado 
experimentalmente que un primer antagonista de Gal-3 de bajo PM TD139, aprobado por la 
FDA, con el núcleo de tio-digalactósido modificado, medido en el mismo ensayo, tiene una 
alta afinidad, con una Kd (Gal-3) = 0,036 μM a 4 °C (0,166 μM a 25 °C) y alta selectividad 
entre Gal-1/Gal-3/Gal-7. Teniendo en cuenta los datos de Kd prometedores del compuesto 
que hemos desarrollado y sintetizado, consideramos interesante estudiar in vivo la eficacia de 
este inhibidor de la Gal-3 de bajo PM. 
 
2) Se prepararon exitosamente nuevas nanocápsulas (NCs) con núcleo de aceite de 
oliva y recubrimiento de ácido hialurónico, utilizando para ello el método de desplazamiento 
de disolvente. Estas NCs tienen la capacidad de encapsular dexametasona (5,6 ± 0,4 mg/mL) 





y el inhibidor de Gal-3 (531 ± 5 μg/mL), tamaño nanométrico (135 ± 9 nm y 122 ± 11 nm, 
correspondientemente), carga superficial negativa y forma esférica regular. 
 
3) Se han desarrollado dos sistemas inyectables basados en hidrogeles de ácido 
hialurónico y fibrina, así como ácido hialurónico-fibrina reticulado con el factor XIII y la α2-
antiplasmina. Los hidrogeles mostraron un tiempo de gelificación, microestructura y 
propiedades mecánicas fácilmente ajustables. Además, los geles permitieron un 30% (v/v) de 
carga de las NCs durante su formación. La viscosidad inicial del sistema fue 
significativamente más baja en comparación con los viscosuplementos comerciales, lo que 
permitió una buena inyección a través de jeringa. Las propiedades reológicas de los 
hidrogeles ensamblados revelaron resistencia a altas deformaciones, presentando 
características de materiales tanto de tipo elástico como sólido, y adecuados para preservar 
las deformaciones intra-articulares. Con respecto a su estructura, la formulación presenta 
poros bien definidos, con NCs dispersas homogéneamente dentro del gel. Este sistema de 
administración de fármacos intra-articular permitió un perfil de liberación del fármaco in 
vitro controlado y prolongado, evitando la descomposición rápida de las NCs en fluido 
sinovial simulado. 
 
4) Se ha llevado a cabo un estudio preliminar in vivo, en modelo de ratas con sinovitis 
aguda en la articulación de la rodilla inducida por carragenano. En estos estudios el inhibidor 
de Gal-3 demostró una notable supresión de la inflamación. Tanto el grupo tratado con NCs 
cargadas con el fármaco, como el grupo tratado con las NCs cargadas con el fármaco 
dispersadas en el gel, se administraron a dosis de microgramos (55 and 200 μg/kg), y 
brindaron mejores resultados en comparación con el grupo control no tratado. Estos 
resultados confirman al inhibidor de Gal-3 como un compuesto líder candidato a fármaco 
inmunoterapéutico para condiciones inflamatorias de la rodilla, en particular para la artritis 
reumatoide. Es de destacar, que los hidrogeles sin fármaco también mostraron una tendencia 
a contribuir a la curación de las articulaciones y a reducir la inflamación sinovial. 
 
En términos generales, el trabajo aquí presentado describe el desarrollo y 
caracterización de un nuevo sistema biodegradable de liberación de fármacos formado por un 
hidrogel inyectable en la cavidad articular y que se forma in situ. El hidrogel sirve como un 
depósito para las NCs cargadas con el fármaco, impidiendo su dispersión, internalización 





celular y rápida eliminación de la cavidad de la articulación, pudiendo liberar el fármaco de 
forma prolongada en el tiempo. Las propiedades reológicas del sistema inicial permitieron 
una buena jeringabilidad y unas características mecánicas deseables para la aplicación 
intraarticular. La actividad preliminar in vivo del inhibidor de la galectina-3 confirmó a la 
galectina-3 como una diana inmunoterapéutica potencial para las enfermedades inflamatorias 
de las articulaciones, tales como la artritis reumatoide. 
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De nouvelles thérapies basées sur les 





La seule chose qui compte, 
c'est l’effort. 
 
Le Petit Prince,  











La plupart des articulations, en raison de leurs caractéristiques anatomiques, se prêtent 
aux injections intra-articulaires (IA). Ces dernières années, il a été démontré que 
l'administration locale de médicaments avec un mode d'action direct pouvait grandement 
améliorer l'efficacité des traitements des maladies articulaires.
1–4
 Les avantages de 
l'administration intra-articulaire comparée aux voies orales ou intraveineuses sont les 
suivantes : (i) biodisponibilité accrue, (ii) réduction de la toxicité du médicament, (iii) 
l’obtention d'une concentration efficace avec une dose minimale de médicament, (iv) 
réduction de l'exposition systémique et des effets indésirables associés, (v) diminution de 
l’apparition de résistance, et (vi) réduction du coût total des médicaments. Les principaux 
médicaments utilisés pour le traitement des arthropathies et l’amélioration de l’hémostase du 
genou qui sont actuellement disponibles sur le marché sont la cyclooxygénase-2 (COX-2), les 
antagonistes des TNF-α, IL-1 et IL-6. Les principales limites de ces médicaments sont le 
manque de spécificité pour les articulations et l'apparition d'effets secondaires 
considérables
2,5–7
 désignant l'administration IA comme une alternative intéressante. 
Les progrès dans le domaine biopharmaceutique au cours des dernières décennies ont 
permis le développement de systèmes de délivrance des médicaments (SDMs) les rendant 
moins toxiques tout en offrant une  libération contrôlée et prolongée des drogues  directement 
au site d’action.
2,4
 Cependant, l'administration de médicaments IA dans l’articulation reste 
complexe, principalement en raison d'efflux rapide dans la cavité synoviale allié à la rotation 




Différents SDMs ont été testés pour le traitement local des arthropathies à partir de 
nano-/microparticules et d’hydrogels.
2,4,6,8
  Les formulations les plus prometteuses et 
avancées portent sur une combinaison des deux systèmes.
9–14
 Ces SDMs permettent une 
rétention suffisante et la libération prolongée de médicaments de faible masse moléculaire 
(MM), connus pour avoir un temps de séjour court dans les articulations
2,15
 lorsqu’ils sont 
administrés en solution IA. 
Le cartilage articulaire a une capacité limitée pour l'auto-régénération.
16–18
 En outre, 
le FS a largement perdu ses fonctions intrinsèques dans des conditions pathologiques des 
articulations.
19
 Avec cela à l'esprit, le recours à des transporteurs de médicaments 
multifonctionnels devrait contribuer à la guérison des pathologies diartrosiques. Outre la 





libération contrôlée et prolongée de médicament, ces systèmes composés de matériaux 
résistants à la déformation peuvent contribuer au maintien de la rotule et à la lutte contre les 
dégradations enzymatiques. Simultanément, les  SDMs pourraient fonctionner comme agents 
de viscosupplémentation pour améliorer l'homéostase du genou et, comme échafaudages 
cellulaires pour la régénération in situ du tissu cartilagineux. 
En même temps, la découverte de nouvelles cibles immunitaires a conduit à  
d’intenses efforts pour la conception et le développement de petites molécules antagonistes 
pour des thérapies efficaces (en particulier pour les différents types de cancer, les maladies 
auto-immunes, le diabète…).
20–23
 Tel est le cas de la protéine galectine-3  
(Gal-3), qui a récemment été identifié comme favorisant l’apparition de la réponse 
inflammatoire.
24,25
 Entre autre, cette protéine favorise la sécrétion de cytokines pro-
inflammatoires, chimiokines par les macrophages,
24
 et l’expression de métalloprotéinases de 
la matrice,
26







1. L’utilisation de nanocapsules (NCs) chargées avec des médicaments dans des 
hydrogels dispersés in situ peut sensiblement augmenter le temps de rétention intra-
articulaire des drogues. Les NCs peuvent agir comme réservoirs pour de multiples 
drogues lipophiles, et permettre leur libération contrôlée, tandis que l'hydrogel in situ 
pourrait protéger les NCs d’une décomposition rapide, l'endocytose et l'efflux de la 
cavité synoviale tout en contribuant également à moduler la libération des drogues. 
De telles compositions  injectables pourraient aussi contribuer à l’hémostase du genou 
si un noyau d'huile d'olive et un revêtement d'acide hyaluronique (HA) 700 kDa, 
connus pour posséder des propriétés anti-inflammatoires, sont utilisés.
28–31
 Nous 
avons aussi imaginé qu’un l'hydrogel de fibrine en 3D renforcé avec de l'acide 
hyaluronique devrait servir de viscosupplément (chaînes réticulées de HA) avec des 




2. Etant donné que le blocage traditionnel de la COX-2 et les cytokines pro-
inflammatoires TNF-α, IL-1 et IL-6 n'a pas conduit à un soulagement adéquat des 
maladies articulaires inflammatoires,
2,4,35–37
 nous avons émis l'hypothèse que le 





ciblage d’une nouvelle cible, la galectine-3, pourrait aider à bloquer toute la cascade 





Sur la base des hypothèses décrites, l'objectif de cette thèse était double, d'une part, de 
développer un nouvel d'hydrogel avec des nano réservoirs injectables pour la libération 
prolongée de médicaments lipophiles dans la cavité intra-articulaire; d'autre part, la synthèse 
d'un nouvel antagoniste de la galectine-3 et son incorporation dans l'hydrogel mentionné ci-
dessus pour l'évaluation in vivo. 
 
La démarche adoptée pour atteindre les objectifs finaux a été décomposée comme 
suit : 
 
1) Développement et validation de SDMs injectables 
 
1. Formuler, optimiser et caractériser de nouveaux NCs, vides ou chargés avec de la 
dexaméthasone (en tant que médicament modèle), en termes de propriétés physico-
chimiques, de stabilité dans un liquide synovial reconstitué et de stabilité au stockage. 
2. Concevoir et développer un nouvel hydrogel injectable intra-articulaire et étudier 
l'influence des paramètres qui peuvent modifier leur temps de gélification, les 
propriétés mécaniques et évaluer leur seringabilité. 
3. La formation d'hydrogel en présence de NCs, la capacité de charge et la modification 
de ses propriétés rhéologiques. Caractériser le comportement rhéologique des 
hydrogels formulés en résence ou en absence de NCs, en termes de surface et de 
tailles. 
4. Optimiser et caractériser deux hydrogels in situ formulés avec des NCs destinés à 
étudier leur effet dans un modèle d'inflammation aiguë chez le rat induit par le 
carraghénane. 
5. Test le profil de libération in vitro de dexaméthasone du gel in situ formulé avec les 
NCs.  
 





Les résultats correspondant à ces tâches sont présentés au Chapitre 1: 
“An injectable, in situ forming hydrogel containing nanocapsules for intra-articular 
drug delivery”. 
 
2) Synthèse du médicament anti-inflammatoire, l'incorporation dans le SDM 
développé et évaluation de l'activité in vivo 
 
6. Concevoir et synthétiser un nouveau « lead » pour le traitement de l’inflammation – 
une petite molécule inhibitrice de la forme extracellulaire de la galectine-3 (Gal-3), 
dérivée de la lactosamine de type II [Gal(1→4)-GlcN], motif naturel reconnu par 
cette lectine, décorée avec des substituants aromatiques en vue d’augmenter son 
affinité et sa spécificité. 
7. Caractériser l’inhibiteur Gal-3 obtenu, vérifier son affinité et sa sélectivité vis-à-vis 
d’un panel de galectines, en comparaison avec une petite molécule inhibitrice dérivée 
de sucre connue, le bis-3-[(3-fluorophényl)triazolyl] thiodigalactoside (souvent 
désigné TD139) qui vient d’être favorablement évalué en étude clinique de phase II 
pour le traitement de la fibrose pulmonaire. 
8. Ajouter l'inhibiteur Gal-3 dans le SDM développé, caractériser les propriétés physico-
chimiques de la formulation obtenue et tester l'activité anti-inflammatoire de cet 
inhibiteur in vivo dans un modèle de synovite aigüe de l’articulation du genou induite 
par la carraghénane chez de rat. 
 
Les résultats liés à ce travail sont présentés au Chapitre 2: 
“New galectin-3 inhibitor as a lead compound for anti-inflammatory drug 
candidates.” 
4. Résultats et discussion 
 
1. Gal-3i en tant que composé principal pour de nouveaux médicaments candidats 
pour le traitement de l'arthrite rhumatoïde 
Compte tenu de son implication dans la physiopathologie de l'arthrite rhumatoïde, la 
galectine-3 (Gal-3) apparaît comme une nouvelle cible potentielle 
immunothérapeutique,
24,27,38–40
 dont le blocage peut empêcher/éviter la cascade 
inflammatoire et la dégradation des articulations qui l’accompagne. Nous avons donc conçu 





et réalisé la synthèse de petites molécules antagonistes de la galectine-3. Les composés ont 
été obtenus à partir d’un ligand naturel de la Gal-3, la lactosamine de type II [Gal(1→4)-
GlcN], modifié avec des substituants aromatiques. Leurs structures présentées dans la 
Figure 1, appelées oxazoline et Gal-3i, par rapport à d'autres inhibiteurs de Gal-3 sont 




Gal-3i, oxazoline et TD139 (un premier antagoniste Gal-3 de faible poids moléculaire 
approuvé par la FDA), testé dans des essais de polarisation de fluorescence compétitive ont 
révélé une sélectivité entre Gal-1/Gal-3/Gal-7. Gal-3i a montré une affinité 7,5 fois plus 
grande pour Gal-3 (Kd = 0,59 μM à 4 °C et 2,99 μM à 25 °C) que l'oxazoline (Kd = 4,4 μM à 
4 °C et 23 μM à 25 °C) et a été sélectionné en tant que composé principal pour évaluer 
l'inhibition de Gal-3 in vivo. 
 
 
Figure 1. Les structures des deux inhibiteurs commerciaux Gal-3 : GM-CT-01 
(DAVANAT®) TD139, oxazoline et Gal-3i synthétisé. 
 
2. Développement et caractérisation d’une application SDM intra-articulaire 
Afin de contourner deux des principaux écueils auxquels les systèmes délivrance de 
médicament IA doivent faire face, l'internalisation cellulaire et l'élimination rapide de la 
cavité synoviale,
2,15
 nous avons développé un SDM composé de NCs dispersées dans un 
hydrogel in situ (Figure 2). 






Figure 2. Représentation schématique de la structure d'une articulation synoviale et de 
l’injection intra-articulaire d’un hydrogel formé in situ, combiné à des nanocapsules chargées 
d'un médicament lipophile. Adapté et modifié avec l'autorisation de 
15
, Copyright© 2009, 
Taylor & Francis. 
 
Les NCs reportés dans ce travail de thèse ont été préparées par une technique de 
déplacement de solvant et sont composées d'huile d'olive (OO), d’agents tensio-actifs 
biodégradables et biocompatibles - lécithine de soja (Lec) et oléylamine (OAm) et, 
finalement, d’acide hyaluronique (HA 700 kDa) en tant que polymère d'enveloppe. Nous 
avons développé des NCs ayant une taille d'environ ~130 nm propres à ne pas créer de 
dommages à l'articulation
11
 tout en permettant d’encapsuler des drogues lipophiles en 
quantité suffisante (un anti-inflammatoire modèle – la dexaméthasone [DXM] et Gal-3i). La 
taille des particules, le potentiel zéta et l'efficacité d'encapsulation des formulations sont 
décrites dans le Tableau 1. 
Les NCs sont stables dans des suspensions aqueuses stockées à 4 °C pendant une 
période d'au moins 1 mois. Les NCs maintiennent leur stabilité dans l'eau mais agrègent dans 
du PBS ou dans le liquide synovial reconstitué. Par conséquent, nous avons développé un 
hydrogel injectable in situ, en présence des NCs préformées pour améliorer la stabilité, avec 
maintien dans la cavité articulaire et une libération prolongée des drogues encapsulées. 
Les gels ont été formés à partir de deux biopolymères HA et de la fibrine capables de 
former un réseau interpénétrant 3D (IPN)
33,52–55
, en raison de l'affinité de HA de haut poids 
moléculaire pour la fibrine.
32,56
 La formation d'hydrogel est basée sur l'activation 
enzymatique du fibrinogène par la thrombine (Thr), et permet de concevoir un IPN pas à pas, 
en présence de HA de différents poids moléculaires, d’agents renforçant la fibrine (facteur 
XIII et α2-antiplasmine) et les NCs chargées avec la drogue. 





Tableau 1. Propriétés physico-chimiques des NCs vides ou chargées en drogue préparée avec 
HA 700 kDa (moyenne ± SD, n = 6). OO: d'huile d'olive, Lec: lécithine de soja, OAm: 
oléylamine, PDI: indice de polydispersité. 
 





















c prototype 1 15 3,75 0,75 128 ± 13 0,2 −27 ± 3 n/a 



















 prototype 1 15 3,75 0,75 160 ± 12 0,2 −20 ± 4 0,75 ± 0,13 







 prototype 2 22 5,625 1,125 122 ± 11 0,2 −29 ± 5 0,53 ± 0,05 
 
L'auto-assemblage des gels a été contrôlée par analyse de turbidité (λ = 350 nm) et 
des études rhéologiques qui identifient le retard de phase, déterminent le point de gel 




Figure 3. Figure 3. Résumé de la détermination du point de gélification par des mesures 
rhéologiques dans des systèmes différents: gels blancs "HA-fibrine" et "HA-fibrine 
renforcées" et ces gels 30% NCs. La ligne en pointillés représente le retard de phase requis 2 
minutes. Les mesures ont été effectuées à 37 ° C Exprimé en moyenne ± SD; n = 3. 
 





Nous avons obtenu un gel de microarchitecture et de temps de gel contrôlés en 
changeant la concentration du Thr, des NCs, des ions Ca
2+
, du facteur XIII et de l’α2-
antiplasmine afin d’obtenir une seringabilité adéquate pour les études in vivo. Un chargement 
des NCs de 30% (v/v) est observé au cours de l’auto-assemblage, et leur répartition 
homogène dans le gel avec des pores bien définis (7,29 ± 1,23 μm et 4,88 ± 1,12 μm, 
respectivement). Les valeurs de la viscosité initiale du mélange physique HA-fibrine (sans 
addition de Thr) étaient de 118,9 mPa·s et 81,3 mPa·s à 20 °C et 37 °C, respectivement, et 
sont sensiblement plus faible par rapport aux viscosuppléments commerciaux
57,58
, fournissant 
ainsi la seringabilité souhaitée pour une injection in situ de l’hydrogel pour des études in vivo. 
L'hydrogel formé in situ possède à la fois des caractéristiques rhéologiques d'un matériau 
élastique, adapté pour soutenir des déformations IA. Finalement, nous avons mis au point 
deux compositions de SDM, "le gel HA-fibrine pas renforcé avec 30% de NCs" et "le gel 
renforcé HA-fibrine avec 30% NCs" (Figure 3), pour d'évaluation chez le rat dans des 
modèles d’inflammation articulaire aiguë et chronique. 
Le profil de libération in vitro de la dexaméthasone "gel HA-fibrine avec 30% de 
NCs" dans le liquide synovial reconstitué a été étendue à 72 h, ce qui peut être très 
avantageux pour l'administration intra-articulaire de la drogue (Figure 4). 
 
 
Figure 4. Libération de la dexaméthasone (DXM) à partir d'hydrogel HA-fibrine chargé avec 
30% de NCs dans du liquide synovial simulé, 37 °C, 72 h. 
 





3. L'activité anti-inflammatoire in vivo de l’inhibiteur de Gal-3  
Dans une étude pilote, un modèle d’inflammation aiguë de courte durée induite par du 
carraghénane
59
, qui fonctionne efficacement pour le criblage de nouveaux médicaments
60
, a 
été choisi pour évaluer l'activité biologique de Gal-3i. 
Les animaux avec une synovite induite ont été divisés en trois groupes selon le 
traitement reçu (100 μL, IA): des NCs vides utilisés comme véhicule contrôle (groupe 1), des 
NCs chargées avec Gal-3i à une dose de 200 μg/kg (groupe 2) et le gel HA-fibrine renforcé in 
situ contenat 30% de NCs chargées avec de la Gal- 3i à une dose de 55 μg/kg (groupe 3). Un 
animal de référence qui n'a pas été traité par du carraghénane a été utilisé en tant que contrôle 
négatif). L'activité de la drogue a été contrôlée à 4 heures après l'induction de la synovite, 
lorsque le pic de gonflement du genou est observé.
59
 Les données de mesure du gonflement 
du genou et l'analyse histopathologique ont montré une activité anti-inflammatoire de Gal-3i 
et l'amélioration de l'état des articulations. Les données de gonflement du genou (Figure 5) 
ont montré une réduction du diamètre du genou: 1,6 fois (groupe 1), 3,5 fois (groupe 2) et 7 




Figure 5. L’effet du traitement avec l'inhibiteur de Gal-3 dans le modèle de l'inflammation 
articulaire induite par la carraghénane en utilisant les NCs et les NCs un gel par rapport à 
NCs vides, et le contrôle de la carraghénane (n = 5 pour les groupes 1 3, n = 1 pour le 
carraghénane seul). Δ est la différence dans le diamètre du genou à différents moments avant 
et après l'injection de carraghénane, exprimée en mm. Les données sont exprimées en 
moyenne ± SEM. 
 





Cette constatation est d'autant plus remarquable que la dose de Gal-3i (55 μg/kg) 
administrée au groupe 3 est nettement plus faible que celle administrée dans le groupe 2 
(200 µg/kg). Finalement, l’hydrogel HA-fibrine semble maintenir de manière efficace les 
NCs dans la cavité articulaire et moduler la libération. Les NCs per se semblent avoir un effet 
bénéfique sur la cicatrisation des articulations. 
Les résultats préliminaires obtenus dans le modèle de synovite aigüe induite chez le 
rat ont montré une suppression marquée de l'inflammation par le Gal-3i encapsulé dans 
l'hydrogel et administré à des doses de l’ordre du microgramme. Ces résultats suggèrent que 
Gal-3i peut être considéré comme un « lead » pour développer de nouvelles drogues 
immunothérapeutiques pour les maladies du genou, en particulier l'arthrite rhumatoïde. Il est 
à noter que le SDM contrôle a également montré une tendance à contribuer à prévenir 
l’inflammation des articulations probablement grâce aux effets protecteurs conjoints de 
l’huile d'olive et de l'acide hyaluronique dans la composition
28,29,61
, tandis que l'hydrogel de 
fibrine de l'acide hyaluronique peut fonctionner en tant que potentielle viscosupplémentation 
pour ses propriétés élastiques, sa persistance dans l’articulation et en tant que structure 




Le projet de thèse comprend la conception et le développement d'une nouvelle plate-
forme de caractère nanotechnologique injectable pour prolonger le temps de séjour intra-
articulaire et libération contrôlée de médicaments. Il est composé d'un hydrogel in situ dans 
lequel sont dispersées des nanocapsules, servant de réservoir pour divers drogues lipophiles 
anti-inflammatoires : i) un médicament modèle – la dexaméthasone; et ii) un nouveau 
composé en tant que molécule immunothérapeutique – un antagoniste de la galectine-3. Les 
résultats expérimentaux ont abouti aux conclusions suivantes : 
 
1) Dans cette étude, un nouvel inhibiteur de haute affinité et sélectif de Gal-3 a été 
mis au point. Son Kd pour Gal-3 déterminé par polarisation de fluorescence est de 0,59 μM à 
4 °C (2,99 μM a 25 °C).  Une caractéristique importante de ce composé est d’être sélectif de  
Gal-3 par rapport à deux autres membres de cette famille de lectine Gal-1 et Gal-7. 
 
 





2) De nouvelles nanocapsules (NCs) composées d’un cœur d'huile d'olive et d’un 
revêtement d'acide hyaluronique ont été préparées avec succès en utilisant une méthode 
simple de déplacement de solvant. Ces NCs ont la capacité d'encapsuler la dexaméthasone 
(5,6 ± 0,4 mg/mL) et l’inhibiteur de Gal-3 (531 ± 5 μg/mL). Ces dernières ont des tailles 
nanométriques (135 ± 9 nm et 122 ± 11 nm, respectivement), une charge de surface négative 
et une forme sphérique régulière. 
 
3) Deux systèmes d'injection hydrogels in situ par un réseau interpénétrant composé 
d'acide hyaluronique-fibrine et d'acide hyaluronique-fibrine renforcée ont été développés. Les 
hydrogels ont montré un temps de gel, de microstructure et de propriétés mécaniques 
facilement modifiables. En outre, les gels permettent de charger des NCs à hauteur de 30% 
(v/v) lors leur auto-assemblage. La viscosité initiale du système est significativement plus 
faible par rapport à des viscosuppléments commerciaux, ce qui permet une bonne 
seringabilité. Les propriétés rhéologiques des hydrogels assemblés ont révélé une résistance à 
des tensions élevées, ce qui correspond à des caractéristiques à la fois de matériaux élastiques 
et de type solide, adapté pour persister intra-articulairement. En ce qui concerne leur 
structure, la formulation a des pores bien définis avec des NCs dispersées de manière 
homogène dans les de gel. Ce système de délivrance de médicament IA (SDM) a donné un 
profil de libération contrôlée et prolongée de drogue in vitro, en évitant une décomposition 
rapide des NCs dans le liquide synovial reconstitué. 
 
4) Des études préliminaires in vivo réalisées dans un modèle de rat de synovite aiguë 
dans l'articulation du genou induite par le carraghénane a montré une suppression de 
l'inflammation par l'inhibiteur Gal-3 que ce soit pour les NCs chargé en inhibiteur que les  
NCs chargées en inhibiteur dispersées dans le gel. Ce résultat suggère que l’inhibiteur de la 
Gal-3 pouvait servir de composé de base pour concevoir des candidats médicaments pour le 
traitement de l’inflammation dans les articulations. Il est intéressant de noter que les NCs non 
chargées ont également montré une tendance à contribuer à réduire l'inflammation synoviale. 
 
D'une manière générale, le travail présenté ici décrit le développement et la 
caractérisation d'un nouveau SDM biodégradable in situ comme potentiel hydrogel injectable 
intra-articulairement. Le système permet la distribution des médicaments lipophiles et devrait 
améliorer les thérapies actuelles des articulations. Les propriétés rhéologiques du système 





initial offrent une bonne seringabilité et des caractéristiques mécaniques souhaitables pour 
l'application intra-articulaire. L’cctivité de l’inhibiteur de la galectine-3 dans une étude 
préliminaire in vivo a confirmé que la galectine-3 était une cible potentielle 
immunothérapeutique pour le traitement des maladies articulaires inflammatoires telles que 
l'arthrite rhumatoïde. 
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Life can only be lived 












1. Intra-articular therapies and local delivery of drugs 
Over the last decades it has become clear that the local delivery of drugs in the intra-
articular (IA) cavity can greatly improve the treatment schemes and effectiveness of joint-
associated pathologies.
1–4
 The current systemic therapies for these pathologies, administered 
by the oral or the intravenous routes, can be classified by the nature of the drug, as 
i) nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen;
5
 ii) corticosteroid anti-
inflammatory drugs (e.g. dexamethasone);
6
 iii) disease-modifying anti-rheumatic drugs 
(DMARDs), e.g. methotrexate;
7,8
 iv) monoclonal antibodies (e.g. infliximab);
9
 and v) natural 
agents, such as oils with anti-inflammatory and anti-oxidant properties.
10,11
 Unfortunately, 
none of these drugs exhibit joint specificity.
2,12,13
 Therefore, medication has considerable 
risks to humans due to the high doses required, with the subsequent systemic adverse effects 
(e.g. the cardiovascular, gastrointestinal complications, kidney dysfunction, skin and muscle 
atrophy, glaucoma, premature mortality).
12,14,15
 Furthermore, after prolonged treatment, joints 
often become resistant to the systemic treatment.
1–3,16
 Within this context, the intra-articular 
modality of administration offers the possibility to concentrate the drug locally,
2,17
 and reduce 
the systemic toxicity.
2,12,18,19
 Nevertheless, IA therapy still remains challenging due to a 
possible induction of septic arthritis (a risk controlled by careful handling of IA 
injections);
2,20,21
 rapid drug elimination from the joint cavity,
2,22,23
 and crystal-induced 
synovitis.
18,22,24
 The latter two could be overcome by the development of drug delivery 
systems (DDSs) that display sufficient IA residence time with controlled and prolonged drug 
release profile.
2,16 
Anatomically, the human knee is a diarthrodial joint filled with 2 - 3.5 mL of synovial 
fluid (SF), a viscous liquid that plays an essential role in the knee homeostasis
3
 (Figure 1), 
providing mechanical, nutritional and immune functions in the knee.
25
 A key component of SF 
is high molecular weight (MW) hyaluronic acid (HA), present at an approximate 
concentration of 3 mg/mL.
26,27
 In addition, HA reduces friction by lubricating the articulating 
joints and adsorbing shocks. Finally, the immune cells presented in the SF, mediated by HA, 










Figure 1. A schematic illustration of a knee joint. Reprinted with permission from The 
McGrow-Hill company, Inc, Copyright © 2009. 
 
Given that in inflammatory conditions swollen knees accumulate between two and 
five times higher volumes of SF, the aspiration to remove the excess of fluid remains the first 
line treatment.
33–36
 Besides, the administration of viscosupplementation agents, mainly HA or 
HA derivatives, has been widely used for improving the normal joints performance.
37,38
 
These products restore joint lubrication, provide elasticity and viscosity, improve the 
mobility, reduce pain, and protect the cartilage.
2,39–42
 However, a limitation of this therapy is 
related to their high viscosity, causing intense IA pressure and pain in the knee joint.
43
 
The marketed viscosupplements can be divided into non-crosslinked HA, that are 
normally highly viscous solutions, and crosslinked HA substances, usually injected as 
preformed hydrogels (Table 1).
2,44–54
 These HA-based medical devices have shown 
significant improvement of viscoelastic properties of SF, increasing joint mobility, relieving 
the pain and inducing chondroprotective effect on osteoarthritis (OA).
55
  
Generally, crosslinked HA has been reported to have a more prolonged residence time 
in the articular cavity, compared to the unmodified molecule.
2,48,56
 As a result, these 
viscosupplements have shown long-lasting effects on OA (up to 26 weeks)
52–54,57–60
 and, in 
some cases, have also been shown to alleviate rheumatoid arthritis (RA) symptoms, although 
they were not specifically designed for this pathology.
61
 The longest therapeutic effect at OA 
was achieved by RenehaVis®
 
(a course of 1-3 injections of a mixture of 1 and 2 MDa HAs, 
12 months) and Crespine®
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of HA 













Supartz® 0.6 – 1.2 MDa HA 2.5 mL, 25 mg 3 – 5 
Seikagaku 
Corp., Japan 
3 – 6 months 
42,63
 















1 MDa (2.2%) and 
2 MDa (1%) HA 
0.7 mL, 15.4 mg (1 MDa),  
0.7 mL, 7 mg (2 MDa) 
 
1 – 3 










 G-F20: a mixture of 80% 
(v/v) of Hylan A fluid, lightly 
crosslinked by formaldehyde and 
20% (v/v) of Hylan B gel, 
crosslinked by sulfonyl-bis-ethyl  
6 mL, 48 mg 









HA crosslinked by dimers of 
cinnamic acid 
3 mL, 30 mg 









 HA with 1,4-butane-diol 
diglycidyl ether crosslinker 
3 mL, 60 mg 






Over 3 months 
(up to 9 months in 










 Crosslinked HA 
(not disclosed) 
4 mL, 88 mg 












A non-chemically crosslinked 
hexadecylamide derivative of HA 
3 mL, 24 mg 












A mixture of non- and 





2 mL, 30 mg 
















When the degenerative illness has progressed, cartilage/osteochondral implants for 
hyaline cartilage or bone repair/substitution are the preferred treatments.
78–81
 A variety of 
injectable in situ hydrogel/gel implants based on natural,82–91 synthetic92–99 and combined 
materials100–107 were evaluated in vivo for articular tissues repair. Despite successful outcomes 
at the research level,
80,81,108
 currently only one in situ hydrogel based on chitosan and glycerol 
phosphate (BST-CarGel®; Biosyntech, Canada)
109





2. Advanced drug delivery systems for intra-articular delivery 
Drug-polymer conjugates constitute a more advanced treatment for IA pathologies 
compared with viscosupplements, which are actually considered as medical devices. They are 
designed to achieve combined effects: the action of the drug and the viscosupplementation of 
the polymer. In this regard, HA is the most used polymer in these products, although other 
examples are found, such as N-(2-hydroxypropyl)methacrylamide (HPMA)-
dexamethasone.
63,112–115
 It is worth mentioning the case of HA-methotrexate (DK226), 
designed specifically for the treatment of RA, which combines viscosupplementation agent 
with the methotrexate anti-inflammatory properties, showing a long lasting effect (24 days) in 
several RA rat models.
116,117
 
The work in the area of IA drug delivery systems, aiming at prolonging the retention 
and controlling the drug release in the articular cavity, is currently moving in two principal 




Figure 2. Different types of systems designed for IA administration. Reproduced with 
permission from
112






2.1. Nano- and microsystems for IA delivery 
Although a number of authors have described the potential use of 
nano-/microformulations for the IA delivery of drugs, the success of these DDS relies on 
their final fate. Nano-/microcarriers can show an increased joint retention time, which is size-
dependent. Nanoparticles (NPs) injected into the joint cavity may penetrate into the cartilage 
extracellular matrix (ECM) and interact with collagen fibers when their particle size is 
generally below 100 nm.
4,118
 For larger sizes, nanoparticles can be internalized by synovial 
macrophages, dendritic cells or chondrocytes,
23,119–121
 or may suffer from a rapid efflux from 
the articular cavity.
2,16
 Similarly, microparticles are also prone to be either phagocytized 
(< 20 µm) or remain in the SF, adhere to the cartilage and synovium or become entrapped 
within synovial folds (> 20 µm).
2,4,23,121
  On the other hand, the diameter of blood capillaries 
(2-3 µm) and the lymph vessels (8-30 µm),
2,122,123
 prevents the elimination of large 
particles.
2,112,124
 An additional advantage of NPs vs. larger particles relies in the small size of 
the needle required for the injection and the fact that smaller particles are expected to cause 
no cartilage damage driven by mechanical damage in the joint.
124
  
At present, only one liposomal formulation for IA application is available for the 
treatment of inflammatory osteoarthritis (OA) (Table 2). This formulation, Lipotalon®, 
which contains dexamethasone 21-palmitate,
125–127
 has shown a maximal therapeutic effect 





(Encapsula NanoSciences LLC, USA), loaded with 
clodronate (antiosteoporotic cytotoxic drug), has been found to be effective in a preliminary 
clinical trial (7 days study) on patients with RA and has been marketed for non-human RA 
model studies (Table 2).
123,129,130
 On the other hand, a new product PLGA microspheres 
(MS), namely Zilretta™/FX006 (Flexion Therapeutics, USA), which contains corticosteroid 
drug triamcinolone acetonide, has recently been approved by FDA and reached the market for 
OA treatment (Table 2).
131,132
 The therapeutic effect of this formulation was maintained for 
up to 12 weeks.
131–134
 Overall, these formulations have been shown to reduce the drug 








Table 2. Marketed formulations or in clinical trials based on nano-/microsystems for joints 

























































The commercialization of these products has encompassed a quite active research 
activity in the field of liposomes and nano-/microparticles for intra-articular application made 
of a variety of biomaterials.
15,137–141
 The most important recent advances with these 
formulations in vivo are summarized in Table 3. Overall, these liposomal or polymeric 
formulations containing anti-inflammatory or disease-modifying anti-rheumatic drugs have 
been evaluated in vivo providing in all cases the expected PK/PD changes of the associated 
drugs, extended residence time, reduced toxicity and prolonged effect.
121,142–159
 
The drugs that have been more extensively studied are corticosteroids (i.e 
dexamethasone, betamethasone, prednisolone), NSAIDs (i.e. diclofenac, indomethacin), 
DMARDs cytotoxic drugs (i.e. methotrexate, paclitaxel, clodronate), and others, i.e. 
kartogenin, actarit, etc.
121,142–159
 With regard to the composition of the nanosystems, in most 
cases they have been made of lipids (liposomes), polyesters (PLGA, PLA nanoparticles) and 
polysaccharides (i.e. chitosan nanoparticles). Despite of the positive initial in vivo data 
obtained with these formulations, their therapeutic responses have not been as long-lasting as 
expected. In fact, the longest response has been reported for the thermo-responsive Pluronic 
F127/chitosan nanospheres for co-delivery of kartogenin and diclofenac (to achieve a dual 








 (Table 3). A strategy to prolong the dwelling time of the nanoparticulated 
systems has relied on making them interactive with the surrounding environment. For 
example, cationic (Eudragit RL100 or PLGA/Eudragit RL) NPs, with the capacity to interact 
with endogenous HA, formed an in situ gel once injected to the rat joint cavity.
124,161
 As a 









Table 3. Formulations based on nano-/microsystems for the treatment of joints pathologies following IA administration.  



























160 nm and 750 nm 
Rabbit antigen-induced 
arthritis 
750 nm liposomes have longer retention time. 






oxide nanoparticles in 
PLGA microparticles, 
~10 µm 







Rats adjuvant-induced arthritis 
and mice with anti-type II 
collagen antibody induced 
arthritis  
Almost complete remission of the inflammatory response 








induced chronic synovitis. 
A rat air pouch was used to 
evaluate the drug release  
The drug release was prolonged to 7 days. The joint 







Mice antigen-induced arthritis 
At 24 h strongly suppressed pro-inflammatory markers of 
M1 phenotype macrophages, strongly diminished joint 










Scintigraphic imaging showed 60% retention of the 











Scintigraphic imaging showed 99% microspheres 
retention at 4 h after injection. At day 30 some drug-
















Rat acute carrageenan-induced 
and chronic  
adjuvant-induced arthritis, 
(daily injections at days 1-14) 
In short RA model the maximal paw edema inhibition 
was observed at 5 h; while in chronic RA model at day 21 












size was not defined 
Rat acute carrageenan-induced 
and chronic  
adjuvant induced arthritis 










(long RA model)   
Concentration of the drug in microspheres was 8.7 folds 









arthritis in rats 
Significantly and dose-dependently ameliorated various 
symptoms of arthritis, improved biochemical markers and 
preserved radiological alterations in joints of arthritic rats 



































Rat antigen-induced arthritis 
1.8 µm liposomes showed better joint retention and more 
effective suppression of inflammation compared to 100 
nm ones. For 1.8 µm liposomes the knee diameter almost 
returned to normal state after 20 days. The treatment 








Healthy rabbit  
After 24 h the drug concentration in the group treated 
with the microspheres is three fold higher compared with 












articular arthritis   
 
35–105 µm microspheres were biocompatible, whereas 
smaller ones (1–20 µm) produced an inflammatory 
response. PLA microspheres significantly reduced all 
























































Microparticles showed longer retention time in the knee 
joint than nanoparticles after IA injection. Both 150 nm 
and 1.8 µm particles showed much less degenerative 










 (covalently conjugated to 
outer shell) and diclofenac 
(encapsulated), 
305 nm (37 °C) and 
650 nm (4 °C) 
Rat surgically 
induced osteoarthritis 
The anti-inflammatory and chondroprotective effects 
were enhanced by cold treatment (4 ºC). 





















The actarit-loaded SLNs exhibited a longer mean 
retention time (13.53 h) compared with the actarit 50% 















Tested the effect of insulin on the diabetic cartilage. 
Microspheres allowed slow insulin release during 3 days. 
Insulin stimulated matrix synthesis in osteoarthritic 
cartilage. Local treatment with insulin overcame 




































Selective delivery of photosensitizers to macrophages and 
photodynamic destruction of macrophages. 
Efficient retention and decreasing the clearance of 
photosensitizers from the inflamed articular joints. For up 
to 24 h they were retained inside the cells and even at day 
8 showed after light exposure showed efficacy of such a 


























Eudragit RL100 NPs, 
130 nm  
Healthy rat 
NPs injected to the synovial cavity form ionically cross-














Microscopic imaging showed improved retention time in 
the knee joint with the filamentous NPs/HA aggregates, 
with over 50% preservation of the fluorescent signal 28 









Hydrogels are insoluble crosslinked 3D structures of polymer chains with water or 
biological fluid swollen inside them. They can be designed with an adequate elasticity, 
mechanical strength, permeability and diffusivity, being versatile DDSs for arthropathies. 
Such hydrogels display highly porous networks, allowing the entrapment of drugs, nano-/ 
microcarriers or cells inside their pores and, depending on the material, the gels may support 
cell adhesion, proliferation, and differentiation.
112,169–172
 
Hydrogels used for IA drug delivery are injectable pre-formed
173
 or in situ forming 
hydrogels
174
 with physically mixed
173
 or chemically bound drugs.
175
 For instance, a hydrogel 
with pre-mixed dexamethasone (DXM) has been shown to significantly reduced the inherent 
DXM toxicity in a rat OA model, providing an anti-inflammatory and chondroprotective effect 
at 12 weeks after the injection.
173
  
A different strategy has relied on the design of in situ forming hydrogels that are easy 
to inject and exhibit a prolonged residence time in the articular cavity. Among them, it is 
worth mentioning a radiotherapeutical pH responsive Holmium-166-chitosan hydrogel,
176
 in 
Phase II clinical trials for the treatment of knee synovitis typical for RA.
177
 Another example, 
is a thermosensitive triblock poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) 
copolymer hydrogel, which has been proposed for the controlled delivery of methotrexate in 
rat joints. The complete drug clearance was monitored during 24 h in plasma and occurred 
slower compared to free methotrexate.
178
 
2.3. Nano-/microsystems incorporated into hydrogels 
Recent attention has been paid to the combination of drug loaded nano-/microsystems 
with hydrogels aiming at improving the residence time in the synovial cavity and the drug 
release profile.
80,179,180
 These nano-/microcarrier-loaded hydrogels have been found to control 
the delivery of the associated drugs for about a month
174,181,182
 or even longer.
183
 
Nevertheless, overall, the reported work of in situ-forming hydrogels containing drug-loaded 
nano-/microparticles is at a very early stage and only a few of these formulations have been 
tested in vivo (Table 4).145,163,184 
In most of the cases these combined systems were tested in healthy animals what did 
not allow to adequately estimate the residence time and prolonged release at inflamed joints. 
However, radio-labelled liposomes (235 nm) incorporated into Carbopol 
940/carboxymethylcellulose gel evaluated at rabbit induced arthritis model demonstrated 






maximal sustained-released reached 42 days post IA injection by using amphotericin B 
precipitates/crystals suspended in glyceryl monooleate-HA hydrogel.183 
An intra-articular DDS should fulfil a number of properties, such as biocompatibility, 
and biodegradability, in addition to an effective and prolonged disease improvement.
185
 
Another distinctive feature is bioadhesiveness,
81
 which allows to increase the residence time 
of DDS in the synovial cavity and impart the chondroprotective effect.
186
 Given the 
complexity of the joints anatomy, drug-loaded in situ hydrogels combined with nano-






Table 4. Nano-/microsystems-loaded hydrogels for IA applications tested in vivo. 
 
Drug Drug delivery systems In vivo model Key observation Ref. 
Celecoxib 
(NSAID) 
Precipitates/crystals (size non specified) 
dispersed in a poly(ɛ-caprolactone-co-lactide)-
b-poly(ethylene glycol)-b-poly(ɛ-caprolactone-




The degradation and the release profiles were tested by 
different routes of administration: 
1) In the articular cavity the DDS degraded between 
week 3 and 4. Release was not evaluated. 
2) At subcutaneous injection in rats gel degradation 
happened in ~12 weeks, ∼30 % celecoxib 
released during the first 3 days followed by a 





Polyethylene glycol (PEG)-microspheres (40–
100 µm) crosslinked by short PLGA chains to a 
hydrogel. Two populations: slow degradable 
and non-degradable 
Healthy sheep 
shoulder joint  
At 4 weeks non-degradable MS and not completely 
degraded MS were found, in synovial fluid and in the 
synovium. Degradable MS caused low inflammation 





Precipitates/crystals (size non defined) 
suspended in glyceryl monooleate-HA hydrogel 
(in situ) 
Healthy rat 
This formulation showed sustained-released during 42 







(MPEG-PCL) micelles  
(25 nm) incorporated into thermosensitive in 







The gel biodegradation was evaluated upon subcutaneous 






Lipogelosomes: Radio-labelled liposomes 
DMPC–CHOL–DCP (235 nm) incorporated 





Scintigraphic imaging showed 67% retention of the 








3. Galectin-3 role in pathophysiology of rheumatoid arthritis  
Galectins are attracting more and more attention of scientists due to their presence in 
most of the tissues and their crucial role in biological processes and pathologies. Galectins 
are proteins able to bind to β-galactoside motifs (noteworthy, lactosamine [Gal(1→3/4)-
GlcN] types, so-called LN1 and LN2) by one or two conserved carbohydrate-recognition 
domains (CRDs) and lack of enzymatic activity.
188–190
 
Galectins are widely distributed in the organism and they are continuously produced 
by different cell lines.
189,191
 Their dual localization, intracellular (in nuclear and cytoplasmic 
compartments) and extracellular (at the cell membrane and extracellular matrix),
192,193
 is 





 inflammation, and immune response
202–207
 (Figure 3). Overall, galectins 
synthesis can represent up to 1% of total protein in the producer cells.
207
 However, during 
pathological processes the level of galectins can raise considerably. For instance, galectins 
local concentration at the inflammation site increases up to 40 mg/kg (of wet tissue), leaving 
the immune cells immersed in a sea of different galectins.
207
 As a consequence, the 
deregulation of the galectins expression have been directly or indirectly associated with at 
least 137 pathologies headed by different cancer types, heart failure and RA, showing the 
potential of lectins as therapeutic targets.
208
 
Currently, galectin family is represented by 15 members in mammals, which 




Proto-type galectins have one CRD and exist as monomers, but in vivo they are able 
to dimerize via non-covalent interactions to form homodimers. The tandem-repeat type is 
composed of two distinct, but homologous CRDs covalently linked to a dimer by a functional 
peptide. Finally, chimera-type galectins are made of one CRD that enables multimerization 
and N-terminal domain, including intermediate lateral collagen-like sequence, which 
implements alternative multimerization upon binding glycan ligands, mostly forming trimers 
and pentamers
207,211–213
 (Figure 3).  
Galectin-3 (Gal-3) is a key member of galectin family and a unique representative of 
the chimera-type.
202
 It is present in vertebrates, protochordates, invertebrates, mushrooms, 
and viruses.
209







 skeletal tissues and brain
218























Figure 3. Intra- and extracellular located galectins and their functions. Proto-type: Galectin-
1, -2, -5, -7, -10, -11, -13, -14, and -15; chimera-type: Galectin-3; tandem-repeat type: 
Galectin-4, -6, -8, -9, and -12. Functional diversification of galectins: (1) Galectin transcripts 
are translated in the cytoplasm, and the proteins can be translocated into the nucleus (2) 
where they can associate with ribonucleoproteins. Via unconventional mechanism(s), 
galectins can be secreted to the extracellular space (3) where they can function as pattern 
recognition receptors for microbial glycans (4), bind to the host cell surface glycans (5), and 
cross-link them with ECM glycans (6) thereby, for example, promoting cell migration. 
Galectins can also cross-link cell surface glycans and induce clustering of microdomains and 
lattice formation at the cell surface (7) that can trigger signaling cascades, or cross-link 
neighbouring cells (8) and promote cell–cell interactions/adhesion. Reproduced with 
permission from,
228
 Copyright © 2012, Vasta et al., Creative Commons Attribution License. 
 
3.1. Galectin-3 intracellular functions 
Multiple functions of Gal-3 greatly comply with the noticeable phenomenon of dual 
localization.
213
 Intracellularly, at the nucleus compartment, Gal-3 regulates pre-mRNA-
splicing
213
 and stabilizes protein-DNA interactions facilitating transcription,
207
 contributing 
to gene expression and regulation.
229
 But shuttling across nuclear pores to the cytoplasm 








controls cell growth and has anti-apoptotic activity by the interaction with the apoptosis 
repressor Bcl-2.
196,231
 Besides, Gal-3 inhibits the apoptosis by preventing the mitochondrial 
cytochrome C release.
207





 and cell proliferation
233




Figure 4. The intracellular functions of galectin-3. Red arrows indicate positive effects, blue 
lines – negative effects. Akt – the serine/threonine kinase Akt, Ask-1 – apoptosis signal-
regulating kinase 1, CBP70 – carbohydrate binding protein 70, Chrp – cysteine- and 
histidine-rich protein, CREB – cAMP-response element-binding protein, ERK – extracellular 
signal-regulated kinase, Gal-3 – galectin-3, GTP – guanosine triphosphate, JNK – c-Jun 
NH2-terminal kinase, MEK – mitogen-activated protein/ERK kinase, P – phosphate, PI3K – 
phosphatidylinositol 3-kinase, Raf-1 – the serine/threonine kinase Raf-1, Tcf-4 – T cell factor 
4, TF – transcription factor, TTF-1 – thyroid-specific transcription factor. Reprinted with 
permission from,
234
 Copyright © 2006, Elsevier. 
 
3.2. Galectin-3 extracellular functions 
Extracellularly Gal-3 releases in vesicles, likely through exosomes or by direct 








 Being abundantly expressed in different tissues, Gal-3 modulates 
distinct cellular processes such as cell-cell and cell-matrix interactions through specific 
binding to extracellular sugar ligands.
208
 In such a manner, this protein takes part in multiple 







immune response and inflammation
204,212,239,240




Figure 5. The extracellular functions of galectin-3. Red arrows indicate positive effects. AGE – 
advanced glycation end products, C4.4A – the GPI-anchoredglycoprotein C4.4A, CEA – 
carcinoembryonic antigen, CRD – carbohydrate-recognition domain, EGFR – epidermal 
growth factor receptor, FcεR – Fcε receptor, Gal-3 – galectin-3, IgE – immunoglobulin E, L1 – 
neural adhesion molecule L1, Lamp 1/2 – lysosome associated membrane protein 1/2, LPS – 
lipopolysaccharide, Mac-2BP – Mac-2 binding protein, MAG – myelin associated glycoprotein, 
N-CAM – neural cell adhesion molecule, NCA-160 – non-specific cross-reacting antigen 160, 
ND – N-terminal domain, NG2 – the transmembrane chondroitin sulfate proteoglycan NG2, 
TβR – transforming growth factor β receptor, TCR – T cell receptor. Reprinted with permission 
from,
234
 Copyright © 2006, Elsevier. 
 
One of the most important extracellular functions of Gal-3 is supporting the control of 
immune and inflammatory response.
207,212,241






involved basically in each process: from controlling the B cells maturation in the bone 
marrow to activation or inhibition of B and T cells apoptosis.
207
 Although resting B and T 
cells do not express it.
213
 Gal-3 is expressed in neutrophils, basophils, eosinophils, 





 and has also considerable effects on both innate and adaptive 
immunity.
207
 Innate immune functions of Gal-3 are cell activation, adhesion, migration, and 





 It is both pro-inflammatory and anti-inflammatory mediator, working as 
a chemoattractant for monocytes, macrophages, followed by macrophages polarization,
246
 
and increasing the amount of neutrophils.
207
 In adaptive immune system Gal-3 exposes 
immunosuppressive effect, restricting T cell receptor recruitment into immune synapses, 
prevents T cell proliferation, differentiation, and directly promotes T cell apoptosis,
207
 
resulting to prolonged inflammation.
247
 On the other hand, Gal-3 anti-inflammatory activity 
includes phagocytosis of dead cells and stimulation of wound healing.
207
 
3.3. Galetin-3 deregulation in RA 
Noticeably, Gal-3 expression is up-regulated in synovial tissues in RA,
213
 its 
concentration in SF increases from about 50 ng/mL up to 130-300 ng/mL
212
 and being a pro-
inflammatory regulator, it amplifies the inflammation.
247
 As reported, Gal-3 stimulates 
synovial fibroblasts as well as infiltrated immune cells to release the pro-inflammatory 
cytokines (TNF-α, IL-6, IL-17) and chemokines (CCL2, CCL3, CCL5, CXCL8),
212
 the 




 and A Disintegrin And 
Metalloproteinase with Thrombospondin Motifs 5 (ADAMTS5).
212
 These enzymes are 
involved in the degradation of the ECM
248
 and type I-III collagen and tissue remodeling.
30,250
 
They also inhibit the osteocalcin production
220
 leading to bone demineralization,
212
 and, 
eventually, causing joint degradation.
19,251
 In addition, IA injection of recombinant galectin-3 
in mice induced cartilage and subchondral bone lesions.
220,247
 Taking into account the 
involvement of Gal-3 into the pathophysiology of RA this protein appears as a novel potential 
immunotherapeutic target. 
3.4. Galectin-3 structure  
Human Gal-3 is a 30-35 kDa protein coded by the LGALS3 gene,
234
 composed by 250 
amino acids (aa) organized into a secondary structure, mostly forming anti-parallel β-sheets 
and only in few regions assemble into α-helixes.
213,252,253
 The protein is divided into 3 








 a lateral collagen-like sequence (19-111 aa), which includes consensus 
sequence of nine PGAYP repeats,
213,254
 which can give rise to multimerization; and the 
carbohydrate recognition domain – CRD (112-250 aa) that includes highly conserved amino 




Gal-3 CRD domain has a structure typical for galectin family members with a 
canonical amino acid sequence,
259
 suggesting that all the Gal-CRDs are able to bind β-
galactoside motifs with similar Kd values for these ligands.
190,256,260
 It is composed of two 
antiparallel β-sheets of six (S1-S6) and five (F1-F5) strands (Figure 6A) and includes highly 
conserved residues (e.g. His158, Asn160, Arg162, Glu165, Asn174, Trp181, Glu184) 
responsible for complexation with carbohydrate ligands and salt-bridge network (Arg162-
Glu165-Glu184-Arg186), determining LN2 binding preference over LN1 core 
(Figure 6B).
190,252,259,261
 Structural alignments and superimposition of CRD domains 
fragments (S4-S6) of human Gal-3 CRD (hGal-3-CRD), Gal-1 (hGal-1) and Gal-7 (hGal-7) 
CRDs are shown in Figure 6C and D.
190
 These similarities explain the low specificity of 
some synthetic Gal-3 inhibitors that have dissociation constants of the same order for these 
three galectins.
262
 It is important to emphasize that two arginine residues (Arg144 and 
Arg186), adjacent to the binding site of Gal-3 CRD, do not participate in natural ligands 
complexation,
259,263
 but offer an opportunity to establish new binding contacts for selective 
targeting of Gal-3
190,252
 (Figure 7A). Thus, one strategy to obtain more affine and specific 
Gal-3 inhibitors consists in the introduction of aromatic substituents to LN2 core to gain 










Figure 6. (A) 3-D structure of human Galectin-3 (hGal-3) CRD complexed with LN1; (B) 
Close-up view of the unique salt bridge networks in hGal-3-CRD and its affinity to LN1 and 
LN2; (C) Structure-based sequence alignment of S4-S6 β-strands of hGal-3-CRD and hGal-
7. Secondary structures were designated according to the resolved X-ray structures. The 
highly conserved LNs-interacting residues among hGal-1, hGal-3-CRD and hGal-7 are 
indicated by asterisks. Residues involved in unique salt bridge network of hGal-1, hGal-3-
CRD and hGal-7 are coloured in either red (Glu/Asp) or blue (Arg); (D) S4-S6 β-strands of 
hGal-1 (pink), hGal-3-CRD (blue) and hGal-7 (green) are superimposed. The unique salt 
bridge network of hGal-1 (R48-D54-E71-R73), hGal-3-CRD (R162-E165-E184-R186) and 
hGal-7 (R53-E58-E72-R74) are shown in stick models. Reproduced with permission from,
190
 










Figure 7. (A) A close-up view of the X-ray structure of Gal-3 CRD complexed with di-
arylated Gal-3 inhibitor by cation- interactions of aromatic substituents with guanidinium 
ions of highly conserved Arg144 and Arg186 residues. Reprinted with permission from
264
, 
Copyright © 2017, Elsevier. (B) Structures of disaccharides N-acetyllactosamine (LacNAc) 
and thio-digalactoside (TDG), as the scaffolds to design galectin inhibitors. Green circles 
denote critical modified positions in search for high-binding affinity and selective galectin 
inhibitors. Modified with permission from
265
 Copyright © 2016 Cagnoni et al., Creative 
Commons Attribution License. 
 
3.5. Galectin-3 synthetic antagonists 
Currently, only three Gal-3 antagonists among the reported inhibitors have entered 
clinical trials. One, designed against colon cancer, named DAVANAT® (GM-CT-01),
208,266
 
undergone phase II clinical trials.
267
 DAVANAT® is obtained from guar gum natural 
galactomannan polysaccharide, where galactose residues are branched to a poly-
mannopyranoside backbone (Figure 8). Initially, Kd of this derivative to Gal-3 was found to 
be 60-70 nM
268
 at 4 °C, but the last findings of the collaborative research, published by 
Klyosov et al. contradicts this, showing no inhibition of Gal-3 (1-5 µM) at the tested 
concentrations of DAVANAT®
 
(1-5 mg/mL). The inhibitor seems to complex with another 
non-canonical binding site/s and has higher affinity to galectin-1 (Kd ~ 10 µM).
269
 Another 
drug candidate for the treatment of non-alcoholic steatohepatitis with advanced 
fibrosis/cirrhosis and plaque psoriasis, named GR-MD-02,
270








 This inhibitor, in combination with Keytruda® and Yervoy®, is in 
Phase I for melanoma cancer immunotherapy.
270,273,274
 GR-MD-02 is a complex carbohydrate 
molecule (galactoarabino-rhamnogalacturonan) (Figure 8), with MW 2-80 kDa, derived from 
a plant,
275
 and binds Gal-3 with Kd 2.9 μM.
276
 Lastly, a very potent Gal-3 inhibitor bis-{3-
deoxy-3-[(3-fluorophenyl)-1H-1,2,3-triazol-1-yl]-β-D-galacto-pyranosyl}sulfane, usually 
referred to as TD139, was efficiently tested in idiopathic pulmonary fibrosis 
treatment,
215,237,261
 and currently finished phase IIb clinical trials.
237,277
 It is a small sugar-
derived molecule inhibitor, based on a C2-symmetrical thio-digalactoside core identified 
from screenings of aromatic substituent libraries
263,278
 (Figure 8). TD139 interacts with Gal-3 





Figure 8. Structures of different commercial Gal-3 inhibitors: DAVANAT® (GM-CT-01), 






According to Nilsson and Leffler’s approach,
260,278
 the increase of the selectivity and 
binding affinity of inhibitors to Gal-3 could be achieved by establishing of cation-π 
interactions between aromatic substituents at positions 3’-C of galactose (Gal) and 2-C of 
glucosamine (GlcN) of type II N-acetyllactosamine (LacNAc) [Galβ(1→4)-GlcN] (Figure 
7B) and guanidinium ions of two Gal-3 CRD Arg144 and Arg186 residues (Figure 7A).
264
 
Following this approach, we report herein the design, synthesis, characterization and in vivo 
activity evaluation of a highly selective and affine Gal-3 inhibitor derived from its natural 
ligand type II LacNAc with aromatic substituents at positions 3’-C of Gal and 2-C of GlcN. 
 
4. Conclusions and perspectives 
 
Important progress has been made in the treatment of arthropathies (mainly in 
osteoarthritis and rheumatoid arthritis) thanks to the development of controlled drug delivery 
systems and nano/microcarriers. Recently, a few liposome-based formulations have been 
approved for the treatment of joints diseases, although their IA residence time can be further 
improved. The development of biodegradable drug delivery systems with a prolonged drug 
release and an adequate IA retention is nowadays conceived as a promising approach to 
improve joints therapies. Besides, the limited ability of the articular cartilage for self-healing 
and the loss of synovial fluid functions requires a versatile carrier, which, apart from a 
controlled drug release, can act as a viscosupplement and an in situ cell scaffold for cartilage 
tissue regeneration. At the same time, the discovery of novel immunotherapeutic targets is 
triggering intensive efforts towards the development of highly specific small molecules-
antagonists for inflammatory diseases therapies. Combination of the innovative approaches in 
both fields might lead to the development of advanced nanotechnological platforms for the 
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Science never solves a 
problem without creating 
ten more. 
 
George Bernard Shaw 






1. Most diarthrodial joints, due to their anatomical features, are well suited and studied 
for intra-articular (IA) injections. The main benefit of IA administration over oral or 
intravenous drug delivery is related to the increased drug concentration at the target 
place and, a consequent reduction of its systemic toxicity.
1–4
 The main drugs used for 
the treatment of arthropathies and improvement of knee homeostasis that are currently 
available on the market are COX-2, TNF-α, IL-1 and IL-6 antagonists administrated 
systematically. Only very few products are available for local delivery.  
2. The advances in the biopharmaceutical field along the past decades have led to the 
development of drug delivery systems (DDSs) that release the drug in a controlled 
manner in the articular cavity, thereby improving the efficacy/toxicity balance of the 
drug.
3,5
 Nevertheless, IA drug delivery remains challenging mainly due to the 
premature elimination of the DDS from the synovial cavity along with fast synovial 
fluid (SF) turnover.
3
 Among the DDSs developed for the local treatment of 
arthropathies are nano-/microcarriers and hydrogels,
2,3,5,6
 being the most promising 
and advanced formulations a combination of both systems.
7–12
 Such DDSs allow 
increased retention and prolonged release of the drugs in the joints compared with the 
same drugs administered in solution.
3,13
  
3. Articular cartilage has a limited ability for self-regeneration.14–16 Besides, SF greatly 
loses its intrinsic functions at pathological joints conditions.
17
 Having this in mind, 
multifunctional drug delivery carriers should contribute to diarthrosis healing. They 
should not only provide a controlled and prolonged drug release, but also be 
composed of deformation-resistant materials that may have a prolonged retention in 
the articulation. Simultaneously, such a nanotechnology-based platform should ideally 
work as a viscosupplementation agent for improving the knee homeostasis, and as an 
in situ cell scaffold for cartilage tissue regeneration.  
4. The discovery of novel immune targets is driving research towards the development 
of highly specific antagonists for more effective therapies.
18–21
 This is the case of the 
extracellular protein galectin-3 (Gal-3), which was recently identified as a primer 
trigger of inflammation.
22,23
 Moreover, this protein favors the secretion of 
macrophage pro-inflammatory cytokines, chemokines,
22
 and matrix 
metalloproteinases,
24











1. The use of drug-loaded nanocapsules (NCs) dispersed in in situ hydrogels, composed 
by hyaluronic acid (HA) and fibrin, can substantially increase intra-articular drug 
retention time. NCs can act as multireservoirs for lipophilic drugs, and will allow 
controlled release, while in situ hydrogel might protect NCs from the fast 
decomposition, endocytosis and efflux from the synovial cavity contribution to the 
modulation of drug release as well. Such an injectable composition of NCs combined 
with in situ hydrogel could also have a role in maintaining the knee hemostasis. This 
is supported by the fact that both, olive oil core and 700 kDa HA coating of the NCs 
that have anti-inflammatory properties.
26–29
 Besides, HA-fortified fibrin 3D hydrogel 
should serve as a viscosupplement with elastic properties for IA persistence and a 




2. Since blocking of traditional COX-2 and pro-inflammatory cytokines TNF-α, IL-1, 
IL-6 has not led to the adequate alleviation of the inflammatory joint diseases,
3,5,33–35
 
we hypothesize that targeting to the novel immune target galectin-3,
22
 could help to 





Based on the background information and outlined hypothesis, the objective of this 
thesis has been double, on the one hand, to develop a new injectable hydrogel 
containingnano-reservoirs for the prolong release of lipophilic drugs to the intra-articular 
cavity; on the other hand, to synthesize a new galactin-3 antagonist and its incorporation in 
the before-mentioned hydrogel for in vivo evaluation. 
 
For this purpose overall aims have been aligned with the following experimental 
activities: 
 
1) Development and in vitro assessment of a new DDS intended for intra-articular 
administration 





1. To develop new dexamethasone (as a model drug)-loaded NCs and to characterize 
them with regard to their physicochemical properties, stability in simulated synovial 
fluid and stability upon storage.  
2. To design and develop a novel injectable intra-articular hydrogel, and study the 
influence of its composition on the gelation time as well as on its rheological and 
mechanical properties. 
3. To study the hydrogel formation in the presence of the NCs and the modification of 
its rheological properties and its microscopic architecture. 
4. To optimize and characterize two DDS made of NCs combined with in situ hydrogels 
designed for acute- and chronic-joint inflammatory rat models differed by additional 
fortification of the interpenetrating network.  
5. To test the in vitro release profile of dexamethasone from the NCs loaded in the gel. 
 
The results corresponding to these objectives are presented in Chapter 1: 
“An injectable, in situ hyaluronic acid-fibrin hydrogel containing nanocapsules for 
prolonged intra-articular drug delivery”. 
 
2) Anti-inflammatory drug synthesis, incorporation into the developed DDS and in 
vivo activity assessment 
 
6. To design and synthesise a small-molecule-antagonist of extracellular galectin-3 (Gal-
3), using its natural ligand type II lactosamine [Gal(1→4)-GlcN] core, modified with 
aromatic substituents to greatly amplify its affinity and specificity. 
7. To characterise the obtained Gal-3 inhibitor, test its affinity and selectivity among 
Gal-1/Gal-3/Gal-7, compare with the first commercial low MW Gal-3 inhibitor 
(TD139) and select the most potent synthetic inhibitor for in vivo evaluation.  
8. To incorporate Gal-3 inhibitor in the developed DDS, characterise its 
physicochemical properties, and test the in vivo anti-inflammatory activity in a 
carrageenan-induced acute knee joint synovitis rat model. 
 
The results related to this work are presented in Chapter 2: 
“New galectin-3 inhibitor as a lead compound for anti-inflammatory drug 
candidates”. 
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Controlled release drug delivery systems (DDSs) that can be easily injectable into the 
intra-articular cavity are appealing for the treatment of joints pathologies. In this work, we 
present a novel intra-articular DDS consisting of nanocapsules (NCs), composed of an oil 
core and a hyaluronic acid (HA) shell, dispersed in an in-situ forming hydrogel. The NCs, 
with a mean particle size of 135 nm and a negative surface charge (−31 ± 5 mV), were loaded 
with the anti-inflammatory drug dexamethasone (DXM) and, subsequently, dispersed in a 
hydrogel consisting of a HA-fibrin interpenetrating network, fortified with factor XIII and α-
2 antiplasmin. The gelation time and microarchitecture of the hydrogel could be controlled by 
adjusting the concentration of thrombin, HA, factor XIII and the MW of HA. Hydrogel 
samples loaded with up to 30% (v/v) of NCs, showed adequate rheological properties for 
intra-articular application. Microscopy studies revealed random distribution of NCs within 
the hydrogels. The morphology and porosity of the hydrogels showed a regular structure with 
a narrow pore size distribution and mean pore diameter of 4.88 ± 1.12 μm. The release 
studies from non-fortified HA-fibrin hydrogels with 30% (v/v) NCs loading showed a 
controlled release of DXM to simulated synovial fluid for 72 hours. In conclusion, this intra-
articular DDS, which has been designed to resist the fast degradation by rheumatic synovial 
fluid enzymes and to serve as a viscosupplement, might be of interest for the treatment of 
















Despite the interest of the intra-articular (IA) administration of drugs for the treatment 
of joint diseases, this type of therapies remain challenging due to the rapid elimination from 
the articular cavity of the injected drugs through the synovial capillaries (for low molecular 
weight drugs) or the lymphatic vessels (for high molecular weight drugs).
1–5
 Intra-articular 
(IA) drug delivery systems (DDSs) have been developed with the objective of improving the 
treatment of arthropathies
3,5
 by reducing systemic exposure and, hence, off-target effects.
3,4,6,7
 
The work in this area, aiming at prolonging drug release in the joint cavity, has been so far 
oriented towards the development of two types of DDSs: nano-/microsystems and hydrogels. 
1.1. Nano- and microsystems for IA delivery 
Nanoparticles (NPs) injected into the joint cavity may penetrate into the cartilage 
extracellular matrix (ECM) and interact with collagen fibers particularly when their particle 
size is < 100 nm. For larger sizes, nanoparticles can be internalized by macrophages, synovial 
macrophages-like cells or dendritic cells. Similarly, microparticles are also prone to be either 
phagocytized (< 20 µm) or remain in the synovial fluid (SF), adhere to the cartilage and 
synovium or become entrapped within synovial folds (> 20 µm).
5,8–10
 
At present, only one liposomal formulation for IA application is available for the 
treatment of inflammatory osteoarthritis (OA) (Table 1). The liposomal formulation, 
(Lipotalon®), which contains dexamethasone 21-palmitate,
11–13
 has shown a maximal 
therapeutic effect on day 4 and the lowest disease activity index score at 16 days post 
injection.
12,14,15
 Another liposomal formulation, Clodrosome®
 
(Encapsula NanoSciences 
LLC, USA), loaded with clodronate (antiosteoporotic cytotoxic drug), has been found to be 
effective in a preliminary clinical trial (7 days study) on patients with RA and has been 
marketed for non-human RA model studies (Table 1).
16–18
 On the other hand, a new product 
PLGA microspheres (MS), namely Zilretta™/FX006 (Flexion Therapeutics, USA), 
containing corticosteroid drug triamcinolone acetonide, has recently been approved by FDA 
and reached the market for OA treatment (Table 1).
19,20
 The therapeutic effect of this 
formulation was maintained for up to 12 weeks.
19–22
 Overall, these formulations have been 
shown to reduce the systemic drug toxicity thanks to the improvement of its retention in the 






Table 1. Marketed formulations or in clinical trials based on nano-/microsystems for joints 
























































The commercialization of these products has encompassed a quite active research 
activity in the field of liposomes and nano-/microparticles for intra-articular application made 
of a variety of biomaterials.
25–30
 The most important recent advances with these formulations 
in vivo are summarized in Chapter Introduction, Table 3. Overall, these liposomal or 
polymeric formulations containing anti-inflammatory or disease-modifying anti-rheumatic 
drugs have shown expected PK/PD changes and increased drug residence time and, 
consequently, an enhancement of their efficacy and a reduction of their systemic toxicity.  
The drugs that have been more extensively studied are corticosteroids (i.e 
dexamethasone (DXM), betamethasone, prednisolone), NSAIDs (i.e. diclofenac, 
indomethacin), DMARDs cytotoxic drugs (i.e. methotrexate, paclitaxel, clodronate), and 
others, such as kartogenin and actarit.
9,31–48
 With regard to the composition of the 
nanosystems, in most cases they have been made of lipids (liposomes), polyesters (e.g. 
PLGA, PLA nanoparticles) and polysaccahrides (e.g. chitosan nanoparticles). Despite of the 
positive initial in vivo data obtained with these formulations, their therapeutic responses have 
not been as long-lasting as expected. In fact, the longest response has been reported for the 
thermo-responsive Pluronic F127/chitosan nanospheres for co-delivery of kartogenin and 






2 week retention time in joints.
48,49
 A strategy to prolong the dwelling time of the 
nanoparticulate systems has relied on making them interactive with the surrounding 
environment. For example, cationic (Eudragit RL100 or PLGA/Eudragit RL) NPs, with the 
capacity to interact with endogenous HA, formed an in situ gel once injected to the rat joint 
cavity.
50,51





Due to their rheological properties hydrogels have received significant attention as IA 
drug delivery systems. As a result of the intense research in that field some formulations has 
already reached the market. This is the case of viscosupplementation agents, consisting of 
crosslinked high MW HA
52–63
 or HA derivatives, an example of which is Hymovis® that 
contains a hexadecylamide derivative of HA.64–66 The prolonged residence time of these 
hydrogels in the articular cavity
5,60,67
 has resulted in a long-lasting effect on OA patients (up 
to 26 weeks),
60,66
 and RA animal models (up to 8 weeks).
67
 The longest therapeutic effect for 
a HA-based hydrogel has been reported for Crespine®
 
(6-8 months), which is indicated for 
the treatment of OA. However, a limitation of these hydrogel therapies is related to their high 




In addition to the viscosupplementation properties, these hydrogels have also been 
used for the controlled delivery of drugs. For example, a crosslinked HA gel with pre-mixed 
DXM has been shown to significantly extend the drug release in an OA rat model. As a 
consequence, the gel significantly reduced the inherent DXM toxicity providing an anti-
inflammatory and chondroprotective effect at 12 weeks after the injection.
71
  
A different strategy has relied on the design of in situ forming hydrogels that are easy 
to inject and exhibit a prolonged residence time in the articular cavity. Among them, it is 
worth mentioning a radiopharmaceutical pH responsive Holmium-166-chitosan hydrogel
72
 
tested in Phase II clinical trials for the treatment of knee synovitis in RA.
73
 Another example, 
so far only tested in rats, is a thermosensitive triblock poly(ε-caprolactone)-poly(ethylene 
glycol)-poly(ε-caprolactone) copolymer hydrogel, which has been proposed for the controlled 
delivery of methotrexate. However, the drug release from this hydrogel could only be 








1.3. Nano-/microsystems-loaded hydrogels 
Recent attention has also been paid to the combination of drug loaded nano-
/microsystems with hydrogels aiming at improving the residence time in the synovial cavity 
and the drug release profile.
75–77
 These nano-/microcarrier-containing hydrogels were 
reported to control the delivery of the associated drugs for about a month
78–80
 or even 
longer.
81
 Nevertheless, overall, the work of in situ-forming hydrogels containing drug-loaded 
nano-/microparticles is at a very early stage and only a few of these formulations have been 
tested in vivo (Table 2).78,79,81,82 
In most of the cases these combined systems were tested in healthy animals and their 
residence time and prolonged release at inflamed joints remains unknown. An exception is 
represented by the radio-labelled liposomes (235 nm) incorporated into a Carbopol 
940/carboxymethylcellulose gel, which was evaluated in a rabbit induced arthritis model, and 
was shown to be 67% retained in the articular cavity at 24 h after injection.34,83 In healthy rat 
joints the maximal sustained-released reached 42 days post IA injection by using 






Table 2. Nano-/microsystems loaded into hydrogels for IA applications tested in vivo. 
 
Drug Drug delivery system In vivo model Key observation Ref. 
Celecoxib 
(NSAID) 
Precipitates/crystals (size non defined) 
dispersed in a poly(ɛ-caprolactone-co-lactide)-
b-poly(ethylene glycol)-b-poly(ɛ-caprolactone-




The degradation and the release profiles were tested by 
different routes of administration: 
3) In the articular cavity the DDS degraded between 
week 3 and 4. Release was not evaluated. 
4) At subcutaneous injection in rats gel degradation 
happened in ~12 weeks, ∼30 % celecoxib 
released during the first 3 days followed by a 





Polyethylene glycol (PEG)-microspheres (40–
100 µm) crosslinked by short PLGA chains to a 
hydrogel. Two populations: slow degradable 
and non-degradable 
Healthy sheep 
shoulder joint  
At 4 weeks non-degradable MS and not completely 
degraded MS were found, in synovial fluid and in the 
synovium. Degradable MS caused low inflammation 





Precipitates/crystals (size non defined) 
suspended in glyceryl monooleate-HA hydrogel 
(in situ) 
Healthy rat 
This formulation showed sustained-released during 42 





Monomethyl poly(ethylene glycol)-poly(ε -
caprolactone) 
(MPEG-PCL) micelles  
(25 nm) incorporated into thermosensitive in 







The gel biodegradation was evaluated upon subcutaneous 






Lipogelosomes: Radio-labelled liposomes 
DMPC–CHOL–DCP (235 nm) incorporated 





Scintigraphic imaging showed 67% retention of the 








1.4. Rational design and selection of the DDS components  
An intra-articular DDS should fulfil a number of properties, such as biocompatibility, 
and biodegradability, in addition to an effective and prolonged disease improvement.
85
 
Another distinctive feature is bioadhesiveness,
86
 which allows to increase the residence time 
of DDS in the synovial cavity and impart the chondroprotective effect.
87
 
Taking these criteria into account, we have developed a novel in situ HA-fibrin 
hydrogel containing HA nanocapsules (NCs). NCs serve as multireservoirs for lipophilic 
drugs, i.e. DXM, used as a model anti-inflammatory drug in this study. The hydrogel 
prevents the fast and uncontrolled biodistribution of the NCs, thereby extending the effect of 




Figure 1. Schematic illustration showing the intra-articular injection of an in situ forming 
hydrogel. Adapted and modified from
8
 with permission, Copyright© 2009, Taylor & Francis. 
 
HA was selected as a biomaterial to form the hydrogel due to it essential role in 
diarthrodial joints homeostasis.
55,88–91





 working as a physical barrier, providing the joint with adequate 
lubrication in addition to a chondroprotective effect.
3,89,90
 Furthermore, HA provides 
viscoelasticity of SF and viscoinduction (promoting the endogenous HA synthesis); it also 
has anti-inflammatory and antinociceptive properties.
88,90,95
  
The other key component of the hydrogel, fibrin, is a biomaterial derived from human 






corporation, USA) for postsurgical tissue healing.
96–98
 It has been used to prepare different 
hydrogels, in combination with other polymers,
86,99–103
 noteworthy, with HA that has received 




Hence, we exploited the affinity of high MW HA to fibrin
108–110
 and their capacity to 
form interpenetrating 3D networks (IPN),
99,101,104
 through covalent and ionic 
interactions.
108,110
 The synergistic effect of HA and fibrin is expected to provide the resulting 
hydrogel with improved mechanical properties and resistance against intra-articular 
deformations.
101,111
 Aiming at extending the residence time in the articular cavity, fibrin was 
fortified by factor XIII (FXIII),
112,113
 its natural covalent crosslinker,
96,114
 and α2-antiplasmin 
(α2AP) in order to reduce the degradation by enzymes of pathological synovial fluid.
115–118
 
Additionally, HA, as the main component of hyaline cartilage, together with fibrin are 
essential for chondrocytes-ECM interactions, migration, proliferation, and differentiation 
what can be an advantage for regeneration of the damaged tissue if they are included in a 
DDS.
105,106







 of the components could contribute to an adequate joint healing. In 
order to validate the potential of our in situ-forming hydrogel we selected DXM, a potent 
synthetic anti-inflammatory corticosteroid,
122
 widely used for the treatment of arthropathies.
71
 
Within the context of this work it is important to mention that RegenoGel™, 
composed of fibrinogen chemically linked to a high molecular weight HA, has been recently 
approved as a medical device of next generation by the Israeli Ministry of Health for 
degenerative joint diseases, primary for OA.
123
 Moreover, its modified form (RegenoGel-
OSP™ that uses autologous patient’s plasma, instead of fibrinogen) now in Phase I/II clinical 
trials, has also shown an unprecedented response in long pain relief, superior stability and 
mechanical integrity, along with a strong chondrogenic effect. No adverse effects, neither 









2. MATERIALS AND METHODS 
 
2.1. Materials  
 
Fibrinogen and thrombin, both from human blood plasma (premium quality grade) 
were purchased from Sigma-Aldrich, Germany. Sodium hyaluronate (research grade) of 
different average molecular weights 51 kDa, 752 kDa and 1.38 MDa, with trade names 
40 kDa, 700 kDa, 1.5 MDa, correspondingly, were acquired from Lifecore Biomedical, USA. 
Factor XIII (FXIII) from the human blood plasma (>95% pure) was obtained from 
Haematologic Technologies, Inc, USA. Alpha-2 antiplasmin (α2AP) from human blood 
plasma (>95% pure) was bought from Lee Biosolutions, USA. Dexamethasone (97.2%) was 
purchased from Acofarma, Spain. The stabilizing surfactants, phosphatidylcholine enriched 
soy lecithin (EPIKURON® 145 V) was a kind gift from Cargill, Spain, and oleylamine and 
Tween 80 were bought from Sigma-Aldrich, Germany, all of high-purity grade. Labrafac
™
 
Lipophile WL1349 was acquired from Gattefossé, France, Poloxamer-407 (Kolliphor® P 
407) was obtained from Basf, Germany, Lipoid PEG-2000 was purchased from Lipoid, 
Germany, all of pharmaceutical grade. Virgin olive oil (extra pure) was purchased from 
Acros Organics, Belgium. Nile red (technical grade), HEPES, BSA (≥98%), sodium chloride, 
calcium chloride dihydrate, potassium chloride, sodium phosphate dibasic and potassium 
phosphate monobasic of ≥99% purity, were acquired from Sigma-Aldrich, Germany. Human 
synovial fluid (rheumatoid arthritis) was purchased from SeraLab, UK. Ultrapure (Milli-Q) or 
endotoxin-free water was used throughout the experiments and organic solvents were of 
HPLC grade.  
 
2.2. Preparation and characterization of HA NCs 
 
2.2.1. Preparation of HA NCs 
 
HA NCs were produced by the solvent displacement technique, adapting the 
procedure earlier described by our group.
126
 Briefly, lecithin (Lec, 5.625 mg), oleylamine 
(OAm, 1.125 mg) and olive oil (OO, 30 mg) were dissolved in 5 mL of ethanol. In the case of 
drug loaded NCs, DXM (8.1 mg or 2.5 mg) was incorporated to the ethanol, and for labeled 






injected under pressure through a needle (23G) to 10 mL of aqueous phase containing 2.5 mg 
of HA 700 kDa, and kept under magnetic stirring at 900 rpm during 10 minutes at room 
temperature. The elimination of organic solvent was performed by evaporation under vacuum 
(Rotavapor Heidolph, Germany) and the final volume was adjusted to 5 mL with ultrapure 
water. Thereafter, the NCs were isolated by ultracentrifugation (Avanti® J-E, 
Ultracentrifuge, Beckman Coulter, USA) at 30,000×g for 1 h at 15 °C. 
 
2.2.2. Physicochemical and morphological properties of HA NCs 
 
The mean size and polydispersity index (PDI) of the HA NCs were measured after 
dilution (100×) with ultrapure water by dynamic light scattering (DLS) at 25 °C with an angle 
detection of 173°. The zeta potential (ζ) was measured by laser Doppler anemometry (LDA) 
after diluting the samples (100×) with ultrapure water. Both DLS and LDA analysis were 
performed in a Zetasizer®, NanoZS, Malvern Instruments, Malvern, UK. Particle size 
distribution and morphology were evaluated by transmission electron microscopy (TEM) 
using a JEOL JEM-2010 microscope, 200 kV, resolution: 0.23 nm (Tokyo, Japan). Samples 
for TEM analysis were diluted (20×), deposited on a copper grid, stained with a 
phosphotungstic acid solution (2% w/v) and allowed to dry overnight prior to analysis. The 
pH of nanoformulations was measured at Sartorius Basic Meter PB-11, Sartorius AG, 
Germany. 
 
2.2.3. Determination of dexamethasone concentration in the formulation 
 
The dexamethasone (DXM) concentration was determined after the isolation of the 
NCs by ultracentrifugation at 30,000×g for 1 h at 15 °C (Avanti® J-E, Ultracentrifuge, 
Beckman Coulter, USA). The amount of the free drug in the undernatant was quantified by 
high-performance liquid chromatography (HPLC), described below. For the extraction of 
DXM 0.1 mL of sample were mixed with 0.9 mL ethanol/acetonitrile (ACN) and kept under 
magnetic stirring at a high speed overnight to obtain a clear solution. The samples were 
analyzed by HPLC, using a method adapted from the literature.
127–129
 The HPLC system 
consisted of a VWR-Hitachi LaChrom Elite® system equipped with a UV detector L-2400 
set at 239 nm and a reverse phase SunFire column 186002560, 100Å, C18 (4.6 ID × 250 mm, 
pore size 5 μm), Waters, USA. The mobile phase was a mixture of methanol and ultrapure 






30 °C and the injection volume was 20 μL. The standard calibration curves of DXM were 
linear in the range of 1-1000 μg/mL (r
2
 = 0.999). Samples were transferred into auto-sampler 
vials, capped and placed in the HPLC auto-sampler. The concentration of DXM in the 
aliquots was used to calculate the free amount of DXM and, indirectly, its concentration in 
the final system. 
 
2.3. Preparation of blank and NCs-loaded HA-fibrin in situ forming hydrogels  
 
2.3.1. Preparation of HA-fibrin in situ forming hydrogels  
 
The HA-fibrin in situ hydrogels matrixes were obtained by thrombin (Thr)-activated 
enzymatic polymerization. For this purpose the following stock solutions were prepared.   
Lyophilized powder of fibrinogen (Fg) from human blood plasma was dissolved in 
0.15 M solution of NaCl at 37 °C to a final concentration of 25 mg/mL, aliquoted and stored 
at -20 °C. Before each experiment, an aliquot was thawed at 37 °C for 30 min and was 
maintained at 37 °C no more than 2 hours.
130
 
Lyophilized powder of thrombin from human blood plasma was dissolved in cooled 
to 4 °C PBS buffer (0.01 M Na2HPO4, 0.0018 M KH2PO4, 0.137 M NaCl, and 0.0027 M 
KCl, pH 7.2) to a final concentration of 100 NIH-U/mL. Thrombin activity is usually 
expressed in NIH-U/mL, established by National Institute of Health standard for the 
calibration of commercial thrombin reagents,
131
 taken 1 NIH-U = 0.324 ± 0.073 μg (9.0 nM). 
Additionally, 1% (w/v) solution of BSA was added as stabilizing agent. Thrombin was 
aliquoted and stored at -20 °C. Before each experiment the aliquot was thawed on an ice 
plate. 
Sodium hyaluronate (HA) of different MW 40 kDa, 700 kDa and 1.5 MDa was 




” (0.02 М HEPES, 0.1 М 
NaCl, 10
-4




” (0.02 М HEPES, 0.1 М 
NaCl, 10
-3
 М CaCl2, pH 7.4) to 0.1%, 0.25%, 0.5% and 0.65% (w/v) solutions. The solutions 
were incubated at 37 °C under shaking during 2 hours to dissolve HA and were stored at 
4 °C. Additionally, HA mixed solutions 0.5% and 0.65% (w/v) made from HA 700 kDa : HA 
1.5 MDa  = 1:1 were prepared.  
Factor XIII from human blood plasma was aliquoted and kept in 50% glycerol, 






Lyophilized powder of α2-antiplasmin (α2AP) from human blood plasma was 
dissolved in PBS buffer (0.01 M Na2HPO4, 0.0018 M KH2PO4, 0.137 M NaCl, and 0.0027 M 
KCl, pH 7.2) + 1% (w/v) BSA as carrier and stored at concentration 0.1 mg/mL at -20 °C. 
The hydrogel preparation was started with testing the gelation time of Fg by the action 





” to final concentration 1 mg/mL and by the action of Thr in the range of concentrations 
0.1-2 NIH-U/mL was converted to the gel.  
Later, we tested the influence of HA on fibrin gelation and obtained so-called HA-
fibrin hydrogel. Fg at a fixed concentration of 1 mg/mL was mixed with HA solutions of 
40 kDa, 700 kDa and 1.5 MDa and theirs mixtures at concentrations of 0.1%, 0.25%, 0.5% 




” gelated upon addition of Thr in the range of 
concentrations 0.1-1 NIH-U/mL. Finally, 0.5% (w/v) mixture of HA 700 kDa : HA 1.5 MDa  
= 1:1 was selected at the optimized third component to enable syringeability due to moderate 
viscosity and postponed gelation time.   
To formulate fortified HA-fibrin hydrogel FXIII at final concentration 10 µg/mL and 
α2AP at final concentration 0.14 µg/mL were added to the Fg (1 mg/mL) and HAs 0.5% 




”. Thr was 
added as the last component at 0.75-1 NIH-U/mL to initiate the polymerization. 
 
2.3.2. Loading of HA NCs into the hydrogel 
 
The maximum loading of isolated HA NCs to in situ hydrogels was performed 
for non-fortified and fortified HA-fibrin hydrogels. Prior the experiments Fg samples, 0.5% 










” and blank or drug loaded HA NCs were warmed up at 37 °C for 30 minutes. For the 
samples preparation, we used fibrin at concentration 1 mg/mL and 1.5 mg/mL, 0.5% (w/v, 









”, and FXIII 10 µg/mL, α2AP 
0.14 µg/mL (in case of fortified HA-fibrin hydrogels), as summarized in Table 3. The 
reaction was initiated by Thr (1-2 NIH-U/mL). In situ hydrogel NCs loading capacity in the 







Table 3. Composition of fortified HA-fibrin hydrogel with 30% loaded NCs. 
Composition Final concentration  
Fg 1-1.5 mg/mL 
Thr (added as a last component) 1-2 NIH-U/mL 





, pH 7.4 
0.5% 
DXM NCs  30% 
FXIII 10 µg/mL 
α2AP 0.14 µg/mL 
 
2.3.3. Determination of the hydrogel gelation time 
 
Determination of the lag-time and the gelation point was performed by turbidity 
analysis using UV-Vis scanning spectrophotometry (Manual Beckman-Coulter DU®730 
spectrophotometer, USA). The device was set up at the mode, allowing the measurement of 
the absorbance at 350 nm each 10 s within 20 min, recording the kinetics of the 
polymerization.  
The gelation point of blank and NCs loaded hydrogels was additionally measured in 
rheology studies, described in Section 2.4.5. 
 
2.4. Physical characterization of the hydrogels containing NCs  
 
2.4.1. Syringeability studies  
 
For this analysis, samples of HA-fibrin and fortified HA-fibrin gels with blank HA 
NCs were prepared as described in Section 2.3.1 and Section 2.2.1, correspondingly. 
Components mentioned in Section 2.3.3 and PBS buffer (0.01 M Na2HPO4, 0.0018 M 
KH2PO4, 0.137 M NaCl, and 0.0027 M KCl, pH 7.2) were warmed up at 37 °C 30 min before 
the experiments. All the components, including 30% NCs, were mixed and transferred to the 
syringe Terumo Myjector U-100 Insulin with superfine 29G needle, as usual Thr was added 
as the last component and mixed again before injection to the vial filled with warmed up to 






Hydrogel samples were prepared in the same way, although were injected to the 
cuvettes with no PBS buffer and were analyzed by UV-spectrophotometry as described in 
Section 2.3.2, to verify whether the value of absorbance correlates with the UV 
spectrophotometry data of gels formed without injection. 
 
2.4.2. Porosity and surface morphology  
 
The samples for SEM were prepared as described in Section 2.3.3. by the injection of 
blank and 30% NCs loaded non-fortified and fortified HA-fibrin in situ hydrogels to PBS 
buffer 1:1 and 1:1.73. Samples were shaken for 20 hours at 37 °C, then, the gels were rinsed 
with ultrapure H2O to extract the salt excess. The samples were frozen at -80 °C and 
lyophilized during 48 hours to preserve the structure. Afterwards, samples were transferred to 
the metal supports and coated with gold nanolayer and additionally sputtered with 5-nm-thick 
layer of Ti with an SPI sputter coater. All SEM images were obtained on SEM EVO LS15 
with EDX, Resolution: 1kv SE e W (Zeiss) and FESEM ULTRA-Plus, Resolution: 1 kV e 
WD (Zeiss).  
 
2.4.3. Distribution of NCs within the hydrogel 
 
Nile Red labeled NCs were prepared according to the procedure described in Section 
2.2.1. The NCs distribution in the gels was analyzed by confocal laser scanning microscopy 
(SP5 Leica AOBS-SP5) without any additional processing. A lamp ion laser operated at 
530 nm wavelengths (corresponding to Nile Red maximum wavelength emission) was used 
as an excitation source. The images were taken at 50 μm and 490 μm the sample depth. 
 
2.4.4. 3D surface and porosity  
 
Non-fortified and fortified HA-fibrin hydrogels without and with NCs were prepared 
as described in Section 2.3.2. and were analyzed by a Wyko-NT1100 microscope (Bruker) 
that enables topographic sample characterization using non-contact White Light Optical 
Interferometry (WLOI) with the Vertical Scanning Interferometry (VSI) method. The images 
were analyzed by WycoVision 32 analytical Software package. The hydrogel hydrated and 






and an intermediate ×0.5 to obtain a magnification of 25.6×, with a field of view of 
241×183 μm
2
 of the samples. At least three zoomed areas from these topographic images 
were analyzed. 
Three-dimensional parameters of surface texture and roughness: arithmetic mean 
height (Sa), root mean squared height (Sq), maximum height (Sz), skewness (Ssk), and kurtosis 
(Sku) represent the statistical distribution of height values and were calculated by standard 
equations according to International Standard ISO 25178-2. The contribution due to dominant 
geometric shape and plane inclination were eliminated in these calculations. Ssk represents the 
degree of symmetry of the surface heights about the mean plane. The sign of Ssk indicates the 
preponderance of peaks (that is Ssk > 0) or valley structures (Ssk < 0) that the surface contains. 
Sku reflects the nature of the height distribution and, therefore it is useful for indicating the 
presence of either peak or valley defects such as scratches. If the surface heights are normally 
distributed (a bell curve) then Sku is equal 3.00. Surfaces composed of inordinately high 
peaks/deep valleys have Sku > 3.00. Sku < 3.00 indicates gradually varying surfaces.  
 
2.4.5. Rheological behavior of hydrogels 
 
A Discovery Hybrid Rheometer (DHR-2 from TA Instruments) with a standard steel 
parallel-plate geometry of 20 mm diameter together with a Physica MCR 101 rheometer 
(Anton Paar, Graz) working with a plate-plate geometry with a diameter of 25 mm and a 
constant gap of 0.5 mm were employed for the rheological measurements of hydrogel 
samples. The agreement between the results in the two devices was checked and achieved in 
both non-linear viscoelastic tests and oscillatory shear mode. Firstly, flow curves for HA-
fibrin hydrogel were carried out with the aim to obtain the initial viscosities. Then, the 
methods employed were oscillatory time sweeps, strain sweeps, and frequency sweeps. Time 
sweep experiments were performed to monitor, into a time frame, the in situ gelation of the 
blank and NCs loaded hydrogel samples. During these time sweeps, a torque of 0.9 N·m 
and a frequency of 0.5 Hz were maintained for a maximum time of 30 min to account for the 
temporal evolution of the elastic or storage modulus G' and the viscous or shear loss 
modulus, G''. Strain sweeps were carried out to characterize and compare G'/G'' ratios under 
the same physical conditions identifying the linear viscoelastic region (LVR) in the strain 
range from 0.1% to 1,000% or until structure breakdown. These tests were set up holding the 






Moreover, hydrogels were also subjected to oscillatory frequency sweep experiments, which 
were performed at frequencies from 0.01 to 100 Hz taking into account the obtained LVR 
profiles. As it is well known, frequency sweep tests are widely used to obtain information 
about the stability of three-dimensional crosslinked networks.
133
  
The measurements were taken at 20 °C and/or 37 °C and all samples were reproduced 
three times with good accuracy. The results were analyzed directly from the software 
controlling the experimental devices (Trios Software for DHR-2 rheometer and Rheoplus 
Software for Physica MRC 101) and the polymerization reactions of hydrogels were studied 
by recording both elastic and viscous modulus. 
 
2.5. In vitro release studies 
 
2.5.1. Simulated synovial fluid (SSF) preparation  
 
SSF was reproduced following the protocol described by Margareth and Raimar
132
 
and contained 0.017 M NaCl, 0.0027 M KCl, 0.01 M Na2HPO4, 0.00176 M KH2PO4, 
3 mg/mL HA (non-specified MW), pH 7.4. We used 1.5 MDa HA as one of the high MW 
HA presented in the normal human SF able to maintain predetermined viscosity.    
SSF was applied to test stability of NCs in the hydrogel, the drug release from this 
system and measurements of refractive index (RI). 
 
2.5.2. SSF refractive index  
 
The measurements of RI values of SSF were performed for further NCs stability 
studies by DLS. SSF sample was prepared as described in Section 2.3.5 and analyzed by 
using an automatic Abbemat-WR refractometer (Dr Kernchen), which has an uncertainty of 
4 × 10
-5
 and control of temperature with 0.01 °C resolution. The apparatus was calibrated by 
measuring Millipore quality water and pure solvents before the sample analysis. The RI 






2.5.3. In vitro DXM release studies from the gel to SSF 
 
To study the release of DXM from the NCs loaded hydrogels to SSF, the samples 
were prepared as described in Section 2.3.2. In situ HA-fibrin hydrogel with 30% DXM 
loaded NCs was formed in SSF, pH 7.4 (a ratio 1:1.3 was selected to comply with in vivo 
model), Table 4.  
 
Table 4. The preparation of HA-fibrin/fortified HA-fibrin hydrogel with 30% loaded DXM 
NCs for release studies. 
 




30% DXM NCs  91.2 
Total gel system 305 
SSF 395 
Total composition 700 
 
Briefly, each vial correspondent to specific time point withdrawal, contained SSF 
were placed in an incubator at 37 °C with horizontal shaking for 20 minutes before warmed 
to 37 °C gel components with and DXM NCs were added to SSF and well-mixed. Hydrogels 
were let 30 minutes to be completely formed at 37 °C with horizontal shaking (300 rpm) and 
maintained at these conditions along the experiment. Once formed, at different time intervals 
(from 0 to 72 h), until the complete gel degradation, 100 µL of the medium surrounding the 
gel were withdrawn and mixed with 300 µl EtOH (1:3) to extract the released DXM. The 
amount of released DXM was determined by HPLC as described in Section 2.2.3. 
 
2.6. Statistical analysis 
 
All the measurements at each experimental condition were carried out in triplicates 
and were expressed as mean ± standard deviation (SD). Statistical analysis of the data was 
performed using a one-way ANOVA and Student’s t test using Microsoft® Excel software; a 






3. RESULTS AND DISCUSSION 
 
In this work, we designed, developed and characterized an injectable in situ forming 
HA-fibrin crosslinked hydrogel loaded with HA NCs. This formulation is intended to extend 
the retention of the NCs in the intra-articular cavity and to control the delivery of the 
associated drug (DMX). This hydrogel is supposed to act as a reservoir for controlled release 
of hydrophobic drugs and a viscosupplement with viscoinductive properties. 
 
3.1. Preparation and characterization of DXM-loaded HA NCs  
 
Although a number of authors have described the potential use of nanosystems for the 
IA drug delivery of drugs, the success of these DDSs relies on their final fate. Indeed, 
nanosystems may suffer from a rapid efflux from the articular cavity
4,5
 and they may also be 
taken-up by synovial macrophages, dendritic cells and chondrocytes.
8,134
 In this regard, it has 
been shown that particles with sizes below 100 nm
135–137
 and above 20 µm are not prone to be 
endocytosed by macrophages and chondrocytes.
8,9,138,139
 On the other hand, the diameter of 
blood capillaries (2-3 µm) and the lymph vessels (8-30 µm),
5,16,140
 prevent the elimination of 
large particles,
5,50,141
 whereas very small NPs may drain to the blood or the lymphatic 
circulation and even diffuse across the cartilage ECM.
8
 An additional advantage of NPs vs. 
large particles relies in the small size of the needle required for the injection and the fact that 
smaller particles were expected to cause no mechanical cartilage damage in the joint.
50
  
Taking this information into account, our objective was to obtain HA NCs with a size 
close to 100 nm and to load them with the model drug DXM prior to their incorporation into 
a hydrogel. The purpose behind this system is to avoid the drainage to the systemic 
circulation and, at the same time reduce the macrophages up-take.  
Prior to the NCs formulation, we performed a thoughtful selection of their 
components. Among the different oils tested (caprilic/capric acid triglicerides and olive oil 
(OO)), we selected extra pure virgin OO due to its anti-inflammatory properties
142,143
 and 
because of its capacity to dissolve DXM.
144
 Soy lecithin (Lec) and oleylamine (OAm) were 
selected in order to produce cationic nanoemulsions to which the HA molecules to be 
attached.
145,146
 HA (700 kDa) was selected as a shell polymer as this molecular weight was 
found to exhibit anti-inflammatory responses.
90
   
HA NCs were prepared by the solvent displacement technique, a mild and easily 
scalable preparation method, previously described in our laboratory.
147






surfactant/cationic surfactant/shell polymer 4:1:0.2:0.5 yielded stable 100 – 200 nm NCs. The 
injection under pressure of the organic phase over the aqueous phase was applied in order to 
decrease the NCs size. The particle size, zeta potential and encapsulation efficiency of two 
different formulations are summarized in Table 5. The first prototype with encapsulated 
DXM was prepared with a ratio slightly modified of DXM/OO/Lec/OAm/HA = 1:6:1.5:0.3:1 
(prototype 1) to better control the NCs physicochemical properties, however, the DXM EE% 
was low (Table 5). On the other hand, in order to increase the DXM loading a new prototype 
of NCs (prototype 2) with a ratio DXM/OO/Lec/OAm/HA = 3.2:8.8:2.3:0.45:1 was prepared, 
with higher amount of oil and surfactants in an attempt to increase the drug content in the 
suspension (Figure 2). 
 
Table 5. Physicochemical characteristics of the nanocapsules (NCs) prepared with 700 kDa 























 prototype 1 15 3.75 0.75 128 ± 13 0.2 −27 ± 3 n/a 










prototype 1 15 3.75 0.75 160 ± 12 0.2 −20 ± 4 0.75 ± 0.125 








Figure 2. Representation of the structure of HA nanocapsule.  
 
The size of the NCs, obtained by DLS, was compared with TEM data. Images from 
electronic microscopy (Figure 3) revealed the spherical shape of NCs with considerably 
smaller particle size values compared to DLS data (Figure 3B and C). These results can be 
explained considering that TEM requires detection of NCs in a dry state, whereas DLS 





                  A                           B 
  
Figure 3. TEM images of HA blank nanocapsules: (A) at magnification 50,000×; (B) and 








3.2. Preparation and characterization of in situ forming hydrogels 
 
In order to increase the residence time of NCs in the articular cavity, we developed an 
in situ forming hydrogel, which in addition to having good rheological properties and high 
resistance to deformation after IA injection, would serve as a reservoir for the NCs. For its 
preparation we used a combination of HA and fibrin with crosslinking agents, i.e. factor XIII 
(FXIII) and α2-antiplasmin (α2AP). 
For the production of fibrin gel, we started with the precursor fibrinogen (Fg), at a 
concentration of 1 mg/mL, and investigated the time required for its polymerization by the 
action of different concentrations of thrombin (Thr, 0.1-2 NIH-U/mL) (Figure 4A and B). 








Figure 4. (A) Influence of thrombin (0.1 or 1 NIH-U/mL) on the fibrin gelation time. (B) 
Fibrin gelation points by the action of thrombin (0.1 - 2 NIH-U/mL) on fibrinogen. The 
range marked by dot-dash line represents the thrombin activity at which the hydrogels 
revealed the best stability profiles. The polymerization kinetics was determined by turbidity 
analysis during 20 minutes at λ = 350 nm. 
Fibrinogen was always taken at concentration 1 mg/mL. For thrombin (Thr), 1 NIH-U = 
0.324 ± 0.073 μg (9.0 nM). Expressed as mean ± SD; n = 3. 
 
 
In the first stage of polymerization, shown as the “fluid” phase in Figure 4A, fibrin is 
presented in the form of soluble fibrin-monomers. The second stage of polymerization
130
 is 
characterized by the lateral association of protofibrils to fibrils and their subsequente 
organization in the form of a 3D-network hydrogel.
150,151
 As shown in Figure 4A this process 






and, hence is named as “gel” phase. The times at which fibrin starts to polymerize (gelation 
points) were calculated from the kinetics curves of polymerization by the method described by 
Chernysh et al.
152
 (Figure 4B). 
Ca
2+
 ions are among the key factors controlling the speed of polymerization and final 
gel rheology, rigidity and porosity. Based on this, the buffer for hydrogel formation was made 
with a Ca
2+ 





 with a composition of 0.02 М HEPES, 0.1 М NaCl, 10
-4
 М CaCl2, pH 7.4. 
Taking advantage of the affinity between HA and fibrin’s positively charged E-
domain and αC-domains
150,151




 we explored the formation of HA-
fibrin hydrogels. We used HA polymers of different MW to study the influence of the 
macromolecule length in the polymerization process. We tested HA of three MW (40 kDa, 
700 kDa, 1.5 MDa) in different concentrations. The gelation point of the HA-fibrin system 
was calculated from the kinetics curves of polymerization, as described earlier for fibrin 
kinetics. For these experiments, 0.1%, 0.25%, and 0.5% (w/v) solutions of HA of each MW 
(40 kDa, 700 kDa and 1.5 MDa) and a mixture of 700 kDa and 1.5 MDa were used (Table 6). 
 
Table 6. Screening of compositions to optimize HA-fibrin gel formation. Fg: fibrinogen, Thr: 
Thrombin, HA: hyaluronic acid, FXIII: factor XIII, α2AP: α2-antiplasmin.  
 










Fibrin gel 1 0.1 - 2 - - - - 
HA-fibrin gel 1 0.5 - 1 
0.1 - 0.5% 40 kDa 
- - 
0.1 - 0.5% 700 kDa 
0.1 - 0.5% 1.5 MDa 
0.5% 
Mix 1:1 of 700 
kDa : 1.5 MDa 
Fortified HA-
fibrin gel 
1 0.75 - 1 0.5% 
Mix 1:1 of 700 
kDa : 1.5 MDa 
10 0.14 
 
As shown in Figure 5, in general, the higher the concentration of HA the higher the 






increase in HA concentration from 0.1% to 0.5% led to a significant increase in the gelation 
time. However, in the case of 40 kDa HA, the influence of the HA concentration had only a 
minor impact on the gelation process. On the other hand, 0.5% 1.5 MDa HA solution was 
highly viscous and, thus, difficult to inject. For that reason, a mixture of HAs (700 kDa : HA 
1.5 MDa = 1:1, 0.5%), with moderate viscosity, was selected to enable proper injection into 
the knee. In addition, the use of a mixture of HA of different molecular weights allowed us to 
modulate the gelation time to the one required for the adequate syringeability. This 
composition was also found to be good for viscosupplementations purposes.
153–155
 In this 
regard, it is worth noting that the marketed product RenehaVis®, which involves a 
combination of 1 MDa (2.2%, w/v) and 2 MDa (1%, w/v) HAs, is highly used for the long 
term treatment (12 months) of OA.
156–159
 Furthermore, HA with a MW of 0.5-1 MDa has been 
found to be effective in reducing synovial inflammation,
55,90,160
 while 1.3-1.7 MDa HAs are 





Figure 5. Comparative studies of the influence of different hyaluronic acid (HA) on fibrin 
polymerization kinetics (indicated as “without HA”). HA, 0.5% (w/v) of 40 kDa, 700 kDa, 





”. The polymerization kinetics was recorded by turbidity 
analysis during 20 minutes at λ = 350 nm. Fibrinogen was always taken at 1 mg/mL 
concentration, activity of thrombin (Thr) = 0.5 - 1 NIH-U/mL. The gelation point was 
calculated from the kinetics curves of polymerization. The numbers above the bars represent 
in how many times the gelation is inhibited compared to fibrin polymerization alone. 






To increase the in vivo half-life of the developed HA-fibrin hydrogel we incorporated 
FXIII and α2AP as fortifying components of the gel. FXIII is a natural fibrin covalent 
crosslinker that fortifies and stabilizes fibrin mesh increasing the resistance against the gel 
degradation by 5 times.
112,113
 Whereas, α2AP, incorporated into fibrin network, greatly 
reduces the degradation of crosslinked fibrin gels by plasmin, normally found in rheumatic 
SF.
115,117,118
 Hence, by adding FXIII and α2AP to in situ HA-fibrin hydrogel a fortified HA-
fibrin IPN was engineered (Figure 6). This combination of materials is expected to resist the 





Figure 6. The schematic illustration of the fortified HA-fibrin gel formation, activated by 
thrombin. HA: hyaluronic acid, FXIII: factor XIII, α2AP: α2-antiplasmin.  
 
We investigated the influence of FXIII and α2AP on the hydrogel formation by 
turbidity analysis. The results gathered in Figure 7 indicate that, as expected, the gelation 
time is reduced upon addition of FXIII. Overall, we could control the polymerization speed 
and the rheological properties of the developed hydrogel by adjusting different parameters, 





3.3. Loading of NCs into the in situ forming hydrogel 
 
We investigated the capacity of the hydrogel to load NCs in the range of 10 – 50% 
(v/v) (blank or drug-loaded NCs concentrated to 1 mL) in HA-fibrin and fortified HA-fibrin 






gel formation process (> 20 min) and even no gelation was observed when the NCs/hydrogel 
v/v ratio was higher than 30% (fibrinogen 1 mg/mL, thrombin 1 NIH-U/mL and HAs 0.5% 




”). Thus, the 
next step was the adjustment of the hydrogel formation conditions (fibrin, thrombin, Ca
2+
 and 
HAs concentrations) for 30% NCs loaded gels. The optimal time for the formation of a HA-
fibrin gel with adequate rheological properties was achieved at a concentration of 1.5 mg/mL 





. In the case of the fortified HA-fibrin hydrogel, 10 µg/mL of FXIII and 
0.14 µg/mL α2AP were additionally used. Figure 7 shows the summary of polymerization 
kinetics observed by turbidity analysis, the lag time was calculated based on 
spectrophotometric determinations, as described in Section 3.2.  
The amount of HA in the gel was envisaged to be ~3 mg/mL, bearing in mind that this 





Figure 7. Comparative studies for the gelation of fibrin (Fn) (without HA), HA-fibrin, and 
fortified HA-fibrin systems, driven by different Ca
2+
 ions concentration in blank and 30% 
NCs loaded gels. The polymerization kinetics was recorded by turbidity analysis during 
20 minutes at λ = 350 nm. Fibrinogen was always taken at 1 mg/mL concentration, activity 
of thrombin (Thr) = 0.5 - 1 NIH-U/mL for blank gels and NCs loaded gels. The gelation 
point was calculated from the kinetics curves of polymerization. The numbers above the bars 
represent in how many times the gelation is inhibited compared to Fn polymerization alone. 






3.4. Rheological behavior of in situ forming the hydrogels  
 
A basic principle for the development of an in situ gelling system is to have a low 
vicosity of the components mixture in order to ensure its good syringeability. The viscosity of 
the HA-fibrin mixture (with no thrombin addition) at 20 °C and 37 °C is 118.9 mPa·s and 
81.3 mPa·s, respectively. As these values are much lower than those of commercial 
viscosupplements,
59,154
 the mixed solutions necessary to form the in situ hydrogel are 
expected to be easily injected intra-articularly in vivo. 
Oscillatory rheological experiments are known to be a useful tool to determine the 
macro- and micro-structural rearrangements that influence the rheological behavior of gels 
with time.
163,164
 The gelling point can be detected by monitoring the gelation process with an 
oscillatory time sweep. The temporal evolution of the elastic or storage modulus (G'), which 
measures the elastic nature of the material, and the viscous or shear loss modulus (G''), which 
measures the viscous nature of the material was monitored upon the tests. 
As an example, Figure 8A and B gathers the gelation process of HA-fibrin and 
fortified HA-fibrin hydrogels with 30% loaded NCs. It can be observed thatthe viscous/shear 
loss modulus (G'') is higher than the elastic/storage modulus (G'). This is logical if we take 
into account that the gel samples are in liquid state, where the viscous properties 
predominate. As soon as the blank or NCs-loaded gels begin to form a crosslinked network 
the two indicated moduli rise. Nevertheless, the increase of G' is faster than that of G'', 
because the elastic nature of the gelling hydrogel starts to dominate. Hence, a crossover point 
appears in the curves is the gelation time of the sample. These gelling times are compared 
with those obtained for HA-fibrin and fortified HA-fibrin blank gels (Figure 9). The results 
of the rheology studies allowed us to detect the starting gelation point, by observing the gel 













Figure 8. Gelation point detection by the response of elastic (G’) and viscous (G”) moduli in 
HA-fibrin with 30% loaded NCs (A) and fortified HA-fibrin hydrogels with 30% loaded NCs 
(B). Fibrinogen was always taken at 1.5 mg/mL concentration, activity of thrombin (Thr) = 




, 10 µg/mL of 
factor XIII and 0.14 µg/mL α2-antiplasmin at 37 °C. Expressed as mean ± SD; n = 3. 
 
To provide an adequate syringeability of in situ hydrogel for in vivo experiments, our 
approach was to delay the gel formation for at least a 2 min (lag-time) after mixing the gel 
components in non- and fortified HA-fibrin blank and 30% NCs loaded gels. The resulting 
gelation times are shown in Figure 9. 
 
 
Figure 9. Summary of gelation time point determination by rheological measurements in 
different systems: HA-fibrin (HA-Fn) and fortified HA-Fn blank and 30% NCs loaded gels. 
For blank gels fibrinogen was always taken at 1 mg/mL concentration, activity of thrombin 
(Thr) = 1 NIH-U/mL. For 30% NCs loaded gels fibrinogen was always taken at 1.5 mg/mL 
concentration, activity of Thr = 2 NIH-U/mL. The dash-and-dot line reflects the 2 minutes 
lag-phase requirements. The measurements were carried out at 37 °C. Expressed as mean ± 






To evaluate the deformation profiles we measured the behavior of the G' and G'' 
moduli of the formed blank and NCs-loaded HA-fibrin and fortified HA-fibrin gels by 
oscillatory strain and frequency sweeps.  
As an example, Figure 10 shows the elastic and viscous moduli of the non- and 
fortified HA-fibrin hydrogel loaded with 30% NCs as a function of the deformation. Initially, 
the linear viscoelastic region, i.e. the region in which deformations are not large enough to 
destroy material structure, was identified through strain sweeps ranging from 0.1% to 1,000 
or 10,000% depending on the parameters of the crossover point. At strains lower than 10-
15% (critical strain), the value of elastic and viscous moduli is constant and independent of 
the deformation, G’>G”. In this linear viscoelastic region the deformation is completely 
recoverable and the material exhibits an elastic “solid-like” behavior. As mentioned earlier, 
HA and fibrin significantly contribute to rheological properties of each other: e.g. high 
hydrophilicity of HA prevents the compression of the fibrin network and improves it 
mechanical properties,
101
 while fibrin provides desired elasticity and resistance to stretching 
for HA gels.
96
 The crossover point of G’ and G” modulus, indicating a sample deformation 
point in this experiment, for NCs loaded fortified HA-fibrin gels was observed at a strain of 
630%, while the NCs loaded non-fortified HA-fibrin gels destroyed at a strain of 100%. 
Thus, fortified NCs loaded gels reveled 6.3 times higher resistance to deformations compared 
to non-fortified loaded gels. Other authors also showed that fibrin hydrogels crosslinked by 
FXIII under physiological conditions are more stable and shows 8 times higher Young’s 
(elastic) modulus values than non-crosslinked one.
96
 Furthermore, FXIII increases the rigidity 
and strength of the fibrin hydrogel and protects it against shear stress in the physiological 
environment.
112,113,165
 Under larger deformations an overshoot phenomenon can be observed 
in the G’ and G” moduli of the fortified HA-fibrin hydrogel loaded with 30% NCs (Figure 
10B). This response is typical for materials with resistance to a permanent deformation, 
which is the evidence of FXIII contribution to the stability profile. Lorand and Muszbek et al. 
have also observed increase in viscous and elastic moduli of fibrin gel crosslinked by FXIII 
as a measure of clot stability against shear stress.
113,114
 At the higher strains applied the values 
of two moduli decreased as the strain increases corresponding to thinning behavior until the 
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Figure 10. Deformation point detection by the response of elastic (G’) and viscous (G”) 
moduli in HA-fibrin (A) and fortified HA-fibrin systems (B) with 30% loaded NCs as a 
function of strain at 1 Hz. The range marked by dot-dash line represents an overshoot 
phenomenon. Fibrinogen was always taken at 1.5 mg/mL concentration, activity of Thr = 2 
NIH-U/mL. The measurements were carried out at 37 °C. Expressed as mean ± SD; n = 3. 
 
The oscillatory frequency sweeps exhibited a plateau-type behavior of the G’ and G” 
modulus in the range 0.01-1 Hz for 30% NCs loaded non- and fortified HA-fibrin gels 
(Supplementary materials, Figure S1), which is indicative of a stable crosslinked network. In 
all the cases the hydrogel samples showed an increase in G' at higher frequencies assuming 
“solid-like” behavior characterized by an increase of the elastic modulus, moreover, the rate 
of increase being highest for 30% NCs loaded hydrogels. Interestingly, gels with incorporated 
30% of NCs showed higher stability to deformations than blank gels and, thus, longer 
persistence, which could be explained by additional crosslinking of IPN by NCs, due to 
covalent and ionic interactions between shell polymer of NCs and fibrin network of the 
hydrogel. 
These results indicate that the hydrogels composed of HA and fibrin, crosslinked with 
FXIII, and combined with NCs can be modulated with regard to their mechanical and elastic 
properties, in order to obtain a system that resists potential deformations in the articular 
cavity. 
 
3.5. Surface morphology and porosity of in situ forming hydrogels 
 
Topographic characterization of HA-fibrin and fortified HA-fibrin loaded with 30% 
of NCs was performed (Supplementary materials, Table S1). As an example, the topography 











Figure 11. 3D topographical image of HA-fibrin hydrogel, obtained with the spatial 
resolution of the optical profiler at the field of view 97×108 μm
2
. HA-fibrin hydrogel was 
prepared from 1 mg/mL fibrinogen, thrombin activity = 1 NIH-U/mL, 0.5% HAs mix 




 at 37 °C. 
 
On the other hand, the average pore sizes for HA-fibrin and fortified HA-fibrin gels 
are summarized in Table 7. All the gel samples presented homogenous and well-determined 
pores with a low value of pore size distribution, which is the evidence of well-organized 
architecture. These data correlate well with the data obtained from SEM (Section 3.8).  
 
Table 7. Mean pore size and depth of the different hydrogel compositions. 
Sample Mean pore diameter (μm) Depth (μm) 
HA-fibrin hydrogel 4.23 ± 0.89 1.07 ± 0.18 
HA-fibrin hydrogel + 30% NCs  7.29 ± 1.23 0.7 ± 0.17 
Fortified HA-fibrin hydrogel 3.26 ± 1.01 1.07 ± 0.41 
Fortified HA-fibrin hydrogel + 30% NCs  4.88 ± 1.12 0.98 ± 0.12 
 
According to these data, blank fortified HA-fibrin gels appeared to be more 
crosslinked with mean pore diameter 3.26 ± 1.01 μm compared to non-fortified HA-fibrin 
gels with mean value 4.23 ± 0.89 μm. The same tendency was observed for 30% NCs loaded 






thus, have smaller pore size (4.88 ± 1.12 μm) than 30% NCs loaded HA-fibrin gels (7.29 ± 
1.23 μm). The average pore diameter of fortified HA-fibrin NCs loaded gels (4.88 μm) only 
slightly exceeds the one of blank fortified HA-fibrin gels (3.26 μm), which is a good 
indication, meaning that FXIII provides sufficient crosslinking canvas and, thus, improves 
and maintains the structural rheology of the NCs-loaded gels. 
At the next stage, NCs-loaded HA-fibrin hydrogels were formed upon mixing all 
components and extrusion by an ultra-fine insulin needle (29G) simulating conditions used 
for in vivo administration. Samples were incubated for 20 h at 37 ºC in order to form mature 
hydrogels, which were, then, lyophilized and analysed by SEM and FESEM (Figure 12A, B, 
C, and D).  
 
 A                                                                          B 
 











Figure 12. SEM images of the blank HA-fibrin (A) and blank fortified HA-fibrin hydrogels 
(B) at magnification is 500×. FESEM images of the blank HA-fibrin (C) and blank fortified 







Analysis of the SEM images allowed us to visually evaluate the differences in non- 
and fortified HA-fibrin gels structure. As previously shown in the topography study, fortified 
HA-fibrin hydrogels have smaller pores compared to HA-fibrin hydrogels for both, blank and 
NCs loaded systems. Thus, SEM/FESEM studies confirmed that fortified HA-fibrin gel has 
more compact structure of the network, as porosity data indicated. We hypothesize, that 
possibly, one of the crosslinks of fibrin chains by FXIII was detected in Figure 12D. 
Microscopy images revealed fibrin gel fibrils with the diameter of 1-2 μm, such fibril 
thickness is an indication of stable fibrin hydrogels was described by several authors.
121,130
 
Microscopy images of NCs-loaded hydrogels are shown at Figure 13A and B. HA 
NCs were found bound to fibrin fibrils. The crystals observed in the images of the gel fibrils 
are probably inorganic salts of CaCl2, which are present in the polymerization buffer, that 
have high affinity to fibrin and are responsible for formation and stabilization of 








Figure 13. FESEM images of the HA-fibrin hydrogel with 30% of blank NCs (A) and 
fortified HA-fibrin hydrogel with 30% blank NCs (B) prepared by injection through the 
needle to PBS buffer (1:1.73). NCs appeared in the images as little round-shape particles 
bound to gel fibrils.  
 
Section 3.6. Distribution of NCs within the in situ forming hydrogel 
 
The distribution of Nile Red labeled NCs within the HA-fibrin hydrogel (30% 






indicate that HA NCs are randomly dispersed in the hydrogel network. Possibly, HA NCs 





Figure 14. Confocal microscopy images of Nile Red-labeled HA NCs dispersed in the HA-
Fibrin hydrogel (30% loading) (A). HA-fibrin hydrogel was prepared from 1.5 mg/mL 





 at 37 °C. Magnification is 320× (A), 1600× (B).  
 
Section 3.7. In vitro DXM release from NCs containing hydrogels 
 
The release studies of DXM were carried out under sink conditions for both, NCs and 
30% NCs-loaded hydrogel, in SSF (RI = 1.334) at 37 °C. 
In the case of the free NCs, a burst of approximately 70% DXM release was observed 
in the first hour of incubation in SSF, reaching 100% after 24 hours (data not shown). In 
contrast, in the case of NCs loaded into the non-fortified HA-fibrin hydrogel (prepared as 
explained in Table 3) a slow release was observed in SSF (Figure 15). In this system, we 
have observed ~30% DXM release in the first time point, and then a slow release up to ~50% 
within 24 hours. In the next phase 24-60 h the drug was released gradually till 60%, between 
60-72 h the gel started to slowly degrade and 100% of DXM release was reached at 72 h. 
Overall, the results underline the importance of the hydrogel in controlling the release of the 
drug that was incorporated within the NCs. Hence, both, the NCs and the hydrogel have a 






It is expected that the release from the fortified HA-fibrin hydrogel might be more 
prolonged due to slower rate of degradation. In this case, FXIII and α2-antiplasmin enzyme 
should retard the gel decomposition
167




Figure 15. DXM release from HA-fibrin hydrogel with 30% loaded NCs to SSF incubated at 
37 °C during 72 h. HA-fibrin hydrogel was prepared from: fibrinogen 1.5 mg/mL, thrombin 




, 30% NCs. 
 
These in vitro release results are in line with other previously reported in the 
literature. For example, Ranch et al. described a fast release of DMX from Carbopol 940-
gellan gum gels,
168
 whereas Borden et al. reported a 72 h in vitro release profile.
169
 On the 
other hand, Webber et al. reported the longest in vitro controlled release of DXM conjugated 
to a peptide-based nanofiber gels during 32 days.
170
 Wu et al. have shown similar 1 month 










A novel in situ hydrogel that involves the mixture of gelling agents (HA, fibrin, 
thrombin and fortifying agents) with a suspension of HA nanocapsules has been developed 
and characterized. The gel is intended for the IA delivery of anti-inflammatory drugs, such as 
DXM. HA nanocapsules with mean particle size of 135 nm and negative surface charge, 
served as multi-reservoirs for DXM. The NCs were dispersed in the gel depot, in order to 
prevent their fast drainage from the articular cavity. The gel provided a controlled DXM 
release in simulated synovial fluid, for 72 h. NCs-loaded hydrogels have a well-organized 
structure with narrow pores sizes distribution and rheological behavior similar to the blank 
hydrogels, exhibiting high resistance to deformation, being suitable for intra-articular 
application. The developed hydrogel might also have self-healing properties, behaving as a 
viscosupplement and could work as an in situ cell scaffold, all these properties being of 
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Figure S1. Deformation point detection by the response of elastic (G’) and viscous (G”) 
moduli in HA-fibrin (A) and fortified HA-fibrin systems (B) with 30% loaded NCs as a 
function of frequency at torque 0.5 µN·m. Fibrinogen was always taken at 1.5 mg/mL 
concentration, activity of Thr = 2 NIH-U/mL. The measurements were carried out at 37 °C. 







Hydrogels 3D roughness parameters (Ssk, which represents the degree of symmetry of 
the surface heights distribution about the mean plane, and Sku, which indicates the nature of 
the height distribution)
171
 are gathered in Table S1. 
 
Table S1. Experimental roughness results from different zoomed areas of hydrogel samples. 
Ssk = 0: Symmetrical about the average line (normal distribution), Ssk > 0: skewed downward 
relative to the average line Ssk < 0: skewed upward relative to the average line. Sku = 3: 
normal distribution, Sku > 3: the height distribution is spiked. Sku < 3: the form of the surface 
roughness height distribution is squashed. 
 
Sample 3D Roughness Parameters 
 Ssk Sku 
HA-fibrin hydrogel   
Area 1 (Field of View 97×108 μm2) 0.01 3.00 
Area 2 (Field of View 63×73 μm2) 0.19 3.42 
Area 3 (Field of View 53×61 μm2) -0.09 3.00 
HA-fibrin hydrogel + 30% NCs   
Area 1 (Field of View 98×124 μm2) -0.17 3.08 
Area 2 (Field of View 103×129 μm2) -0.30 3.17 
Area 3 (Field of View 87×109 μm2) -0.61 3.23 
Fortified HA-fibrin hydrogel   
Area 1 (Field of View 84×108 μm2) 0.25 3.11 
Area 2 (Field of View 90×110 μm2) 0.62 7.21 
Area 3 (Field of View 74×94 μm2) 0.36 3.51 
Fortified HA-fibrin hydrogel + 30% NCs 
Area 1 (Field of View 97×136 μm2) 0.34 7.28 
Area 2 (Field of View 101×131μm2) -0.03 2.67 









New galectin-3 inhibitor as a lead compound 




All the truths are easy to 
understand once they are 
discovered; the point is to 
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Rheumatoid arthritis (RA) is a chronic autoimmune disorder that primarily affects the  
joints. This disease is characterized by synovial inflammation and swelling, finally leading to 
joints cartilage and bone destruction. Nowadays RA is a non-curable disease guiding to the 
lethal outcome. The etiology of this disease is vague and remains the subject of intense 
research. Current therapies for RA include antagonists of COX-2 and pro-inflammatory 
cytokines TNF-α, IL-1, IL-6, however do not lead to the adequate alleviation of the 
inflammatory joint diseases.  
The extracellular protein galectin-3 (Gal-3) has recently found to be a primer trigger 
of inflammation in autoimmune diseases, in particular in RA, attracting attention as a new 
potential immunotherapeutic target. The inhibition of Gal-3 by high-affine compounds based 
on β-galactoside motifs has recently seen major breakthrough. The design, synthesis and 
characterization of a highly selective and potent Gal-3 antagonist are reported in this chapter. 
To this aim, aromatic substituents have been introduced at positions 3’-C of the galactose and 
2-C of the glucosamine residues of type II lactosamine core [Gal(1→4)-GlcN], used as the 
starting material. Such modifications resulted in considerably enhanced affinity, Kd = 590 nM 
(4 °C), due to the establishment of cation- interactions between the arene substituents with 
guanidinium ions of two key arginine residues (Arg144 and Arg186) of the Gal-3 
carbohydrate recognition domain. Subsequently, the inhibitor was encapsulated in an in situ 
hydrogel developed for intra-articular administration (described in Chapter 1, Section 2.3). 
First, the inhibitor was encapsulated in hyaluronic acid (HA) nanocapsules (NCs) that act as 
lipophilic reservoirs for the drug, and later, the NCs were included in a HA-fibrin hydrogel. 
Anti-inflammatory properties of Gal-3 inhibitor were evaluated in a rat carrageenan-induced 
knee joint synovitis model. The inhibitor incorporated in the hydrogel and administered intra-
articularly at microgram scale doses, showed a remarkable suppression of inflammation, 









Rheumatoid arthritis (RA) is a chronic autoimmune disorder that primarily affects 
diartroidal joints causing synovial inflammation and swelling.
1–3
 Besides, the disease is 
characterized by the production of autoantibodies and, at advanced stages, cartilage and bone 
destruction.
4
 The etiology of this disease is vague and remains the subject of intense 
research.
1,5,6
 So far, RA is a non-curable disease, affecting about 1% of globe population and 
guiding to the lethal outcome.
1,7
 Over the last decades, the pace of development of RA 
significantly increased with a tendency ~4.1% for USA inhabitants per year.
3,7,8
 
RA affects mostly small joints, leading to their deformation and affecting theirs 
performance. As the disease progresses, symptoms often spread to the wrists, knees, ankles, 
elbows, hips and shoulders. In most of the cases, symptoms occur in the same joints on both 
sides of the body representing bilateral symmetry.
3,9
 In addition, RA may produce extra-
articular manifestations, affecting other organs of the body, e.g. skin, eyes, lungs and blood 
vessels.
10
 The factors amplifying the risk of RA development include non-modifiable: i) 
gender (women are more predisposed to develop RA than men, 4:1, respectively)
11
; ii) age 
(RA typically occurs between the ages of 40 and 60); iii) genetics (it can be inherited due to 
the family history)
7




As an autoimmune disorder, RA occurs when the immune system mistakenly attacks 
the synovial membrane. Among the immune cells involved in this disease are leukocytes 




 T cells and B-cells), monocytes, synovial 
macrophages, dendritic cells and mast cells.
6
 These cells play important roles in the 
autoimmune process, releasing pro-inflammatory cytokines (TNF-α, IL-1, IL-6, and TGF-β), 
chemokines, matrix metalloproteinases (MMPs), cathepsins, vasoactive amines and 
proteases.
1,13,14
 These molecules lead to hyperplasia of synovial tissues,
7
 synovial fluid (SF) 
accumulation,
15
 followed by joint inflammation,
7
 pain, stiffness, swelling
16
 and subsequent 
degradation of articular cartilage,
2
 bone and ligaments
1,17
 (Figure 1). 
Current therapies for RA include antagonists of COX-2 and pro-inflammatory 









 etc. However these treatments do not lead to the adequate alleviation of the 








Protein galectin-3 (Gal-3), once shuttled to the extracellular space, has recently been 
found to be a primer trigger of inflammation that favours the secretion of macrophage pro-
inflammatory cytokines.
27–32,13
 Gal-3 is expressed in neutrophils, basophils, eosinophils, 
macrophages, dendritic,
33–37
 and mast cells,
24
 and has considerable effects on both innate and 
adaptive immunity.
30
 Innate immune functions of Gal-3 are cell activation, adhesion, 
migration, and promotion of pathogens phagocytosis (including mycobacteria, fungi, and 
parasites)
30
 as well as autophagy.
38
 It is both pro-inflammatory and anti-inflammatory 
mediator, working as a chemoattractant for monocytes, macrophages, followed by 
macrophages polarization,
39







Figure 1. Pro-inflammatory cytokines signaling pathways involved in rheumatoid arthritis. 
Reproduced with permission from,
17
 Copyright © 2001 Massachusetts Medical Society. 
 
In adaptive immune system, Gal-3 exhibits immunosuppressive effect, restricting T 
cell receptor recruitment into immune synapses, prevents T cell proliferation, differentiation, 
and directly promotes T cell apoptosis,
30
 resulting in prolonged inflammation.
40










As reported, Gal-3 expression is up-regulated in synovial tissues in RA,
24
 reaching a 
concentration in SF of 130-300 ng/mL (once about 50 ng/mL found at normal state)
13
 and 
being a pro-inflammatory regulator and presenting immunosuppressive effect, it amplifies 
and prolong the inflammation.
30,40
 Noticeably, Gal-3 stimulates synovial fibroblasts and 
immune cells to release pro-inflammatory cytokines (TNF-α, IL-6, IL-17), chemokines 
(CCL2, CCL3, CCL5, CXCL8)
13
 and the expression of different matrix 
metalloproteinases.
41,42
 These enzymes are involved in the degradation of the extracellular 
matrix (ECM)
41
 and destroy specifically type I-III collagen, leading to tissue remodelling.
43,44
 
Besides, they inhibit the osteocalcin production,
36
 leading to bone demineralization,
13
 and, 
finally, causing joint degradation.
6,45
 In addition, IA injection of recombinant galectin-3 in 
mice induced cartilage and subchondral bone lesions.
36,40
 Taking into account such 
involvement into pathophysiology of RA, Gal-3 appears as a novel potential 
immunotherapeutic target. 
Currently, three Gal-3 antagonists have entered clinical trials for the treatment of 
different pathologies: DAVANAT® (GM-CT-01), GR-MD-02, and TD139.
46–54
 However, 
none of them was tested for RA treatment. Taking into account their success in clinical trials, 
it could be extremely useful to synthetize novel Gal-3 inhibitor and prolong its action 
administering it in a drug delivery system (DDS) to the articular cavity. Gal-3 inhibitors 
based on the lactosamine (LacNAc) core to mimic Gal-3 natural ligand complexation might 
represent an adequate strategy. However, to enhance its affinity and selectivity and facilitate 
its binding with highly conserved amino acids of Gal-3 carbohydrate-recognition domain 
(CRD), specific modifications have to be introduced to establish the complexation in multiple 









Figure 2. X-ray crystal structure of human galectin-3 carbohydrate-recognition domain with 
bound lactosamine moiety representation in yellow. The molecular surface was generated 
using GRASP with a probe radius of 1.4 Å. Blue and red regions indicate positive and 
negative electrostatic potentials, respectively. Reproduced with permission from,
55
 Copyright 









2. MATERIALS AND METHODS 
 
2.1. Materials and animals 
 
All the reagents for the organic synthesis were acquired from commercial sources and 
used without further purification. Fibrinogen from human blood plasma (premium quality 
grade) and thrombin from human blood plasma (premium quality grade) were purchased 
from Sigma-Aldrich, Germany. Sodium hyaluronate (HA, research grade) of different 
average molecular weight 51 kDa, 752 kDa and 1.38 MDa, with trade names 40 kDa, 700 
kDa, 1.5 MDa, correspondingly, were acquired from Lifecore Biomedical, USA. Factor XIII 
(FXIII) from the blood plasma (>95% pure) was obtained from Haematologic Technologies, 
Inc, USA. Alpha-2 antiplasmin (α2AP) from human blood plasma (>95% pure) was bought 
from Lee Biosolutions, USA. Dexamethasone (97.2%) was purchased from Acofarma, Spain. 
The stabilizing surfactants, phosphatidylcholine enriched soy lecithin (EPIKURON® 145 V) 
was a kind gift from Cargill, Spain and oleylamine was bought from Sigma-Aldrich, 
Germany all of high-purity grade. Virgin olive oil (extra pure) was purchased from Acros 
Organics, Belgium. HEPES, BSA (≥98%), sodium chloride, calcium chloride dihydrate, 
potassium chloride, sodium phosphate dibasic and potassium phosphate monobasic of ≥99% 
purity, were acquired from Sigma-Aldrich, Germany. Carrageenan was purchased from 
Sigma Aldrich (St. Louis, MO). ELISA kit for IL-6 determination in rat plasma was 
purchased from Sigma. All the testing materials were obtained in sterile conditions using of 
endotoxin-free water and all other ingredients were of analytical grade. Ultrapure (Milli-Q) or 
endotoxin-free water was used throughout the experiments and organic solvents were of 
HPLC grade. The laboratory glassware used for in vivo formulations preparation was 
previously sterilized by autoclave (Systec, Wettenberg, Germany).  
 
Animals 
18 male Sprague-Dawley rats (200/225 g), were acquired from Charles River, 
Germany. They were used after 1-week acclimatization to the laboratory environment and 
housed in polypropylene cages (maximum five per cage) under standard controlled 
conditions (24 ± 1 °C, 12 h light/dark cycle), were fed commercial chow and acidified 






All animal experiments were carried out in accordance with the EU Directive 
(2010/63/EU), Portuguese law (DL 113/2013) and all relevant legislations. The experimental 
protocol was approved by Direcção Geral de Alimentação e Veterinária (DGAV). 
 
2.2. Gal-3 inhibitors preparation, purification and control 
 
Gal-3 inhibitors were synthesized according to the designed protocols; each reaction 
step was controlled by thin-layer chromatography (TLC) on 0.25 nm silica gel plates with 
fluorescent indicator (GF254) and visualized under UV light. Detection was further achieved 
by charring with vanillin in sulfuric acid/ethanol (1.5:95 v/v). Flash chromatography 
purifications were made on silica gel columns (4 to 80 g, 240-400 mesh) using an automated 
Reveleris® Flash Chromatography system (Grace Alltech) equipped with both Evaporative 
Light Scattering (ELS) and UV/diode array allowing the simultaneous use of two 
customizable wavelengths detectors.  
All NMR experiments were performed at 400.13 MHz using Bruker Avance 




C ATMA grad 5 mm probe. 
Assignments were performed be stepwise identification using COSY and HSQC experiments 
using standard pulse programs from the Bruker library. Chemical shifts are given to external 
TMS with calibration involving the residual signals. 
High-resolution mass spectra were recorded in positive mode on Waters SYNAPT 
G2-Si HDMS with detection by a hybrid quadripole time of flight (Q-TOF) detector. The 
compounds were individually dissolved in MeOH at a concentration 1 mg/mL and then 
infused into the electrospray ion source at a flow rate of 10 µL/min at 100 °C. The mass 
spectrometer was operated at 3kV whilst scanning the magnet at a typical range of 4000-
100 Da. The mass spectra were collected as continuum profile data. Accurate mass 
measurement was achieved based on every five second auto-calibration using leucine-
enkephalin (m/z = 556.2771 [M+H]
+








2.2.1. Experimental procedures for the synthesis of compounds 1-8. Approach A, using 
iodosulfonamidation as a key reaction  
 
D-Lactal/1,5-Anhydro-2-deoxy-4-O-β-D-galactopyranosyl-D-arabinohex-1-enitol (4) 
This step included 4 reactions. Lactose (20.0 g, 58.4 mmol, 1 
eq.) was dissolved in AcOH (107 mL) and Ac2O (53 mL, 560 
mmol; 8.4 eq), HClO4 (few drops) was added to initiate the 
reaction. After 1 hour of strong stirring at room temperature 
(RT) TLC monitoring showed that the reaction was complete 
and peracetylated lactose was obtained (1). TLC Rf = 0.5 (cyclohexane/ethyl acetate 1:1).  
Reaction mixture containing intermediate 1, was next cooled to 0 °C, before the 
addition of HBr (60 mL) via a dropping funnel. After 1 hour of strong stirring at 0 °C the 
reaction was complete (confirmed by TLC). The reaction mixture was diluted upon addition 
of CH2Cl2 (150 mL) and washed with H2O (50 mL). Organic layer was separated and 
extracted with saturated NaHCO3 (2 × 50 mL) and brine (50 mL). The organic layers were 
collected, dried over Na2SO4, filtrated, concentrated under reduced pressure and 
recrystallized in EtOAc (30 mL) at 4 °C, overnight. The derivative acetobromo--D-lactose 2 
was further filtrated and washed with cyclohexane giving a pure white compound (38.5 g, 
94%). TLC Rf = 0.44 (cyclohexane/EtOAc 1:1).  
Zn powder (20.00 g, 330 mmol; 6 eq.) was activated by 1N HCl (a volume to cover 
Zn layer) with strong stirring during 10 min and washed with AcOH. A solution of 
AcOH/H2O 1:1 (80 mL) was added to the flask with Zn and cooled to 0 °C. Meanwhile 
compound 2 (38.5 g, 55 mmol; 1 eq.) was dissolved in EtOAc (50 mL) and was added via a 
dropping funnel to the cold flask under strong stirring. The reaction was carried 48 h at 4 °C. 
The solution of intermediate peracetylated lactal 3 was filtrated and washed with small 
portions of EtOAc and H2O. The filtrate was diluted with CH2Cl2 (100 mL) and H2O 
(50 mL). The organic layer was recovered and further extracted with saturated NaHCO3 (2 × 
50 mL) and brine (50 mL). The organic layers were collected, dried over Na2SO4, filtrated, 
concentrated under reduced pressure and dried under vacuum, giving a compound 3 (22.92 g, 
72%). TLC Rf = 0.5 (cyclohexane/ethyl acetate 1:1). 
To a solution of derivative 3 (22.92 g, 39.6 mmol; 1 eq.) in MeOH (325 mL) was 
added solid Na2CO3 (119.6 mmol, 6.5 eq.). The reaction mixture was stirred at RT for 7 h. 






reduced pressure, to give compound 4 (9.64 g, 79%). TLC Rf = 0.05 (CH2Cl2/MeOH 9:1). 
 
[3-O-(3,5-dimethoxybenzyl)-O-β-D-galactopyranosyl]-D-arabinohex-1-enitol (6a) 
At the step 1 compound 4 (2.0 g, 6.5 mmol; 1 
eq.) and Bu2SnO (1.78 g, 7.15 mmol; 1.1 eq.) 
were dried under vacuum overnight. Later they 
were dissolved in dry MeOH (distilled over 
Mg pellets) (57 mL) and refluxed during 5 
hours under argon. The solvent was evaporated to dryness under reduced pressure to give 
stannylidene intermediate 5. At the step 2 the residue 5 was dissolved in CH2Cl2 (11.5 mL) in 
the presence of 3,5-dimethoxybenzyl bromide (1.8 g, 7.8 mmol; 1.2 eq.) and stirred under 
argon at RT. After 48 h of TLC showed the reaction was completed. The solvent was reduce 
under reduced pressure and the title compound 6a was purified by flash chromatography on 
silica column (eluent: CH2Cl2/MeOH to 100:0 CH2Cl2/MeOH 70:30) giving (1.86 g, yield 
63%), TLC Rf = 0.65 (CH2Cl2/MeOH 9:1). 
1
H NMR  (400 MHz, CDCl3) δ 6.66 (2 H, t, J = 
2.3 Hz, 2 H arom), 6.40 (1 H, t, J = 2.3 Hz, 1 H arom), 6.39 ( 1 H, dd, J = 1.9 and 5.8 Hz, H-
1), 4.74 (1 H, br d, J = 12.2 Hz, CHH), 4.72 (1 H, dd, J = 2.1 and 5.8 Hz, H-2), 4.63 (1 H, d, 
J = 12.2 Hz, CHH), 4.47 (1 H, d, J = 7.8 Hz, H-1’), 4.34 (1 H, dt, J = 2.1 and 6.8 Hz, H-3), 
4.04 (1 H, dd, J = 1.0 and 3.2 Hz, H-4’), 3.97 (1 H, dd, J = 3.9 and 10.4 Hz, H-6), 3.91 (1 H, 
dd, J = 2.5 and 10.4 Hz, H-6), 3.87-3.73 (4 H, m, H-4, H-5, H-2’ and H-6’), 3.80 (6 H, s, 2 
CH3), 3.71 (1 H, dd, J = 4.4 and 8.7 Hz, H-6’), 3.57 (1 H, ddd, J = 1.0, 3.8 and 8.0 Hz, H-5’), 
3.48 (1 H, dd, J = 3.2 and 9.6 Hz, H-3’); 
13
C NMR (75 MHz, CD3OD) δ 160.2 (C arom), 
143.7 (C-1), 140.8 (C arom), 105.3 (C arom), 103.8  (C-1’), 102.1 (C-2), 99.3 (C arom), 80.7 
(C-3’(C-4), 77.4 (C-5), 75.5 (C-5’), 70.9 (CH2), 70.5 (C-2’), 68.2 (C-3), 65.7 (C-4’), 61.2 (C-






The procedure was reproduced using (2-
naphthyl)methyl bromide (1.55 g; 7 mmol; 
1.2 eq.) and catalytic amount of Bu4NI as 
electrophile agent at the step 2, to give a 
derivative 6b (1.08 g, 42% yield).  TLC Rf = 0.65 
(CH2Cl2/MeOH 9:1).  
1








m, 3 H arom), 7.61 (1 H, dd, J = 1.6 and 8.4 Hz, 1 H arom), 7.51-7.44 (2 H, m, 2 H-arom), 6.38 
(1 H, dd, J = 1.8 and 6.0 Hz, H-1), 4.95 (1 H, d AB system, J = 12.1 Hz, CHH), 4.85 (1 H, AB 
system, J = 12.1 Hz, CHH), 4.71 (1 H, dd, J = 1.3 and 6.0 Hz, H-2), 4.48 (1 H, d, J = 7.8 Hz, 
H-1’), 4.37 (1 H, dt, J = 1.3 and 6.9 Hz, H-3), 4.06 (1 H, d, J = 3.2 Hz, H-4’), (1 H, dd, J = 3.9 
and 10.4 Hz, H-6), 3.91 (1 H, dd, J = 2.5 and 10.4 Hz, H-6), 3.87-3.73 (4 H, m, H-4, H-5, H-2’ 
and H-6’), 3.72 (1 H, dd, J = 4.4 and 11.4 Hz, H-6’), 3.57 (1 H, dd, J = 4.4 and 7.7 Hz, H-5’), 
3.48 (1 H, dd, J = 3.2 and 9.7 Hz, H-3’); 
13
C NMR (100 MHz, CD3OD) δ 143.7 (C-1), 136.9, 
133.4, 133.1, 127.6, 127.5, 127.3, 126.3, 125.8, 125.7 and 125.5 (10 C arom), 103.8 (C-1’), 
102.1 (C-2), 80.9 (C-3’), 78.6 (C-4), 77.4 (C-5), 75.5 (C-5’), 71.3 (CH2), 70.6 (C-2’), 68.3 (C-
3), 65.8 (C-4’), 61.1 (C-6’), 60.2 (C-6); HR-ESI-MS: m/z calculated for C23H28O9 [M+Na]
+
 
471.1631, found 471.1628. 
  
1,5-Anhydro-2-deoxy-[3-O-(3,5-dimethoxybenzyl)methyl-2,4,6-tri-O-triethylsilyl--D-
galactopyranosyl]-(1-4)-3,6-di-O-triethylsilyl-D-arabinohex-1-enitol (7a)  
Chlorotriethylsilane (TES-Cl, Et3Si-Cl) 
(11.8 mL, 70.5 mmol; 9 eq.) and imidazole 
(9.6 g, 140.94 mmol; 18 eq.) were dissolved in 
DMF (28 mL) and activated during 20 min 
under argon, before the addition of compound 
6a (2.415 g, 7.83 mmol). After 12 h stirring at RT TLC showed the reaction was completed. 
The crude mixture was poured into the beaker with H2O (50 mL) and after extracted with 
diethyl ether (3 × 20 mL). The organic layers were collected, dried over MgSO4, filtrated, 
concentrated under reduced pressure and dried under vacuum to give a compound 7a (7.39 g, 
95%) which was used in the next step without further purification. TLC Rf = 0.71 




The same reaction was reproduced to 
compound 6b to obtain derivative 7b (2.97 mg, 
yield 95%) which was used in the next step 
without further purification. TLC Rf = 0.71 








2.2.2. Experimental procedures for the synthesis of compounds 9-16. Approach B, using 
azidophenylselenation as a key reaction  
 
Similar to the previous synthetic pathway, it is started from the D-lactose modification 
to obtain D-lactal. First 4 reactions of the sequence were performed by the protocols 
described at the Approach A (Section 2.2.1.). 
 
1,5-Anhydro-2-deoxy-[2,3,4,6-tetra-O-triethylsilyl--D-galactopyranosyl]-(1-4)-3,6-di-O-
triethylsilyl-D-arabinohex-1-enitol (9)  
A persilylation reaction was held (by previously described 
protocol as for compound 7 in iodosulfonamidation 
approach) to give compound 9 (11.52 g, yield 95%) which 
was used in the next step without further purification, 




A compound 9 (11.52 g, 11.297 mmol; 1 eq.) was 
dissolved in CH2Cl2 (30 mL) and cooled to -20 °C 
before the addition of diphenyl diselenide 
(Ph2Se2) (3.53 g, 11.30 mmol; 1 eq.), followed by 
azidotrimethylsilane (1.49 mL, 11.30 mmol; 
1 eq.) and iodobenzene diacetate PhI(AcO)2 
(3.64 g, 11.297 mmol; 1 eq.) of. The temperature -20 °C was kept 10 min, after the reaction 
mixture was allowed to warm to -10 °C during next 1-2 h under argon before TLC showed 
the reaction was complete. The title compound was extracted in with diethyl ether (30 mL) 
and H2O (2 × 60 mL) and brine (60 mL). The organic layers were collected, dried over 
Na2SO4, filtrated, concentrated under reduced pressure, to provide known compound 10 
(5.61 g, 40.5%) after flash-chromatography on silica gel (eluent: gradient of cyclohexane/ 










Phenyl 2-azido-2-deoxy-4-O-(-D-galactopyranosyl)-1-seleno--D-glucopyranoside (11) 
To persilylated derivative 10 (4.75 g, 4.42 mmol) in 
solution in DMF (20 mL) was added CsF (4.03 g, 
26.55 mmol). The reaction mixture was stirred at 
RT under argon for 4 h and then concentrated to 
dryness under reduced pressure. The crude residue 
was purified by flash chromatography on the silica 
column (eluent: CH2Cl2/MeOH) to give compound 11 (2.13 g, 93%). TLC Rf = 0.08 
(CH2Cl2/MeOH 9:1); 
1
H RMN (400 MHz, CD3OD) δ 7.63-7.60 (m, 2H, Ar-H), 7.33-7.28 (m, 
3H, Ar-H), 5.90 (d, J = 4.3 Hz, 1H, H-1), 4.44 (d, J = 7.6 Hz, 1H, H-1'), 4.12 (br dt, J = 3.2, 
9.2 Hz 1H, H-5), 3.94 (dd, J = 3.4, 12.3 Hz, 1H, H-6), 3.91 (d, J = 3.3 Hz, 1H, H-4'), 3.83-
3.76 (m, 4H, H-2, H-3, 2 H-6’), 3.75 (dd, J = 3.4, 12.3 Hz, 1H, H-4) 3.69 (dd, J = 2.4, 12.3 
Hz, 1H, H-6), 3.65-3.57 (m, 2H, H-2', H-5'), 3.52 (dd, J = 3.2, 9.7 Hz, 1H, H-3'); 
13
C RMN 
(100 MHz, CD3OD) δ 134.4 (2 C-Ar), 128.8 (2 C-Ar), 128.6 (C-Ar), 127.5 (C-Ar), 103.7 (C-
1’), 87.1 (C-1), 78.8 (C-4), 75.7 (C-5'), 73.6 (C-3’), 73.4 (C-5), 72.9 (C-3), 71.3 (C-2'), 69.0 
(C-4’), 64.3 (C-2), 61.2 (C-6'), 59.8 (C-6); HR-ESI-MS: m/z calculated for C18H25N3O9Se 
[M+Na]
+




Derivative 11 (2.01 g, 4 mmol) and 
dibutyltin oxide (Bu2SnO, 1.09 g, 4.4 
mmol) in dry MeOH (57 mL) was 
refluxed for 5 h. Then the crude 
mixture was evaporated to dryness 
under reduced pressure. The residue 
was dissolved in DMF (11.5 mL) in 
the presence of 3,5-dimethoxybenzyl bromide (1.10 g, 4.8 mmol) and Bu4NI (147 mg, 
0.4 mmol) and stirred under argon at RT for 48 h. The reaction mixture was concentrated 
under reduced pressure and the crude residue purified by flash chromatography on silica gel 
column (eluent: CH2Cl2/MeOH) to give compound 12 (1.09 g, 48%); TLC Rf = 0.52 
(CH2Cl2/MeOH 9:1); 
1








7.18 (m, 3H, Ar-H), 6.56 (d, J = 2.2 Hz, 2H, Ar-H), 6.37 (t, J = 2.2 Hz, 1H, Ar-H), 5.70 (d, J 
= 4.7 Hz, 1H, H-1), 4.65 (d, J = 11.0 Hz, 1H, CHH), 4.57 (d, J = 11.0 Hz, 1H, CHH)  4.45 (d, 
J = 7.5 Hz, 1H, H-1'), 4.12 (d, J = 9.6 Hz 1H, H-5),  4.02-3.65 (m, 9H, H-2, H-3, 2 H-6, H-2', 
H-3’, H-4’, 2 H-6’), 3.73 (s, 6H, 2 OMe), 3.59-3.57 (m, 1H, H-5'), 3.40 (m, 1H, H-4); 
13
C 
RMN (100 MHz, CD3OD) δ 160.9 (2 C-Ar), 140.1 (C-Ar), 134.7 (2 C-Ar), 129.2 (2 C-Ar), 
128.3 (C-Ar), 128.0 (C-Ar), 105.9 (2 C-Ar), 103.3 (C-1’), 99.6 (C-Ar), 85.1 (C-1), 80.8 (C-
4), 78.9 (C-3’), 75.0 (C-5'), 73.1 (C-3 and C-5), 71.7 (CH2), 70.3 (C-2'), 66.6 (C-4’), 63.8 (C-
2), 62.0 (C-6'), 60.8 (C-6), 55.4 (2 CH3); HR-ESI-MS: m/z Calculated for C27H35N3O11Se 
[M+Na]
+




To a solution of compound 12 (0.96 g, 
1.47 mmol) in CH2Cl2 (25 mL) cooled 
at 0 °C were successively added Ac2O 
(0.83 mL, 8.09 mmol) and DIPEA 
(1.54 mL, 8.09 mmol) and a catalytic 
amount of DMAP (17.9 mg, 
0.15 mmol). The reaction mixture was 
allowed to warm to RT and stirred during next 12 h. The crude reaction mixture was diluted 
with CH2Cl2 (30 mL) and extracted with H2O (60 mL), saturated aqueous NaHCO3 (2×30 
mL), and brine (30 mL). The organic layers were collected, dried (Na2SO4), filtered and 
concentrated under reduced pressure. The crude residue was purified by flash 
chromatography on silica gel (eluent: cyclohexane/ethyl acetate) to give compound 13 (1.3 g, 
97%); TLC Rf = 0.64 (cyclohexane/ethyl acetate 1:1); 
1
H RMN (400 MHz, CDCl3) δ 7.60 (br 
d, J = 5.7 Hz, 2H, Ar-H), 7.33-7.28 (m, 3H, Ar-H), 6.44-6.38 (m, 3H, Ar-H), 5.89 (d, J = 5.3 
Hz, 1H, H-1), 5.48 (dd, J = 1.1, 3.4 Hz 1H, H-4’), 5.27 (dd, J = 9.4, 10.3 Hz, 1H, H-3), 5.08 
(dd, J = 7.9, 10.0 Hz, 1H, H-2’), 4.62 (d, J = 12.4 Hz, 1H, CHH), 4.46-4.40 (m, 1H, H-5), 
4.42 (d, J = 8.1 Hz, 1H, H-1’), 4.35 (d, J = 12.4 Hz, 1H, CHH),  4.32 (dd, J = 2.1, 10.0 Hz, 
1H, H-6), 4.22-4.12 (m, 3H, H-6, 2 H-6’), 3.96 (dd, J = 5.3, 10.3 Hz, 1H, H-2), 3.82-3.72 (m, 
2H, H-4, H-5’), 3.80 (s, 6H, 2OMe), 3.51 (dd, J = 3.4, 10.0 Hz, 1H, H-3’), 2.19 (s, 3H, 
CH3), 2.14 (s, 3H, CH3), 2.10 (s, 3H, CH3), 2.06 (s, 6H, 2CH3), 2.04 (s, 3H, CH3); 
13
C NMR 







160.9 (2 C-Ar), 139.7 (C-Ar), 134.4 (2 C-Ar), 129.2 (2 C-Ar), 128.1 (C-Ar), 105.6 (2 C-Ar), 
101.0 (C-1’), 99.7 (C-Ar), 84.0 (C-1), 76.9 (C-3’), 76.2 (C-4), 72.1 (C-3), 71.4 (C-5), 71.2 
(CH2), 71.0 and 70.7 (C-2’and C-5’), 65.6 (C-4’), 62.7 (C2), 62.2 (C-6), 61.5 (C-6’), 55.3 (2 
OMe), 20.8, 20.8, 20.7 and 20.7 (5 CH3); HR-ESI-MS m/z Calcd for C37H45N3O16Se 
[M+Na]
+




To a solution of compound 13 (1.18 g, 
1.26 mmol) in THF (3.5 mL) was 
added PMe3 (1 M Solution in THF) 
(1.3 mL, 1.50 mmol) and stirred 1 h at 
RT under argon. H20 (25 µL, 
1.36 mmol) was then added and the 
reaction mixture and further stirred at 
50 °C for 5 h. The crude reaction mixture was concentrated under reduced pressure and 
purified by flash chromatography on silica gel (eluent: cyclohexane/ethyl acetate) to give 
compound 14 (1.06 g, 93%); TLC Rf = 0.11 (cyclohexane/ethyl acetate 1:1); 
1
H RMN (400 
MHz, CD3OD) δ 7.65-7.62 (m, 2H, Ar-H), 7.33-7.28 (m, 3H, Ar-H), 6.47-6.38 (m, 3H, Ar-
H), 5.84 (d, J = 4.9 Hz, 1H, H-1), 5.54 (dd, J = 1.1, 3.4 Hz 1H, H-4’), 4.98 (dd, J = 8.0, 10.3 
Hz, 1H, H-2’), 5.08 (dd, J = 9.0, 9.6 Hz, 1H, H-3), 4.58 (d, J = 8.0 Hz, 1H, H-1’), 4.62 (d, J = 
12.1 Hz, 1H, CHH), 4.43-4.38 (m, 1H, H-5), 4.36 (d, J = 12.1 Hz, 1H, CHH),  4.32 (dd, J = 
2.1, 10.0 Hz, 1H, H-6), 4.24-4.13 (m, 3H, H-6, 2 H-6’), 4.00 (dt, J = 1.2, 6.5 Hz, 1H, H-5’), 
3.79 (s, 6H, 2OMe), 3.80-3.72 (m, 2H, H-4, H-3’), 3.14 (dd, J = 4.9, 10.6 Hz, 1H, H-2), 
2.16 (s, 3H, CH3), 2.14 (s, 3H, CH3), 2.07 (s, 3H, CH3), 2.04 (s, 6H, 2CH3), 2.02 (s, 3H, 
CH3); 
13
C NMR (75 MHz, CD3OD) δ 171.3 (C=O), 170.9 (C=O), 170.7 (C=O), 170.6 (C=O), 
170.0 (C=O), 161.0 (2 C-Ar), 140.1 (C-Ar), 133.8 (2 C-Ar), 128.9 (2 C-Ar), 127.5 (C-Ar), 
105.3 (2 C-Ar), 100.8 (C-1’), 99.2 (C-Ar), 90.4 (C-1), 77.2 and 76.3 (C-3’ and C-4), 74.4 (C-
3), 71.8 (CH2), 71.3 (C-5), 71.0 (C-2’), 70.7 (C-5’), 66.5 (C-4’), 62.5 (C-6), 61.5 (C-6’), 55.3 
(C2), 54.4 (2 OMe), 20.1, 20.0, 19.4, 19.3 and 19.3 (5 CH3); HR-ESI-MS m/z Calculated for 
C37H47NO16Se [M+H]
+









O-(3,5-dimethoxybenzyl]--D-galactopyranosyl)-1-seleno--D-glucopyranoside (15)  
To a solution of compound 14 (1.06 g, 
1.25 mmol) in CH2Cl2 (15 mL) were 
successively added 3,5-
dimethoxybenzoyl choride (0.76 mL, 
3.75 mmol), DIPEA (0.44 mL, 
2.5 mmol) and DMAP (15.5 mg, 
0.13 mmol) at 0 °C. The reaction 
mixture was then stirred at reflux for 
14 h under argon. After cooling, the crude reaction mixture was diluted with CH2Cl2 (50 mL) 
and extracted with H2O (2  50 mL) and brine (50 mL). The organic layers were collected, 
dried (Na2SO4), filtered and concentrated under reduced pressure. The crude residue was 
purified by flash chromatography on silica gel (eluent: cyclohexane/ethyl acetate) to give 
compound 15 (941 mg, 76%); Rf = 0.20 (ethyl acetate/cyclohexane 1:1); 
1
H RMN (400 MHz, 
CD3OD) δ 7.58-7.56 (m, 2H, Ar-H), 7.30-7.25 (m, 3H, Ar-H), 6.93 (d, J = 2.3 Hz, 2H, Ar-
H), 6.68 ( t, J = 2.3 Hz, 1H, Ar-H), 6.45 (d, J = 2.3 Hz, 2H, Ar-H), 6.41 ( t, J = 2.3 Hz, 1H, 
Ar-H), 6.07 (d, J = 5.0 Hz, 1H, H-1), 5.54 (dd, J = 1.1, 3.3 Hz 1H, H-4’), 5.22 (dd, J = 8.6, 
11.1 Hz, 1H, H-3), 5.00 (dd, J = 8.0, 10.1 Hz, 1H, H-2’), 4.65 (d, J = 8.0 Hz, 1H, H-1’), 4.60 
(d, J = 11.7 Hz, 1H, CHH), 4.61-4.55 (m, 1H, H-2), 4.47-4.40 (m, 2H, H-5, H-6), 4.37 (d, J = 
11.7 Hz, 1H, CHH),  4.22 (dd, J = 6.4, 11.8 Hz, 1H, H-6), 4.19-4.14 (m, 2H, 2 H-6’), 4.03 (t, 
J = 6.6 Hz, 1H, H-5’), 3.95 (br t, J = 9.2 Hz, 1H, H-4), 3.83 (s, 6H, 2OMe), 3.80-3.75 (m, 
1H, H-3’), 2.14 (s, 3H, CH3), 2.12 (s, 3H, CH3), 2.10 (s, 3H, CH3), 2.08 (s, 6H, 2CH3), 2.05 
(s, 3H, CH3); 
13
C NMR (75 MHz, CD3OD) δ 171.6 (C=O), 171.3 (C=O), 170.8 (C=O), 170.7 
(C=O), 170.6 (C=O), 170.1 (C=O), 161.1 (2 C-Ar), 161.0 (2 C-Ar), 140.0 (C-Ar), 135.5 (C-
Ar), 133.8 (2 C-Ar), 128.9 (2 C-Ar), 128.5 (C-Ar), 127.5 (C-Ar), 105.3 (2 C-Ar), 105.0 (2 C-
Ar), 103.6 (C-Ar), 100.9 (C-1’), 99.2 (C-Ar), 86.0 (C-1), 77.1 and 76.2 (C-3’ and C-4), 71.7, 
71.7, 71.4, 71.0 and 70.7  (C-3, C-5, C-2’, C-5’ and CH2), 66.5 (C-4’), 62.3 (C-6), 61.4 (C-
6’), 54.7 (2 OMe), 54.4 (2 OMe), 53.9 (C-2), 19.9, 19.7, 19.4, 19.4, 19.3 and 19.3 (5 CH3); 
HR-ESI-MS m/z Calculated for C46H55NO19Se [M+Na]
+










A solution of compound 15 (420 mg, 
0.42 mmol) in CH2Cl2 (5 mL) and cooled to 
-20 °C before the addition of 24 µL (0.46 
mmol) of Br2. The reaction was stirred 1 h 
under argon and then quenched upon 
addition of Et3N. The solvent was 
evaporated and the crude residue purified by 
flash-chromatography (eluent: cyclohexane/ethyl acetate) to give oxazoline 16 (216 mg, yield 
61%) as a foam.  Rf = 0.23 (ethyl acetate/cyclohexane 1:1); 
1
H RMN (400 MHz, CD3OD) δ 
7.18 (d, J = 2.0 Hz, 2H, Ar-H), 6.68 (br s, 1H, Ar-H), 6.42 (br s, 2H, Ar-H), 6.40 (br s, 1H, 
Ar-H), 611 (d, J = 7.0 Hz, 1H, H-1), 5.75 (br s, 1H, H-3),  5.45 (br d, J = 3.3 Hz 1H, H-4’), 
5.08 (t, J = 8.4 Hz, 1H, H-2’), 4.65-4.59 (m, 2H, H-1’, CHH), 4.37-4.33 (m, 2H, H-2, CHH), 
4.27-4.22 (m, 1H, H-6), 4.16-4.05 (m, 2H, H-6, H-6’), 4.02-3.95 (m, 1H, H-6’), 3.85 (s, 6H, 
2OMe), 3.80 (s, 6H, 2OMe), 3.90-3.80 (m, 1H, H-4), 3.69 (t, J = 6.0 Hz, 1H, H-5), 3.63-
3.57 (m, 1H, H-5’), 3.52 (dd, J = 3.1, 9.6 Hz 1H, H-3), 2.18 (s, 3H, CH3), 2.15 (s, 3H, CH3), 
2.10 (s, 3H, CH3), 2.03 (s, 3H, CH3), 2.01 (s, 3H, CH3); 
13
C NMR (75 MHz, CD3OD) δ 
170.5, 170.4, 170.3, 169.4 and 169.2 (5 C=O and C=N), 160.9 (2 C-Ar), 160.8 (2 C-Ar), 
139.8 (C-Ar), 127.4 (C-Ar), 106.2 (2 C-Ar), 105.7 (2 C-Ar), 105.2 (C-1), 105.0 (C-Ar), 101.5 
(C-1’), 99.6 (C-Ar), 77.4 and 77.2 (C-4 and C-3’), 71.3, 71.1, 71.0, 70.3 and 67.7 (C-3, C-5, 
C-2’, C-5’ and CH2), 65.7 (C-4’), 65.6 (C-2), 63.4 (C-6), 61.5 (C-6’), 55.6 (2 OMe), 55.3 (2 
OMe), 21.0, 20.8, 20.8, 20.7, 20.6 (4 CH3); HR-ESI-MS m/z Calculated for C40H49NO19 
[M+Na]
+







2.2.3. Experimental procedures for the synthesis of compounds 18-28. Approach C, using 
“1+1” donor-acceptor glycosylation as a key reaction (The synthesis has been carried out in 
collaboration with a post-doctoral fellow from the lab – Dr. Christophe Dussouy) 
 
Methyl 3-O-(2-naphthyl)methyl--D-galactopyranoside (18) 
A mixture of methyl β-D-galactopyranoside 17 (1.84 g, 
9.48 mmol) and dibutyltin oxide (2.6 g, 1.04 mmol) in 
dry MeOH (55 mL) was refluxed for 5 h. Then the 
solvent was distilled to give a syrup, which was 
evaporated to dryness under reduced pressure. The 
residue was dissolved in DMF (10 mL) in the presence of (2-naphthyl)methyl bromide (2.52 
mg, 11.38 mmol) and a catalytic amount of Bu4NI and stirred under argon at 40 °C overnight. 
The reaction mixture was concentrated under reduced pressure and the crude residue purified 
by flash chromatography on silica gel (eluent: CH2Cl2/MeOH 100:0, CH2Cl2/MeOH 90:10) 
to give compound 18 (1.63 g, 50%); TLC Rf = 0.63 (CH2Cl2/MeOH 9:1); 
1
H NMR (400 
MHz, CD3OD) δ 7.96 (1 H, br s, 1 H arom), 7.85-7.81 (3 H, m, 3 H arom), 7.67-7.58 (3 H, m, 
3 H arom), 4.93 (1 H, AB system, J = 11.1 Hz, CHH), 4.83 (1 H, AB system, J = 11.1 Hz, 
CHH),  4.17 (1 H, d, J = 7.7 Hz, H-1), 4.10 (1 H, br d, J = 3.2 Hz, H-4), 3.79-3.74 (2 H, m, 2 
H-6), 3.73 (1 H, dd, J = 7.7 and 9.6 Hz, H-2), 3.54 (1 H, s, CH3), 3.47 (1 H, br t, J = 6.4 Hz, 
H-5), 3.44 (1 H, dd, J = 3.2 and 9.6 Hz, H-3); 
13
C NMR (100 MHz, CD3OD) δ 136.0, 135.5, 
133.3, 128.1, 127.6, 127.5, 126.2, 125.8, 125.7 and 125.5(10 C arom), 100.0 (C-1), 81.0 (C-
3), 75.1 (C-5), 71.2 and 70.4 (CH2 and C-2), 65.7 (C-4), 61.1 (C-6), 55.9 (CH3); HR-ESI-MS 
m/z calculated for C18H22O6 (M + Na)
+
 357.1315, found 357.1314. 
 
Methyl 2,4,6-tri-O-acetyl-3-O-(2-naphthyl)methyl--D-galactopyranoside (19) 
To a suspension of triol 18 (2.45 g, 6.34 mmol) in dry 
CH2Cl2 (10 mL) at 0°C were successively added Ac2O 
(2.7 mL, 28.5 mmol), Et3N (3.42 mL, 22.2 mmol) and 
DMAP (77 mg, 0.63 mmol). The reaction mixture was 
reacted at RT for 24 h. The crude reaction mixture was 
then diluted with CH2Cl2 and successively washed with 0.1 N aqueous HCl, aqueous 
saturated NaHCO3 and brine. The extract was dried over Na2SO4, filtered and concentrated 








cyclohexane/ethyl acetate 50:50) of the resulting residue provided the peracetylated 
derivative 19 (2.45 g, 85%); TLC Rf = 0.29 (ethyl acetate/cyclohexane 3:7); 
1
H NMR (400 
MHz, CDCl3) δ 7.80-7.75 (3 H, m, 3 H-arom), 7.69 (1 H, br s, 1 H-arom), 7.46-7.33 (3 H, m, 
3 H-arom), 5.53 (1 H, br d, J = 3.5 Hz, H-4), 5.14 (1 H, dd, J = 8.0 and 9.8 Hz, H-2),  4.82 (1 
H, AB system, J = 12.4 Hz, CHH), 4.53 (1 H, AB system, J = 12.4 Hz, CHH),  4.24 (1 H, d, J 
= 8.0 Hz, H-1), 4.20-4.11 (2 H, m, 2 H-6), 3.76 (1 H, br t, J = 6.6 Hz, H-5), 3.57 (1 H, dd, J = 
3.5 and 9.8 Hz, H-3); 3.43 (1 H, s, CH3), 2.08, 2.03 and 2.0 (3 x 3 H, 3 s, 3 CH3); 
13
C NMR 
(100 MHz, CD3OD) δ 170.3, 170.2 and 169.4 (3 CO), 135.0, 133.2, 133.0, 128.1, 127.8, 
127.7, 126.5, 126.2, 126.0 and 125.7 (10 C-arom), 102.0 (C-1), 76.6 (C-3), 71.3, 70.8 and 
70.4 (CH2, C-2 and C-5), 66.0 (C-4), 61.9 (C-6), 56.6 (CH3), 20.9, 20.7 and 20.6 (3 CH3); 
HR-ESI-MS m/z calculated for C24H28O9 (M + Na)
+




A stirred solution of methyl glycoside 19 (2.4 g, 
5.3 mmol) in Ac2O/H2SO4/CH2Cl2 
(1.97:0.055:24 mL) was warmed from -15 °C to 4 °C 
overnight and then was neutralized upon addition of 
NaHCO3 at 0 °C. The reaction mixture was diluted 
with ethyl acetate and washed with water and brine. The organic layer was dried (Na2SO4), 
filtered and purified by flash chromatography (eluent: cyclohexane/ethyl acetate 100:0 to 
cyclohexane/ethyl acetate 40:60) to give tetra-acetylated intermediate 20 (2.4 g, 95%). TLC 
Rf   = 0.55 (cyclohexane/ethyl acetate 6:4). Peracetylated derivative 20 (2.4 g, 4.92 mmol) was 
further reacted with piperidine (583 µL, 5.9 mmol) in dry THF (10 mL) at RT under inert 
atmosphere overnight and then quenched with aq. HCl 1N. The solvent was evaporated under 
reduced pressure and the crude residue was purified by flash chromatography (eluent: 
cyclohexane/ethyl acetate 100:0 to cyclohexane/ethyl acetate 80:20) to provide 2,4,6-tri-O-
acetyl-3-O-(2-naphthyl)methyl-D-glucopyranose (2.12 g, 95%) as an colorless oil. TLC Rf = 
0.56 (cyclohexane/ethyl acetate 1:1). To a solution of this intermediate (2.12 g, 4.75 mmol) in 
CH2Cl2 (15 mL) were added trichloroacetonitrile (4.76 mL, 47.5 mmol) and 1,8-
diazabicyclo(5.4.0)undec-7-ene (DBU, 355 µL, 2.38 mmol) dropwise at 0 °C. The mixture 
was then stirred at RT for 2 h and then concentrated in vacuo. The residue was purified by 







0.1 % Et3N in cyclohexane/ethyl acetate 80:20) to give glycoside donor 21 (2.03 g, 73%) as a 
pale yellow oil as a mixture of α/β (85/15) anomers. Rf = 0.84 (cyclohexane/ethyl acetate 
1:1); 
1
H NMR (300 MHz, CDCl3) (α anomer) δ 8.61 (1 H, s, NH), 7.88-7.80 (3 H, m, 3 H-
arom), 7.78 (1 H, br s, 1 H-arom), 7.50-7.41 (3 H, m, 3 H-arom), 6.60 (1 H, d,  J = 3.5 Hz, H-
1),  5.72 (1 H, d,  J = 2.8 Hz, H-4), 5.33 (1 H, dd, J = 3.5 Hz and  J  = 10.5 Hz, H-2), 4.91 (1 
H, AB system, J  = 12.1 Hz, CHH), 4.68 (1 H, AB system, J  = 12.1 Hz, CHH), 4.37 (1 H, br t, 
J = 6.2 Hz, H-5), 4.24 (1 H, dd, J  = 6.1 Hz, J = 11.4 Hz, H-6), 4.14-4.07 (2 H, m,  H-3 and H-
6), 2.19, 2.05 and 2.01 (3 x 3 H, 3 s, 3 CH3); 
13
C NMR (100 MHz, CDCl3) δ 170.4 (COα), 
170.2 (COα), 170.0 (COα), 160.7 (C=NH), 134.8, 133.2, 133.1, 128.1, 127.8, 127.7, 126.8, 
126.2, 126.1 and  125.9 (10 C-arom), 94.0 (C-1α), 90.9 (CCl3), 72.4 (C-3), 71.7 (CH2),  69.6 
(C-5), 68.9 (C-2), 66.7 (C-4), 61.9 (C-6), 20.7, 20.6 and 20.5 (3 CH3); HR-ESIMS: m/z 
Calculated for C25H26Cl3NO9 [M + Na]
+




A stirred solution of known compound 22
56
 (2.23 g, 4.53 
mmol) in 0.8 M ethylenediamine in MeOH (9.6 mL) was 
warmed at 50 °C for 5 h. Then the solvent was evaporated 
under reduced pressure and the crude residue was purified by 
flash chromatography (eluent: CH2Cl2/MeOH 100:0 to 
CH2Cl2/MeOH 90:10) to give the free amine intermediate 
(1.6 g, 97%). TLC Rf = 0.46 (CH2Cl2/MeOH 9:1). To a solution of this free amine 
intermediate (770 mg, 2.12 mmol) in dry CH2Cl2 (15 mL) at 0 °C were successively added 
triethylamine (311 µL, 2.23 mmol) and 3-methoxybenzoyl chloride (313 µL, 2.23 mmol). 
The reaction mixture was reacted from 0 °C to RT under inert atmosphere for 6 h. The crude 
reaction mixture was then diluted with CH2Cl2 and successively washed with 0.2 N aqueous 
HCl, aqueous saturated NaHCO3 and brine. The extract was dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash chromatography on 
silica gel (eluent:  cyclohexane/ethyl acetate 100:0 to cyclohexane/ethyl acetate 50:50) to 
give 2-azidoethyl 6-O-tert-butyldimethylsilyl-2-deoxy-2-(3-methoxybenzamido)-β-D-
glucopyranoside, compound 23 (840 mg, 80%). TLC Rf = 0.23 (cyclohexane/ethyl acetate 
1:1); HR-ESIMS: m/z Calculated for C22H36N4O7Si [M + Na]
+







This intermediate (830 mg, 1.67 mmol) was further reacted with pyridine (270 µL, 
3.34 mmol) and acetyl chloride (131 µL, 1.84 mmol) in dry THF (15 mL) at -20 °C to RT 
under inert atmosphere for 5 h. The solvent was evaporated under reduced pressure and the 
crude residue was then solubilized with ethyl acetate and successively washed with 0.2 N 
aqueous HCl, aqueous saturated NaHCO3 and brine. The extract was dried over Na2SO4, 
filtered and concentrated under reduced pressure and then purified by flash chromatography 
(eluent: cyclohexane/ethyl acetate 100:0 to cyclohexane/ethyl acetate 65:25) to provide 
glycosamine acceptor 24 (679 mg, 76%). TLC Rf = 0.42 (cyclohexane/ethyl acetate 1:1); 
1
H 
NMR (400 MHz, CDCl3) δ 7.34 (1 H, br s, 1 H-arom), 7.30-7.24 (2 H, m, 2 H-arom), 7.00 (1 
H, dt, J = 2.1 and 7.4 Hz, 1 H-arom), 6.79 (1 H, d, J = 9.2 Hz, NH), 5.35 (1 H, dd, J = 9.4 and 
10.2 Hz, H-3), 4.75 (1 H, d, J = 8.3 Hz, H-1), 4.20 (1 H, q, J = 9.1 Hz, H-2), 4.02-3.88 (3 H, 
m, 2 H-6 and 1 OCHH), 3.81 (1 H, t, J = 9.3 Hz, H-4), 3.78 (3 H, s, OCH3), 3.71-3.64 (1 H, 
m, OCHH), 3.57-3.51 (1 H, m, H-5), 3.47-3.38 (1 H, m, CHH), 3.29 (1 H, dt, J = 4.2 and 
13.2 Hz, CHH), 2.07 (3H, s, CH3), 0.92 (3  3 H, s, SiC(CH3)3), 0.13 (3 H, s, SiCH3), 0.12 (3 
H, s, SiCH3); 
13
C NMR (100 MHz, CDCl3) δ 172.3 and 167.9 (2 CO), 159.8, 135.8, 129.6, 
118.9, 117.8 and 112.5 (6 C-arom), 101.0 (C-1), 75.58 (C-3), 74.8, (C-5), 71.3 (C-4), 67.6 
(OCH2), 64.4 (C-6), 55.40 (OCH3), 54.3 (C-2), 50.8 (CH2), 25.9 (3 SiC(CH3)), 21.09 (CH3), 
18.34 (SiC(CH3)3), - 5.35 and - 5.37 (2 SiCH3); HR-ESIMS: m/z Calculated for 
C24H38N4O8Si [M + Na]
+




A solution of TBSOTf (1 M in 
CH2Cl2; 70 mL, 0.070 mmol) was 
added to a mixture of acceptor 24 
(200 mg, 0.37 mmol) and donor 21 
(273 mg, 0.46 mmol) in anhydrous 
dichloromethane at -20 °C under 
argon and further stirred at this temperature, followed by TLC (cylohexane/ethyl acetate 6:4). 
After 1 h, 21 was entirely consumed, as monitored by TLC (cyclohexane/ethylacetate 6:4), 
and DiPEA (14 mL, 0.08 mmol) was added. The solvent was evaporated under reduced 
pressure, and the crude residue was purified by flash chromatography (eluent: 







hydrolyzed donor, and acceptor. Then the mixture was treated with HF-pyridine (2 mL) in 
CH3CN (2 mL) at 0 °C for 2 h. The crude reaction mixture was then diluted wit ethyl acetate 
and washed with aqueous saturated NaHCO3 (2 × 20 mL), and brine. The extract was dried 
over Na2SO4, filtered, and concentrated under reduced pressure. Flash chromatography 
(eluent : cyclohexane/ethyl acetate 100:0 to 40:60) of the resulting residue provided 
disaccharide 25 (100 mg, yield 32%); TLC Rf = 0.49 (cyclohexane/ethyl acetate 0:1); 
1
H 
NMR (400 MHz, CDCl3): δ = 7.85–7.78 (m, 3H), 7.69 (br s, 1H), 7.51–7.45 (m, 2H), 7.37–
7.32 (m, 2H), 7.28–7.23 (m, 1H), 7.19 (t, J = 7.9 Hz, 1H), 7.00–6.93 (m, 2H), 5.52 (d, J = 3.5 
Hz, 1H), 5.27 (dd, J = 9.0, 10.7 Hz, 1H), 5.02 (dd, J = 8.0, 10.0 Hz, 1H), 4.81 (AB system, J 
= 12.3 Hz, 1H), 4.66 (d, J = 8.3 Hz, 1H), 4.53 (AB system, J = 12.3 Hz, 1H), 4.49 (d, J = 8.0 
Hz, 1H), 4.40–4.30 (m, 1H), 4.14 (dd, J =6.9, 11.0 Hz, 1H), 4.06 (dd, J = 6.9, 11.6 Hz, 1H), 
3.98 (ddd, J = 3.6, 5.6, 11.1 Hz, 1H), 3.94–3.87 (m, 2H), 3.84–3.78 (m, 1H), 3.77–3.70 (m, 
2H), 3.57 (dd, J = 3.5, 10 Hz, 1H), 3.43–3.33 (m, 1H, H-5), 3.29 (ddd, J =3.6, 5.6, 13.3 Hz, 
1H), 2.11, 2.07. 2.00 and 1.99 ppm (4 s, 4V3H); 
13
C NMR (100 MHz, CDCl3): δ = 171.6, 
170.6, 170.3, 169.5, 167.7, 159.8, 135.8, 134.8, 133.2, 133.2, 129.5, 128.3, 127.9, 127.8, 
126.8, 126.3, 126.2 and 125.7, 119.0, 117.6, 112.8, 101.5, 101.4, 76.6, 75.6, 75.5, 73.5, 71.6, 
71.0, 70.9, 68.1, 65.7, 61.6, 60.7, 55.4, 53.9, 50.6, 20.9, 20.8, 20.7 ppm; HR-ESIMS: m/z 
Calculated for C41H48N4O16: 875.2963 [M+Na]
+
; found: 875.2993. 
2-Azidoethyl [3-O-(2-naphthyl)methyl--D-galactopyranosyl]-(1-4)-2-deoxy-2-(3-
methoxybenzamido)--D-glucopyranoside (26) 
Disaccharide 25 (99 mg, 0.12 
mmol) was dissolved in MeOH 
(2 mL) and treated with sodium 
methoxide (10 µL of a 25% w/v 
solution in MeOH) at RT for 2 h. 
The reaction mixture was then 
neutralized with IR 120 (H
+
) resin, filtered, and concentrated under vacuum. The crude 
mixture was purified by flash chromatography on silica gel (eluent: CH2Cl2/MeOH 100:0 to 
90:10) to give compound 26 (60 mg, 75%); TLC Rf = 0.34 (CH2Cl2/MeOH 95:5); 
1
H NMR 
(400 MHz, DMSO-d6) δ  8.26 (1 H, d, J = 8.9 Hz, NH), 7.94 (1 H, s, H arom naphthyl), 7.93-
7.85 (3 H, m, 3 H arom naphthyl), 7.60 (1 H, dd, J = 1.6 and 8.4 Hz, 1 H arom naphthyl), 
7.54-7.46 (2 H, m, 2 H-arom naphthyl), 7.42 (1 H, dd, J = 1.6 and 7.6 Hz, 1 H-arom MeOBz), 






7.39-7.34 (2 H, m, 2 H-arom MeOBz), 7.12-7.04 (1 H, m, 1 H-arom MeOBz), 5.34 (1 H, d, J 
= 5.2 Hz, OH), 4.87 (1 H, AB system, J = 12.4 Hz, CHH), 4.74 (1 H, AB system, J = 12.4 Hz, 
CHH), 4.71-4.63 (4 H, m, 4 OH), 4.61 (1 H, d, J = 8.7 Hz, H-1), 4.31 (1 H, d, J = 7.8 Hz, H-
1’), 3.99-3.94 (1 H, m, H-4’), 3.92-3.81 (3 H, m, OCHH, H-6a’, H-2), 3.80 (3 H, s, CH3), 
3.75-3.51 (6 H, m, H-3, H-6b’, OCHH, H-2’, H-6a, H-6b), 3.50-3.34 (6 H, m, H-5’, H-4, 2 
CHHN3, H-5, H-3’); 
13
C NMR (100 MHz, DMSO-d6) δ 165.8 (CONH), 159.0 (C arom 
MeOBz), 136.6 and 136.5 (C arom naphthyl and C arom MeOBz), 132.8 and 132.4 (2 C 
arom naphthyl), 129.2 (C arom MeOBz), 127.6, 127.5, 126.0, 125.8 and 125.7 (7 C arom 
naphthyl), 119.4, 116.6 and 112.6 (3 C-arom MeOBz), 103.9 (C-1’), 100.7 (C-1), 81.4 and 
81.2 (C-4 and C-3’), 75.5 and 75.3 (C-5 and C-5’), 72.2 (C-3), 70.4 (CH2), 69.7 (C-2’), 67.1 
(CH2), 64.7 (C-4’), 60.7 and 60.5 (C-6’ and C-6), 55.2 (CH3), 55.1 (C-2), 50.2 (CH2); HR-
ESIMS: m/z Calculated for C33H40N4O12 [M + Na]
+




To a solution of azido derivative 26 
(55 mg, 80.3 µmol) in THF (2 mL) 
were added PMe3 (1 M in THF) 
(120 µL, 1.5 eq.) under argon and 
further stirred one day at RT. H2O was 
then added to the mixture, which was 
further heated at 50 °C overnight. The crude mixture was then evaporated to dryness under 
reduced pressure and the residue purified by flash chromatography on silica gel (eluent: 
CH2Cl2/MeOH 100:0 CH2Cl2/MeOH 50:50) to give compound 27 (53 mg, 80%); TLC Rf = 
0.05 (CH2Cl2/MeOH 90:10); 
1
H NMR (400 MHz, CD3OD) δ 7.93 (1 H, br s, 1 H arom 
naphthyl), 7.87-7.83 (3 H, m, 3 H-arom naphthyl), 7.60 (1 H, dd, J = 1.4 Hz and 8.5 Hz, 1 H-
arom naphthyl), 7.50-7.44 (2 H, m, 2 H-arom naphthyl), 7.46-7.34 (3 H, m, 3 H arom 
MeOBz), 7.12-7.08 (1 H, m, 1 H arom MeOBz), 4.96 (1 H, AB system, J = 12.1 Hz, CHH), 
4.84 (1 H, AB system, J = 12.1 Hz, CHH), 4.62 (1 H, d, J = 8.3 Hz, H-1), 4.45 (1 H, d, J = 7.8 
Hz, H-1’),  4.08 (1 H, d, J = 3.0 Hz, H-4’), 4.01 (1 H, dd, J = 8.3 and 9.5 Hz, H-2), 4.00-3.82 
(4 H, m, 2 H-6’, OCHH and H-3), 3.85 (3 H, s, CH3), 3.84-3.73 (1 H, m, H-6), 3.73 (1 H, br t, 
J = 7.8 Hz, H-2’),  3.74-3.48 (5 H, m, H-6, H-4, CHH, H-5 and H-5’), 3.47 ( 1 H, dd, J = 3.0 
and 9.4 Hz, H-3’), 2.80 (2 H, br s, CH2); 
13







159.8 (C arom MeOBz), 136.0 and 135.9 (C arom naphthyl and C arom MeOBz), 133.3 and 
133.1 (2 C arom naphthyl), 129.2 (C arom MeOBz), 127.6, 127.5, 127.3, 126.3, 125.8, 125.7 
and 125.5 (7 C arom naphthyl), 119.0, 117.0 and 112.4 (3 C-arom MeOBz), 103.8 (C-1), 
101.6 (C-1’), 80.9 (C-3’), 80.0 (C-4), 75.6 (C-5), 75.3 (C-5’), 72.6 (C-3), 71.3 (CH2), 70.6 
(C-2’), 70.0 (CH2), 65.8 (C-4’), 61.1 (C-6), 60.6 (C-6’), 55.8 (C-2), 54.5 (CH3), 40.6 (CH2); 
HR-ESIMS: m/z Calculated for C33H43N2O12 [M + Na]
+





To a solution of azido derivative 27 
(20 mg, 0.030 mmol) in THF (2 mL) 
were added PMe3 (1 M in THF, 60 µL) 
under argon and further stirred one day 
at RT. H2O was then added to the 
mixture which was further heated at 50 
°C overnight. The crude mixture was evaporated to dryness under reduced pressure then 
diluted with DMF (2 mL). To this solution N,N-diisopropylethylamine (7.6 mL, 0.044 mmol) 
and fluorescein isothiocyanate (14.8 mg, 0.038 mmol) were added under argon and stirred 
overnight at RT. The mixture was concentrated under reduced pressure and then purified by 
flash chromatography (eluent: CH2Cl2/MeOH 100:0 to CH2Cl2/MeOH 95:5) to provide the 
flurescent compound 28 (16.1 mg, 55%). TLC Rf = 0.26 (CH2Cl2/MeOH 9:1); ESIMS: m/z 
Calculated for C54H52N3O17S [M - H]
-







2.3. Affinity studies (Experiments have been carried out by the lab technician Dr. Annie 
Lambert) 
 
Fluorescence polarization (direct assay) was used to evaluate the affinity of an 
inhibitor coupled with a fluorescent tag towards human recombinant Gal-1, Gal-3 and Gal-7, 
expressed in E. coli.  Fluorescence anisotropy was measured on a Tecan infinite M1000 plate 
reader with an excitation at 470 nm and emission at 525 nm, using Greiner 96 flat bottom 
black plate. Fixed probe concentration (0.1 µM) is added to an increasing concentration of 
galectin (0.001 to 200 µM) in a final sample volume of 200 µL (PBS containing 5% DMSO). 
Each measurement is realized after 1 hour incubation at room temperature or at 4 °C under 
100 rpm (in duplicate). 
Kd, Amax and A0 were characterized for every galectin/labeled inhibitor pair tested 
using PRISM 7 software (GraphPad, USA). 
Kd values for 28 were determined by fitting anisotropy data using non-linear least 




Whereby, Y = fluorescence anisotropy (A or mA); X = galectin concentration (μM); 
A0 = Ymin; Amax = Ymax Ymin; Cl = labeled inhibitor concentration (μM); Kd = labeled 
inhibitor dissociation constant (μM). 
 
For competitive fluorescence anisotropy assays, each inhibitor was incubated at a 0.2 
to 180 μM concentrations with a mixture of compound 26 (at a 0.1 μM concentration) and 
galectin-1 C3S, galectin-3 or galectin-7 (at a 1 μM concentration). Measurements were 
undertaken according to the same procedure reported for saturation polarization experiments. 













2.4. Preparation and characterization of HA NCs 
 
2.4.1. Preparation of HA NCs 
 
HA NCs were prepared by the solvent displacement technique, adapting the procedure 
earlier described by our group.
57
 Briefly, lecithin (Lec, 5.625 mg), oleylamine (OAm, 
1.125 mg) and olive oil (OO, 30 mg) were dissolved in 5 mL of ethanol. In the case of drug 
loaded NCs, Gal-3 inhibitor (2.5-5 mg) was incorporated to this phase. Then, the organic 
phase was injected through a needle (23G) to 10 mL of aqueous phase containing 2.5 mg of 
HA 700 kDa, and kept under magnetic stirring at 900 rpm during 10 minutes at room 
temperature. The elimination of organic solvent was performed by evaporation under vacuum 
(Rotavapor Heidolph, Germany) and the final volume adjusted to 5 mL with ultrapure water. 
Thereafter, the NCs were isolated by ultracentrifugation (Avanti® J-E, Ultracentrifuge, 
Beckman Coulter, USA) at 30,000×g for 1 h at 15 °C. 
 
2.4.2. Physicochemical and morphological properties of HA NCs 
 
The mean size and polydispersity index (PDI) of the HA NCs were measured after 
dilution (100×) with ultrapure water by dynamic light scattering (DLS) at 25 °C with an angle 
detection of 173°. The zeta potential (ζ) was measured by laser Doppler anemometry (LDA) 
after diluting the samples (100×) with ultrapure water. Both DLS and LDA analysis were 
performed in a Zetasizer®, NanoZS, Malvern Instruments, Malvern, UK. Particle size 
distribution and morphology were evaluated by transmission electron microscopy (TEM) 
using a JEOL JEM-2010 microscope, 200 KV, resolution: 0.23 nm (Tokyo, Japan). Samples 
for TEM analysis were diluted (20×), deposited on a copper grid, stained with a 
phosphotungstic acid solution (2% w/v) and allowed to dry overnight prior to analysis. The 
pH of formulations was measured at Sartorius Basic Meter PB-11, Sartorius AG, Germany. 
 
2.4.3. Gal-3 inhibitor encapsulation efficiency of the NCs 
 
The encapsulation efficiency (EE%) of Gal-3 inhibitor was determined after the 
isolation of the NCs by ultracentrifugation at 30,000×g for 1 h at 15 °C (Avanti® J-E, 






(EE% by direct method), the free drug in the undernatant (EE% by indirect method) and the 
total drug in the non-isolated NCs were quantified by high-performance liquid 
chromatography (HPLC), described below. For the extraction of Gal-3 inhibitor from the 
non-isolated, isolated NCs and undernatant, 0.1 mL of each sample were mixed with 0.9 mL 
ethanol/acetonitrile (ACN) and kept under magnetic stirring at a high speed overnight to 
obtain a clear solution. The samples were analyzed by HPLC method, developed specifically 
for this molecule based on the methods described for saccharides.
58–60
 The HPLC system 
consisted of a VWR-Hitachi LaChrom Elite
®
 system equipped with a UV detector L-2400 set 
at 254 nm and a reverse phase SunFire column 186002560, 100Å, C18 (4.6 ID × 250 mm, 
pore size 5 μm), Waters, USA. The mobile phase was a mixture of ACN and ultrapure water 
(60:40% v/v), isocratic, and the flow rate was 1 mL/min. The column was set at 30 °C and 
the injection volume was 20 μL. The standard calibration curves of Gal-3 inhibitor were 
linear in the range of 1-1000 μg/mL (r
2
 = 0.999). Samples were transferred into auto-sampler 
vials, capped and placed in the HPLC auto-sampler. The concentration of Gal-3 inhibitor in 







2.5. NCs loaded HA-fibrin in situ hydrogels  
 
Non-fortified HA-fibrin hydrogel samples with 30% of blank or Gal-3 inhibitor 
loaded NCs were prepared and characterized as described in Chapter 1 (Section 2.1). Briefly, 
fibrinogen (Fg), HAs, NCs were mixed in polymerization buffer and the gelation process was 
initiated by thrombin (Thr).   
 
2.6. In vivo studies 
 
2.6.1. Carrageenan-induced acute knee joint inflammation (synovitis) model 
 
At the day of experiment, animals were randomly separated into three groups (of at 
least 5 animals per group) and two reference animals (one was used for a carrageenan test and 






were anesthetized by intra-peritoneal injection (300 µL) of a solution containing ketamine 
(75 mg/kg) and medetomidine (0.50 mg/kg) and thereafter the skin around the knee joints 
was shaved.  
Carrageenan-induced knee joint inflammation model (synovitis) was used to evaluate 
the anti-inflammatory effect of the selected formulations. The acute synovial inflammation of 
the rat knee was induced 1 hour after the treatment by intra-articular (IA) injection of a 
freshly prepared solution of carrageenan (50 µL, 3% w/v) in physiological saline (0.9% w/v 





2.6.2. In vivo treatment  
 
Before distributing the animals according to the tested treatments, one animal was 
induced with carrageenan (identified I, Table 1), acting as a disease control  and one animal 
served as reference for gel syringeability test (identified II, Table 1), receiving 100 μL of 
HA-fibrin in situ gel with 30% blank NCs and without further inflammation induction. 
First group of animals was treated with blank NCs, used as vehicle control (group 1). 
Second group received Gal-3 inhibitor loaded NCs administered at the dose of 200 µg/kg 
(group 2). The third group was treated with HA-fibrin in situ gel with 30% Gal-3 inhibitor 
loaded NCs at the dose of 55 µg/kg (group 3). Groups 1-3 received an IA injection (100 μL) 
of the formulations using low dead space 30G  1/2'' Omnican 50 (BBraun) syringes 1 hour 
prior the injection of carrageenan. All the components were mixed in the syringe and 
immediately injected into the right knee. The left knee without injection was used as a 
control. Table 1 summarizes the animal distribution to the certain groups according to the 
tested materials and Gal-3 inhibitor doses. 
Samples for animal II and group 3, consisted of HA-fibrin hydrogel with 30% of 
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Table 2. The samples “HA-fibrin hydrogel + 30% NCs” composition. 
 
Composition Final concentration Volume (µL) 
Fg in 0.15 M NaCl 1.5 mg/mL 6 









Blank or Gal-3i NCs 30% 30 
Thr in PBS + 1% BSA 
(added as a last component) 
2 NIH-U/mL 2 
Total volume 100 
 
At time 4 hours after carrageenan injection (the peak of inflammation) 3 animals of 
each group were sacrificed by isoflurane inhalation and blood was collected by cardiac 






2.6.3. Knee swelling measurement   
 
The diameter of each rat shaved knee (in mm) was measured by digital calliper 
(150 mm / 6" - 0.01 mm, Perel Tools), before treatment and 2, 4, 6 and 24 hours after 
carrageenan injection. Before measurements, rats were additionally anaesthetized (if it was 
necessary) with inhaled isoflurane. Knee swelling was expressed as the change  in the 
knee diameter before and after the induction of inflammation: 
Knee swelling  = A - B, 
where A represents the knee diameter at different time points after injection, and B represents 
the knee diameter before injection. 
While, the percentage of increase in knee diameter (knee edema) of the right knee of 
each rat at each time point was calculated by the following equation: 
Percentage of increase = (A - B)/B  100, 
where A represents the knee diameter at different time points after injection, and B represents 
the in knee diameter before injection. 
 
2.6.4. Whole blood, plasma tests and histopathology studies  
 
Blood was collected into heparinized tubes and was used for whole blood analysis 
immediately. 
 The animal paws were surgically cut at the level above the patella. All the paws were 
fixed in 10% buffered formalin and decalcified with 10% formic acid before 
histopathological analysis. In order to evaluate the surroundings of the site of application, 
decalcified paws were processed for embedding in paraffin wax by using routine protocol. 
Sections (5 µm thick) were stained with haematoxylin and eosin (H&E). The slides were 
examined using light microscopy at 40, 100, 400 magnification using an Olympus BX40 
microscope coupled with an Olympus DP 10 camera (Olympus, Shinjuku, Tokyo, Japan). 
The images were obtained using the respective Olympus DP 10 camera software and edited 
with Microsoft Image Composite Editor. The histopathological appearance of tissues was 
compared for structure changes, edema and inflammatory cell infiltration (mononuclear 







2.7. Statistical analysis 
 
All the measurements at each experimental condition were carried out in triplicates 
and were expressed as mean ± standard deviation (SD). Statistical analysis of the data was 
performed using an one-way ANOVA and Student’s t-test using Microsoft® Excel software; 
a value of p < 0.05 was considered significant. 
Regarding the in vivo data, the mean ± standard error of mean (SEM) was determined 
for each treatment group (n = 5). The statistical analysis was carried out using a two-way 
ANOVA test followed by Bonferroni's post-hoc test. All other analyses were performed using 
a Student's t test. Differences were considered statistically significant at p < 0.05. 
 
3. RESULTS AND DISCUSSION 
 
3.1. Synthesis of galectin-3 inhibitors  
 
The natural ligands for Gal-3 are polylactosamine and LacNAc of both types I and 
II.
63
 Lactosamine type II core (Gal-β(14)GlcN) has been selected for the inhibitors 
preparation due to higher intrinsic affinity to Gal-3, Kd (LN2) = 33 µM versus Kd (LN1) = 
93 µM
64
. Gal-3 sugar binding site comprises 7 highly conserved amino acid residues (His158, 
Asn160, Arg162, Glu165, Asn174, Trp181, Glu184.
55,65
 Five of them (His158, Asn160, 
Arg162, Asn174 and Glu184) and highly conserved water molecules are involved in the tight 
cooperative hydrogen bonding with Gal O-5, OH-4 and OH-6 and GlcNAc OH-3, while 
Trp181 stabilizes the galactose residue through H- stacking
55
 (Figure 3). Other LacNAc 
positions do not contribute significantly to the binding.
28,55,63
 Especially important are the 
residues Arg144 and Arg186, because their guanidinium ions can establish cation-π 
interactions with aromatic substituents at Gal 3’-C and GlcN 2-C positions, increasing 
compound affinities and selectivities
28,51,66–68
 (Figure 3 and Figure 7, Chapter 
Introduction). Indeed, amino acids residues Arg144, Ala146 and Asn160 from the CRD side 
chains form a polar pocket that due to Arg144 presence, binds strongly to introduced 
aromatic substituents at 3’-C position of Gal by cation-π interactions.
28
 Similarly, Arg186 can 
bind introduced aromatic substituents at 2-C position of GlcN by mentioned interactions.
51,69
 
Additionally, aromatic substituents at both 3’-C and 2-C positions of the inhibitor are 








 Combination of aromatic substitutations at 3’-C and 2-C positions can provide 
additive or even synergistic effect to the binding when carried out on lactosamine or thio-
digalactoside scaffolds, respectively.
68,69
 While both scaffolds are able to discriminate 
between different galectins,
70
 the lactosamine one offers the unique advantage of further 
derivatization at its reducing end to obtain multivalent,
71,72
 grafted or labelled derivatives 
(Figure 4). All these possibilities make inhibitors based on LacNAc attractive and well-






Figure 3. Scheme showing possible modification of LacNAc unit with aromatic substituents 
at Gal 3’-C position and GlcN 2-C positions (surrounded with red circles) to increase affinity 
to Gal-3 CRD. 
 
We developed a first generation of inhibitors using 3-methoxyphenyl as the aromatic 
ring.
68,71
 Based on Nilsson and coworkers’ results, we hypothesized that 3-methoxyphenyl 
ring could be advantageously replaced by either a 2-naphthyl or a 3,5-dimethoxyphenyl at the 
Gal 3’-C position. In their hands, such substituents lead to 5× and 2× more affine inhibitors 
as well as considerably enhanced specificity towards Gal-7, respectively. It was also 
suggested that introduction of 3,5-dimethoxyphenyl, but not 2-naphthyl at GlcN 2-C position 
could provide more efficient stacking
69









Figure 4. A schematic representation of the strategy selected for Gal-3 inhibitors synthesis. 
 
Lactosamine is not commercially available at a reasonable price. Therefore access to 
the planned inhibitors could rely on amine functionalization at 2-C of D-lactal, in turn 
obtained from D-lactose in four steps or, alternatively, according to a glycosylation reaction 
between advanced galactose donor and glucosamine acceptor intermediates. 
Synthesis of inhibitors had been initially envisaged according to strategies (A) and 
(B), which differ from each other by the key reactions applied for lactal functionalization: (A) 





 as presented in Scheme 1.  
Synthetic pathways for both approaches started from D-lactal 4, derived from 
commercially available D-lactose in four known steps comprising peracetylation, bromation, 
zinc-mediated reductive elimination and Zemplén deacetylation,
76,77
 as detailed in Scheme 2. 
Subsequently regioselective arylation of the OH group at Gal-3 position of lactal 4 was 
envisaged using stannylene chemistry.
78
 To this aim, D-lactal was treated with dibutyltin 
oxide in refluxing methanol and the resulting unstable intermediate further treated with either 
3,5-dimethoxybenzyl bromide or (2-naphthyl)methyl bromide to provide derivatives 6 with 
63% and 42% yields, respectively. These intermediates were treated with an excess of 
chlorotriethylsilane in the presence of imidazole for protection of free hydroxy groups 
resulting to 3’-C substituted persilylated lactal 7 in quantitative yields 95% for both. 
Iodosulfonamidation and azido-phenylselenation were attempted in parallel on both 
derivatives. However, both procedures led to complex mixtures (monitored by TLC) and low 
yield of expected products, probably due to partial iodine oxidation of the naphthyl and 
considerable oxidation of highly electrophilic, dimethoxy substituted phenyl rings.  
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Scheme 1. A short scheme of derivatives preparation by 3 approaches: iodosulfonamidation 
(A), azidophenylselenation (B) and 1+1 glycosylation (a donor-acceptor coupling approach) 
(C). 
 
We, thus, envisaged to modify the original strategy and to carry out the 1-C, 2-C 
lactal functionalization prior to the introduction of the 3’-C aromatic group to circumvent 
these side-reactions. This novel approach was, however, attempted only for the 
azidophenylselenation-based strategy, which appeared more promising (Scheme 3). 
D-lactal 4, was persilylated as described previously to give intermediate 9 
(quantitative). Compound 9 was further treated with iodosylbenzene diacetate in the presence 
of diphenyl diselenide and trimethylsilyl azide to give 2-azido-1-phenylseleno disaccharide 
10 in the expected “gluco” configuration. Key intermediate 10 was deprotected to give 
polyhydroxylated derivative 11. Regioselective arylation of 11 using 3,5-dimethoxybenzyl 
bromide gave rise to intermediate 12, which was further acetylated to furnish azide 13 (96% 
yield). Azido group in 13 was reduced using an excess of trimethylphosphine to give amine 

































[DMF], imidazole, RT, 
12 h, 95% 
1. Acetylation: AcOH, Ac
2
O, HClO; RT, 1-2 h 
2. Bromination: HBr; [AcOH], 0 °C, 1 h, 94% 
 
3. Reduction: Zn, [AcOH/H
2
O]; 0 °C, 48 h, 72%. 
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reflux< 65-67 °C, 5 h. 
 
b) 3,5-diMeOBnBr 
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[DCM], DIEA, DMAP 
0-30 °C, 14 h 






Attempts to activate the phenylselenide at the anomeric position of the GlcN moiety e.g. 
using bromine to pursue the functionalization of this derivative led to the formation of 
unprecedented oxazoline 15. This compound was finally deprotected under Zemplén 
conditions to provide a first potential inhibitor 16. 
Having a 3,5-dimethoxyphenyl derivative in hands, we decided to prepare an inhibitor 
with a (2-naphthyl)methyl substituent to give enhanced and more specific interaction with the 
Gal-3, since larger π-systems are more polarizable and form stronger interactions with 
Arg144 cation in the polar pocket.
67
 This modification at the Gal 3’-C position is known to 
increase more than five times the affinity of the LacNAc to Gal-3 compared to a 3-
methoxybenzyl substituent,
79
 while conferring full and 22 times more selectivity for this 
galectin versus the galectin-7 and galectin-1, respectively.
69
 Thus, we devised a new synthetic 
approach (Scheme 1, route (C)), named “1+1” glycosylation, relying on the glycosylation 
reaction between a galactosyl donor and a glucosamine acceptor for its assembly to a 
disaccharide. The latter was thought to be equipped with an azido spacer to afford further 
modulation of its properties.  
This synthetic route started with regioselective alkylation of commercially available 
methyl β-D-galactopyranoside 17 using (2-naphtyl)methyl bromide as the electrophile. 
Resulting derivative 18 was acetylated to give 19, which, in turn, was submitted to acetolysis. 
Maintaining the reaction temperature below 4 °C proved essential to prevent premature 
hydrolysis of the napthyl ether group as a side-reaction. Intermediate 20 was finally 
transformed into galactosyl trichloroacetimidate donor 21. In parallel, removal of the 
phthaloyl protecting group of the known 2-azidoethyl glucosamine derivative 25
56
 with 
ethylenediamine followed by acylation (23) and selective acetylation of the 3-OH gave key 
acceptor 24. Glycosylation of donor 21 with acceptor 24 followed by desilylation furnished 
the expected disaccharide 25 in a moderate yield, consequence of the disarming effect of both 
3-methoxybenzamido and acetate on 24, together with important amount of desilylated 
acceptor. Final step consisted in the deacetylation of 25 to give di-aromatic inhibitor 26 (2-
azidoethyl [3-O-(2-naphtyl)methyl-β-D-galactopyranosyl]-(1-4)-2-deoxy-2-(3-
methoxybezamido)-β-D-glucopyranoside). Azido group of 26 was next reduced in the 
presence of trimethylphosphine to give amino intermediate 27. Compound 27 was reacted 
with fluorescein isothiocyanate to give a fluorescent probe 28 for further affinity evaluation 
























Scheme 4. The sequence of the reactions in 1+1, donor-acceptor coupling 













< 65-67 °C, 5 h. 
 
b) NaphtylMeBr  





   










 [DCM], -15 °C   4 °C, 12 h 
 
b) piperidine, THF, RT, 12 h,  
c) Cl3CCN, DBU cat, [DCM], 
RT, 





], -30 °C, 1 h; 
b) HF-py, [ACN], 0 °C, 2 h, 32% 








FITC, DiPEA, [DMF], 55% 
 
 a) Ethylenediamine 
  [MeOH], 50 °C, 5 h, 97% 
 
b) 3-Methoxybenzoyl-Cl 
[DCM], Et₃N, RT, 6 h, 80% 
c) AcCl, Py 
 THF, -20°C, 5 h, 76% 
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26   R = 







Finally, the introduction of a spacer arm at position 1-C of GlcN, initially envisaged 
for all the approaches, may be used to modulate the properties of the inhibitor: providing the 
hydrophobicity (for following encapsulation), grafting to the polymers or binding to the 
scaffolds for multivalent inhibitors preparation.  
 
3.2. Affinity studies 
 
An intact inhibitor 16, 26, fluorescein-labeled derivative 28, an intact inhibitor and 
TD139 were selected for affinity studies by direct fluorescence polarization assay (Table 
3).
80
 In vitro evaluation of dissociation constants has been carried out at two different 
temperatures for the recombinant human galectin-1 C3S (a stable mutant in which Cys is 
substituted for oxidation-insensitive Ser),
81
 galectin-3 and galectin-7.  
 
Table 3. Dissociation constants of FITC-labeled compound 16, compound 26, compound 28 
and TD139 and galectin-1 C3S, galectin-3 and galectin-7. 
                             Kd (µM)
[a]  
Compound Galectin-1[b] Galectin-3 Galectin-7 Affinity 
Temperature 4 °C 
LacNAc-β-OMe [c] 65 ± 28 n.d.  550 ± 98 + 
16 112 ± 7 4.4 ± 0.25 249 ± 21 ++ 
26 27 ± 5 0.59 ± 0.11 90 ± 35 +++ 
28 16 ± 1 0.014 ± 0.005 21 ± 1 ++++ 
TD139 2.2 ± 1.4 0.036 ± 0.023 32 ± 17 ++++ 
TD139[e] 0.012 ± 0.003 0.014 ± 0.003 1.9 ± 0.38  ++++ 
RT 
LacNAc-β-OMe [c] n.d. 59 ± 12 n.d. + 
16  n.d. 23 ± 0.31 n.d. ++ 
26  n.d.
[d] 2.99 ± 0.17 n.d. +++ 
28  43 ± 4 0.082 ± 0.014 129 ± 18 ++++ 
TD139  n.d. 0.166 ± 0.091 n.d. ++++ 
TD139 [f] 0.22 ± 0.05 0.068 ± 0.01 38 ± 0.71 ++++ 
[a] Mean values from two assays; [b] Galectin-1: galectin-1 C3S (this study) or native 
galectin-1 (last two rows) [c] Determined by fluorescence polarization (from 
reference67); [d] n.d. = not determined; [e] Measured by fluorescence polarization at RT 






Fluorescence polarization is sensitive to experimental temperature and higher affinity 
is observed at lower temperature in these studies. Moreover, the fluorescein tag has been 
shown to contribute galectins binding.
63,67,70
 Compound 28 displayed very high selectivity: 
Kd(Gal-1)/Kd(Gal-3) = 524 and Kd(Gal-7)/Kd(Gal-3) = 1573 at RT or  
Kd(Gal-1)/Kd(Gal-3) = 1143 and Kd(Gal-7)/Kd(Gal-3) = 1500 at 4 °C. 
This derivative was also used as probe for competitive fluorescence polarization 
assays at 0.1 µM with 1 µM galectin. Inhibitors 26 and 16 as well as TD139 as a positive 
control were assessed for binding affinity to Gal-1 C3S, Gal-3 and Gal-7 at 4 °C or RT. 
Compound 26 was much less recognized than 28 by these lectins, which supports the idea 
that the fluorescent tag facilitates galectin recognition,
28
 having Kd values in the sub-
micromolar range toward Gal-3. Noticeably, compound 26 was selective for Gal-3 over Gal-1 
(Kd(Gal-1)/Kd(Gal-3) = 46) as well as highly selective over Gal-7, (Kd(Gal-7)/Kd(Gal-3) = 
152. The same tendency was observed for compound 16 – Gal-3 over Gal-1 
(Kd(Gal-1)/Kd(Gal-3) = 25.5 and Gal-3 over Gal-7 (Kd(Gal-7)/Kd(Gal-3) = 57. To ascertain 
these experimental data, TD139 was introduced as a positive control and the determined 
values compared to that reported in the literature. While determined Kd of TD139 for the 
galectin-3 was in good agreement with the values reported by Leffler et al., some 
discrepancies were noted, in particular, regarding galectin-1
82
 (Table 3). Indeed, TD139 was 
claimed not to discriminate between galectin-1 and galectin-3, what is in disagreement with 
our results. Although both series of data were obtained by fluorescence anisotropy assays, the 
use of different probes at different concentrations might explain the observed bias. However, 
our data correlate well with reported Kd values of TD139 for Gal-1, Gal-3 and Gal-7 
determined by isothermal titration calorimetry (ITC).
51
 
As we proved, careful choice of aromatic substituents (2-naphthyl)methyl or 3,5-
dimethoxybenzyl at 3’-C position of Gal has enhanced both the affinity and the specificity 
toward galectin-3. As expected, methoxy-substituents at meta-position of the introduced 
aromatic ring of compound 16 facilitate the complexation between the tested inhibitor and 
CRD of Gal-3.
28
 Interestingly, binding of compound 16 to Gal-7 or Gal-1 is in the same order 
or even less, respectively, than naked type II lactosamine, suggesting that oxazoline 
substituent is counter-productive to Gal-7 and Gal-1 recognition. This inhibitor can, however, 
be accommodated by Gal-3 CRD with a potency in the µM range. Thus, inhibitor 26 






4 °C and RT, correspondingly, designing the derivative 26 as a lead compound for evaluation 
of Gal-3 inhibition in vivo. 
 
3.3. Development and characterization of Gal-3 inhibitor loaded NCs 
 
To avoid a rapid removal of compound 26, named as the Gal-3 inhibitor (Gal-3i), 
from the intra-articular cavity, we decided to load this derivative in the previously developed 
DDS (Chapter 1). Thus, first we designed, produced and characterized Gal-3i loaded NCs to 
be later incorporated into a HA-fibrin hydrogel. 
Blank and Gal-3i-loaded HA NCs were successfully prepared using the simple 
solvent displacement technique. The particle size, zeta potential and encapsulation efficiency 
of the formulations are summarized in Table 4.  
 
Table 4. Physicochemical characteristics of the nanocapsules (NCs) prepared with 700 kDa 
HA (mean ± SD; n = 3). PDI: polydispersity index, EE%:  
 










Blank 121 ± 10 0.2 −30 ± 3 n/a n/a 
Gal-3i NCs 122 ± 11 0.2 −29 ± 5 0.53 ± 0.05 11 ± 2% 
 
For the preparation of HA-based NCs, we used the following components: olive oil 
(OO), lecithin (Lec), oleylamine (OAm) and HA. The ratio Gal-3i/OO/Lec/OAm/HA was 
0.9:4:1:0.2:0.44. In order to obtain small particle sizes, the preparation of the NCs was made 
injecting the organic phase over the aqueous phase through a needle. The particle size for 
drug loaded formulations, determined by DLS, was 122 ± 11 nm, PDI 0.2 and ζ-potential −29 
± 5 mV, encapsulation efficiency 11 ± 2% (531 ± 5 µg/mL).   
 
3.4. Stability of the NCs 
 
No drug leakage was observed upon 5 days storage of NCs and after 5 months 74 ± 







3.5. NCs loading into in situ hydrogel 
 
We have shown the capacity of HA-fibrin in situ hydrogels to load HA NCs (Chapter 
1, Section 3.1). Maximal incorporation capacity of Gal-3i loaded NCs to in situ HA-fibrin 
hydrogel was 30% (v/v). Gelation process of blank and NCs loaded hydrogels was monitored 
by turbidity analysis and verified by rheology studies. Complete characterization of NCs 
loaded hydrogels is given in the Chapter 1 (Section 3.2).  
None of the DDS components doses is suppose to cause any inflammatory response in 
vivo. Cirino et al. found that thrombin administrated intra-articularly mediates inflammation 
in the rat paw at doses 1-10 NIH-U/paw.
84
 Although the hydrogel formation is activated by 
Thr at dose 0.2 NIH-U per injection, this value is 5 times below the limit causing transient 
edema or moderate inflammation.  
 
3.6. In vivo studies 
 
3.6.1. Carrageenan-induced acute knee joint synovitis 
 
The homology between human and rat Gal-3 CRDs is about 96.5%, confirmed by 
structure-based sequence alignment of mammalian Gal-3s’ CRD S4-S6 β-strands 
fragments,
64
 which make the rat models appropriate for in vivo testing of human Gal-3 
inhibitors.  
There are different models of RA in rats: acute (short term inflammation) and chronic 
(long-lasting inflammation), that share similar features with human RA. Thus, acute models 
are induced by carrageenan (1% - 3% solutions)
62,85–95
 or type-II collagen,
23,96–101
 while 
chronic models include antigen-induced arthritis by methylated BSA,
102–105
 adjuvant-induced 
arthritis by Mycobacterium butyricum
85,87




Short term models are the preferred for drug screening and testing of cell therapies, 
they constitute useful tools to designed specific therapeutic interventions to suppress synovial 
inflammation.
85
 Therefore, an acute carrageenan-induced synovitis model was selected for 
Gal-3i evaluation. Carrageenan-induced knee swelling is a two-step process: during 1 hour 
the release of histamine, serotonin and bradykinin is observed, as well as initial levels of 






generation, polymorphonuclear leucocytes infiltration and release of pro-inflammatory 
markers, NO, and free radicals.
107,108





3.6.2. Anti-inflammatory activity of Gal-3 inhibitor in synovitis rat model 
 
Intra-articular injections of carrageenan led to significant increase of the knee 
diameter of hindpaw (~ 40%) due to the swelling process, which correlates well with the 
results described by Ekundi-Valentim et al.
62
 At 4 hours after carrageenan injection the knee 
diameter reached the maximum value (Figure 5). Interestingly, the treatment with blank 
NCs, Gal-3i NCs and “HA-fibrin hydrogel + 30% Gal-3i NCs” prevented this tendency. In 
this way, blank NCs showed to slightly diminish the inflammation. This can be explained by 
the rational selection of components; on the one hand, olive oil core presents anti-
inflammatory functions, due to the high content of oleocanthal with ibuprofen-like 
activity.
94,109,110
 On the other hand, the NCs shell polymer, 700 kDa HA, is known to be the 
most effective among hyaluronans of different MWs in reducing synovial inflammation.
111
 
Gal-3i NCs at the dose of 200 µg/kg reduced the inflammation in about 3.5 times at Δ4 hours 
compared to carrageenan control and 2 times compared with blank NCs. Noticeably, HA-
fibrin hydrogel with 30% Gal-3i NCs caused an effective swelling inhibition in about 7 times 
compared to carrageenan control (Figure 5). This becomes more remarkable if we consider 
that the dose used for group 3 is considerably lower than for the group 2 (55 vs 200 µg/kg). 
Possibly, HA-fibrin hydrogel effectively keeps NCs within the articular cavity, modulates the 









Figure 5. Effect of the treatment with Gal-3 inhibitor on the carrageenan-induced joint 
inflammation model using NCs, and NCs in a gel compared to blank NCs and carrageenan 
control (n = 5/6 for groups 1-3, n = 1 for carrageenan and gel control). Δ is the difference in 
knee diameter at different time points before and after injection of carrageenan, expressed in 
mm. Data is expressed as mean ± SEM. 
 
3.6.3. Blood tests (immune cells level changes) 
 
Blood samples were collected at 4 hours after carrageenan injection (n = 3), before the 
animals were euthanized, and analyzed on the same day. The total leucocytes formula and 
amount of lymphocytes, neutrophils and monocytes are presented in Figure 6, which 
illustrates the changes in cell levels. 
The inflammation process is accompanied by rapid inversion of the leukogram ratio: 
decrease of lymphocytes and increase of neutrophils,
62
 which in turn attract macrophages and 
dendritic cells,
112
 presented at the Figure 6 as total monocytes. Considering the obtained 
results, Gal-3i loaded NCs in the hydrogel is able to prevent this tendency, improving the 












Figure 6. Effect of the treatment with Gal-3 inhibitor on leukocyte levels at the blood plasma 
at different doses administered in NCs, and the gel compared to blank NCs and carrageenan 
control (n = 5 for groups 1-3, n = 1 for carrageenan and gel control). Data expressed as mean 
± SEM. 
 
3.6.4. Histopathological scores 
 
After decalcification process the rat hind paws and knees specimens were sliced, 
stained and analyzed by light microscopy (Figure 7). 
Articular cartilage from carrageenan control rat had a normal histological appearance. 
Leukocytes margination and moderate infiltration of neutrophils and its accumulation in the 
synovial membrane surface, sometimes with synovial membrane surface cell loss were 
observed. Articular cavity included several neutrophil and fibrin agglomerates. In the 
surrounding tissues edema and neutrophil infiltration into the capsule and into the skeletal 






membranes with great emphasis on vascular phenomena. Hence, carrageenan control 
exhibited a pronounced inflammatory response (Figure 7A), which is consistent with the 
reported histological data by other authors.
62,113
   
The treated groups 1-3 revealed no microscopic changes in the articular cartilage. 
Congestion of synovial membranes was observed in all the groups, however accumulation of 
neutrophils and fibrin in the surface of synovial membrane was detected in both groups 1 
(Figure 7B) and 2 (Figure 7C), while only light/moderate neutrophils infiltration was found 
in group 3 (Figure 7E). Additionally, loss of surface synovial cells was also present in 
groups 1 and 2. Similarly for these two groups, surrounding tissues lesion extension was 
presented as synovitis of variable intensity with neutrophil infiltration in the periarticular 
tissue, as well as disperse hemorrhages; however edema in group 2 was less intensive than in 
group 1. In contrast, in the case of group 3, only light edema and mild neutrophil infiltration 
in the periarticular tissue with no hemorrages were observed. Surrounding tissues from 
groups 1 and 2 reflected strong inflammatory reaction and neutrophil infiltration through the 
muscular tissue and periosteum. The articular cavity contained several neutrophil, 
erythrocytes and fibrin agglomerates for both group 1 and 2, while articular cavity of group 3 
presented a few neutrophil agglomerates with no fibrin deposition and heterogeneous 
synovial membrane changes with no evidence of inflammatory reaction. Similar histological 




The rat knee, injected with Gel + 30% blank NCs with no carrageenan, did not show 
microscopic articular cartilage neither synovial membrane changes. Besides, articular cavity 
was free of neutrophils and no signs of cell infiltration were detected in the surrounding 
tissues (Figure 7D), suggesting that the DDS is well-tolerated in vivo. 
In conclusion, the improvement on the histological level was gradually observed from 
group 1 to 3, suggesting that Gal-3i in its final DDS (Gel + 30% NCs) has the most detectable 
impact on the inhibition of synovial inflammation and the articular tissues integrity in rat 
synovitis model. 
Of note, the current study is a preliminary and unprecedented in vivo evaluation of a 
novel galectin-3 inhibitor effects in short RA rat model. More tests are required to understand 
Gal-3 inhibitor behavior and its impact on the inflammatory cascade of RA in rat joints. For 








Figure 7. Microphotographs from rat knee joints stained with haematoxylin and eosin; low 
(40×), medium (100×) and high (400x) magnification (columns 1, 2 and 3 respectively). The 
square areas in the images reveal the amplified regions of the photograph. Groups: control of 
carrageenan (row A), blank NCs + carrageenan (row B), Gal-3i NCs + carrageenan (row C), 
blank NCs + gel (row D) and Gal-3i NCs + gel + carrageenan (row E). Abbreviations: SM, 






As shown by a number of authors, HA-fibrin hydrogel is a perspective biocomposite 
with versatile functions, which alone or in combinations with other materials have also 
received major breakthrough at different biomedical applications,
43,115–119
 in particular in 
tissue engineering (TE).
120
 In the light of the above, Zhang et al. developed a HA-fibrin in 
situ hydrogel, prepared by orthogonal fibrinogenesis and disulfide crosslinking reaction 
between chemically modified HA-molecules and fibrinogen, designed for cell encapsulation. 
This hydrogel also included aprotinin (a synthetic inhibitor of fibrinolysis) aimed to prolong 
gel half-life and demonstrated complete degradation profile in vitro in the solution of 
nattokinase in 5 days, notably, 50% of degradation is observed between day 1 and 2, and 
complete degradation is between day 4 and 5.
118
 Another HA-fibrin hydrogel for TE was 
developed by Lee and Kurisawa, where HA was modified with tyramine to improve the gel 
mechanical properties and prevent degradation by enzymes. These highly crosslinked gels 
incubated with low dose of plasmin or hyaluronidase showed 100% matrix stability in vitro 
during 7 days, despite they were able to support less amount of proliferated cells in its 
matrixes, compared to the gels that lost 50% in diameter within 2 days.
43
 Park et al. designed 
fibroin-fibrin-HA hydrogel to create a mechanically strong and slowly degradable cell 
scaffold for cartilage regeneration. The authors showed maintenance of about 95% of initial 
gel volume in chondrocyte culture during 4 weeks.
119
 Ultimately, the same group has also 
developed fortified fibrin-HA composite gel with chondrocytes for implantation. In order to 
inhibit the degradation, gels were fortified with FXIII and aprotinin and tested in nude mice 
subcutaneously and, thus, demonstrated huge endurance in vivo up to 4 weeks.
121
 Clearly, 
reinforced by supplementary crosslinking agents and fibrinolysis inhibition factors HA-fibrin 
gel scaffolds demonstrate better performance in vivo. 
Given that articular cartilage has limited ability to self-healing,
122
 fortified HA-fibrin 
gel (designed and described in Chapter 1) may contribute to restore the integrity of cartilage 
in longer chronic rat inflammatory models, serving as a temporary matrix for in vivo cells 
encapsulation.
118
 In vivo gel half-life time in rat joint was not evaluated in this study, but 
might be interesting for further exploration of DDS performance. Such a composite might 
result to a synergistic effect in tissue self-healing properties – HA-fibrin matrix plays a major 











4. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Despite the growing interest for the galectin family, to date only few reports mention 
the use of small molecule inhibitors to interfere with galectin-mediated biological 
processes.
131–135
 Some of them made used of poor and unspecific inhibitors such as lactose, 
making necessary to apply high doses to observe significant effects.
136
 In this work, a novel 
highly affine and potent monovalent Gal-3 inhibitor, composed of two different moieties 
assembled to a modified lactosamine core was designed and synthesized. The hydrophobic 
form of Gal-3 inhibitor was included within hyaluronic acid NCs although the encapsulation 
efficiency makes necessary a further optimization. Then, NCs were loaded into in situ HA-
fibrin hydrogel designed for intra-articular administration. A pronounced anti-inflammatory 
activity was found in rat carrageenan-induced knee synovitis model for the inhibitor 
encapsulated in HA NCs included to the hydrogel. Treated rats showed improvement on the 
histological and white blood cells levels as well as in the knee swelling tests. The inhibition 
of galectin-3 is a promising strategy for the treatment of inflammatory knee diseases with 
particular interest for rheumatoid arthritis. These findings present Gal-3 inhibitor as a lead 
compound for anti-RA drug candidates. Efficiency of Gal-3 inhibitor could be further 
enhanced by preparation of multivalent inhibitors using synthetic scaffolds mimicking lactose 
units. Apart from joints pathologies, Gal-3 mono- or multivalent inhibitors could be applied 
for the treatment of other inflammatory conditions, e.g. cancer, bowel diseases, etc. 
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The advances in the biopharmaceutical field along the past decades have allowed the 
development of drug delivery systems (DDS) that can display long residence at the biological 
media with controlled and prolonged drug release directly to the targeted place.
1,2
 At the same 
time, the discovery of novel immunotherapeutic targets has triggered intensive efforts towards 
the development of highly specific small molecules-antagonists for effective therapies.
3–6
 
In this work, we have focused our efforts on the design, development and 
characterization of a controlled release DDS that can be easily injectable to the intra-articular 
(IA) cavity and display sufficient residence time for the treatment of joints pathologies 
(Figure 1). We described a new system that involves a combination of an in situ formed 
hydrogel with polymeric nanocapsules (NCs) dispersed on it. The injectable in situ hydrogel 
consists of interpenetrating network (IPN) hyaluronic acid (HA) crosslinked with fibrin. HA 
NCs serve as multireservoirs for lipophilic drugs. Hence, in situ hydrogel protects NCs from 
the fast degradation in synovial fluid (SF), cell internalization and its elimination from the IA 
cavity, allowing prolonged and controlled release of the drug. 
  
 
Figure 1. Schematic illustration of the structure of a synovial joint and intra-articular 
injection of in situ forming hydrogel combined with lipophilic drug-loaded nanocapsules. 
Adapted and modified from Burt et al.
7
 with permission, Copyright© 2009, Taylor & 
Francis. 
 
The developed hydrogel maintains good rheological properties and high resistance to 






distributed and the final gel behaves similar to blank hydrogel, demonstrating features of both 
elastic and solid-like behavior material, displaying the designed hydrogel suitable for IA 
application. This formulation is intended to extend the NCs retention in the IA cavity, to 
control the delivery of the associated drug and to act as a viscosupplement with 
viscoinductive properties, potentially improving the knee homeostasis. 
The physico-chemical characterization, encapsulation efficiency, and release profile 
of the IA DDS was firstly evaluated with a model lipophilic drug, dexamethasone (DXM). 
This anti-inflammatory and immunosuppressive corticosteroid drug is commonly used for 
systemic and local treatment of rheumatoid arthritis (RA).
1,8
 Later on, the same technology 
was applied to a new galectin-3 inhibitor (Gal-3i) that we designed and synthesized as a 
potential anti-inflammatory drug for autoimmune diseases, in particular for RA. 
Galectin-3 (Gal-3), a β-galactoside binding lectin, is an appealing protein to target due 
to its presence in most of the tissues and its participation in many pathologies.
9–16
 In this 
work, we focused on one of the most important extracellular functions of Gal-3, supporting 
the control of immune and inflammatory response by triggering the pro-inflammatory 
cascade. Noticeably, Gal-3 expression is up-regulated in synovial tissues in RA,17 its 
concentration in SF increases from about 50 up to 130-300 ng/mL,
15
 amplifying the 
inflammation
9–15
 and contributing to the joint degradation.
18,19 Inhibition of extracellular 
Gal-3 by highly affine ligands based on β-galactoside motifs has recently seen major 
breakthrough. Thus, aiming to develop a potent Gal-3i, aromatic substituents have been 
introduced at positions 3’-C of galactose and 2-C of glucosamine residues of type II 
lactosamine core [Gal(1→4)-GlcN], selected as starting material. Such modifications result 
in considerably enhanced affinity and selectivity due to the establishment of cation- 
interactions between the arene substituents of the inhibitor and guanidinium ions of two key 
arginine residues (Arg144 and Arg186), adjacent to the binding site of the Gal-3 
carbohydrate-recognition domain (CRD).  
Gal-3 inhibitor was further encapsulated in the developed NCs to be later included in 
the hydrogel. Anti-inflammatory properties of Gal-3i and performance of DDS were 
evaluated in vivo in a rat carrageenan-induced knee synovitis model. Finally, we discussed 
some prospects on the challenges to be addressed for the further success of the novel 
immunotherapeutic antagonist – Gal-3i and its DDS that may further be explored for multiple 







1. Development and characterization of IA DDS: in situ hydrogel containing drug-
loaded NCs 
Aiming at prolonging drug release in the joint cavity, reducing the cell internalization 
and rapid efflux from the synovial cavity,
1,7
 we decided to develop a DDS composed of NCs 
dispersed in an in situ hydrogel. Thus, primarily we designed, produced and characterized 
NCs to be later incorporated during the gel formation. Among the possible components for 
NCs preparation we selected: i) extra pure virgin olive oil (OO) due to its anti-inflammatory 
properties
20,21
 and because of its capacity to solubilize DXM;
22
 ii) soy lecithin (Lec) and 
oleylamine (OAm), as surfactants, in order to produce cationic nanoemulsions to which the 
HA molecules could be attached;
23,24
 iii) HA (700 kDa) as a shell polymer due to its anti-
inflammatory responses
25
 (Figure 2A). 
Two prototypes of drug-loaded HA NCs, differed by the amount of OO and 
surfactants, were successfully prepared using the simple solvent displacement technique, as 
previously described in our laboratory.
26
 We intended to develop NCs with a size close to 100 
nm that are not expected to cause cartilage or other mechanical damage in the joint
27
 and to 
load them with drugs prior to their incorporation into a hydrogel. We developed NCs with an 
average particle size of 122 ± 11 nm (Gal-3i NCs for extracellular Gal-3 targeting) and 135 ± 
9 nm (DXM NCs for multiple extracellular targeting). The particle size, zeta potential and 
encapsulation efficiency of the formulations are summarized in Table 1.  
The size of the NCs, obtained by DLS, was compared with TEM data. Resulting TEM 
images revealed the spherical shape, which is one of the key parameters for IA drug delivery 
at RA
28,29
 and regular morphology of these nanosystems with considerably smaller particle 
size values and homogeneity compared to DLS data (Figure 2B). These results can be 
explained considering that TEM requires detection of NCs in a dry state, whereas DLS 
analyzes NCs in aqueous suspension, measuring the hydrodynamic diameter.
30
 
NCs maintained their stability only in water and aggregated in PBS and simulated 
synovial fluid (SSF). Thus, we developed an injectable in situ hydrogel, formed in presence 
of the NCs to improve their stability, along with their retention in the articular cavity 







Table 1. Physicochemical characteristics of the blank and drug-loaded nanocapsules prepared 
with 700 kDa HA (mean ± SD; n = 6). PDI: polydispersity index. 





















 prototype 1 15 3.75 0.75 128 ± 13 0.2 −27 ± 3 n/a 













 prototype 1 15 3.75 0.75 160 ± 12 0.2 −20 ± 4 0.75 ± 0.125 























Figure 2. (A) Representation of the structure of drug-loaded hyaluronic acid nanocapsule; 
(B) TEM images of hyaluronic acid blank nanocapsule: at magnification 50,000×. 
 
At this step, among the variety of potential materials for gel preparation, we selected 
biopolymers HA and fibrin that allowed us to form an interpenetrating 3D network,
31–35
 using 
the affinity of high MW HA to fibrin.
36,37
 Later on, the gel was fortified with cross-linker 
factor XIII (FXIII) and with α2-antiplasmin (α2-AP), to gain advanced mechanical stability 
and prevent fast degradation by enzymes of pathological synovial fluid.
38–46
 
The hydrogel formation, that relies on the enzymatic activation of fibrinogen by 
thrombin (Thr), let us to stepwise design an IPN in the presence of HAs, fibrin-stabilizing 






adjusting different parameters, such as the temperature, the amount of thrombin, the MW and 
concentration of HA, the concentration of Ca
2+
 and FXIII. The targeted gelation lag-time was 
2 minutes, a time that was sufficient to provide an adequate syringeability of the hydrogel for 
in vivo experiments. 
We developed two DDS compositions of hydrogels to be tested in acute- and chronic-
RA rat models: “HA-fibrin gel” and “fortified HA-fibrin gel” (fortified with cross-linker 
FXIII and with α2-AP, both of them with a 30% NCs. The gel formation was monitored by 
turbidity analysis (at λ = 350 nm) and rheology studies that allowed us to detect the starting 
gelation point (Figure 3), by observing the gel evolution in time and the endpoint at which 




Figure 3. Summary of gelation time point determination by rheological measurements in 
different systems: HA-fibrin (HA-Fn) and fortified HA-Fn blank and 30% NCs loaded gels. 
For blank gels fibrinogen was always taken at 1 mg/mL concentration, activity of thrombin 
(Thr) = 1 NIH-U/mL. For 30% NCs loaded gels fibrinogen was always taken at 1.5 mg/mL 
concentration, activity of Thr = 2 NIH-U/mL. The dash-and-dot line reflects the 2 minutes 
lag-phase requirements. The measurements were carried out at 37 °C. Expressed as mean ± 
SD; n = 3. 
 
The viscosity values of the HA-fibrin mixture (without no thrombin addition) at 20 °C 
and 37 °C are 118.9 mPa·s and 81.3 mPa·s, respectively, much lower compared to the 
commercial viscosupplementation agents.
47,48
 Thereby the mixed solutions necessary to form 






The rheological behavior of both non-fortified and fortified HA-fibrin gels was tested 
in oscillatory strain and frequency sweeps tests and the results indicated that the gel has high 
elasticity and resistance against applied deformations. Interestingly, gels loaded with 30% of 
NCs showed higher moduli of deformations than blank gels and, thus, longer persistence, 
which could be explained by additional crosslinking of IPN by NCs, due to ionic interactions 
between shell polymer of NCs and fibrin network of the hydrogel. The behavior of the elastic 
modulus against the oscillatory frequency exhibited a plateau-type in the range of 0.1-3 Hz, 
which is indicative of stable cross-linked networks. Thus, fortified HA-fibrin gel + 30% of 
NCs, combines features of both elastic and solid-like behavior material and displays long 
persistence, making this DDS appropriate for intra-articular application.  
Topographic characterization of HA-fibrin and fortified HA-fibrin blank and loaded 
with 30% of NCs was performed by interferometric microscopy to evaluate the changes in the 
surface structure and the pores sizes caused by the NCs and fibrin-stabilizing components. All 
the gel samples presented quite homogenous and well-determined pores with a low value of 
pore size distribution, which is the evidence of a well-organized architecture. According to data 
in Table 2, fortified HA-fibrin gels (both blank and NCs loaded) appeared to be more 
crosslinked compared to non-fortified ones. Moreover, the average pore diameter of fortified 
HA-fibrin NCs loaded gels (4.88 μm) is only slightly larger than for blank fortified HA-fibrin 
gels (3.26 μm), meaning that FXIII provides sufficient crosslinking to maintain the 
microarchitecture of the NCs-loaded gels.  
Table 2. Mean pore size and depth of the different hydrogel compositions. 
 
Sample Mean pore diameter (μm) Depth (μm) 
HA-fibrin hydrogel 4.23 ± 0.89 1.07 ± 0.18 
HA-fibrin hydrogel + 30% NCs  7.29 ± 1.23 0.7 ± 0.17 
Fortified HA-fibrin hydrogel 3.26 ± 1.01 1.07 ± 0.41 
Fortified HA-fibrin hydrogel + 30% NCs  4.88 ± 1.12 0.98 ± 0.12 
 
These data correlate well with morphology studies of the gels injected by syringes to 
PBS buffer, and incubated at 37 °C during 20 hours, lyophilized and analyzed by scanning 
electron microscopy (SEM/FESEM) (Figure 4A-D). Analysis of the SEM images allowed us 
to visually evaluate the differences in non- and fortified HA-fibrin gels structure. Thus, 






network, as porosity data indicated. Gel fibrils revealed the proper fibrils thickness of 1-2 μm 
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Figure 4. SEM images of (A) the blank HA-fibrin and (B) blank fortified HA-fibrin 
hydrogels at magnification is 500×. FESEM images of (C) the blank HA-fibrin and (D) 
blank fortified HA-fibrin hydrogels at magnification is 10,000×. 
 
 
The distribution of Nile Red labeled NCs within the HA-fibrin hydrogel (30% 
loading) was observed by confocal electron microscopy on the deepness 50 μm and 490 μm 
at different magnification, as illustrated in Figure 5A and B. The images indicate that HA 
NCs are randomly dispersed in the hydrogel network and, possibly, interact with the 











     
  
Figure 5. Confocal microscopy images of Nile Red-labeled HA NCs dispersed in the HA-fibrin 
hydrogel (30% loading). Magnification is 320× (A), 1600× (B). 
 
Finally, the release studies of DXM were carried out under sink conditions for both, 
NCs and 30% NCs-loaded hydrogel, in simulated synovial fluid (SSF, RI = 1.334) at 37 °C. 
In the case of the free NCs, a burst of approximately 70% DXM release was observed in the 
first hour of incubation in SSF, reaching 100% after 24 hours (data not shown). In contrast, in 
the case of NCs loaded into the HA-fibrin hydrogel a slow release profile was observed in 
SSF (Figure 6), characterized by an initial ~30% DXM release, followed by a slow release 
up to ~50% within 24 hours. In the next phase (24-60 h), the drug was released very slowly 
till 60%, and finally 100% of DXM release was reached at the last time point (72 h) after the 
gel started to slowly decrease in volume (between 60-72 h). Overall, the results underline the 
importance of the hydrogel in controlling the release of the drug that was incorporated within 
the NCs. Hence, both, the NCs and the hydrogel have a role in terms of controlling the 
release of DMX. 
These in vitro release results are in line with other previously reported in the 
literature. For example, Ranch et al. described a fast release of DMX from Carbopol 940-
gellan gum gels, ranging from 5 to 25 hours depending on the composition,
51
 whereas Borden 
et al. reported a 72 h in vitro release profile.
52
 On the other hand, Webber et al. reported the 








 Similar results were shown by Wu et al. with 1 month in vitro release 
profile of DXM from micelles loaded into a PEG-PCL-PEG hydrogel.
54
 
   
 
Figure 6. Dexamethasone (DXM) release from the hyaluronic acid-fibrin hydrogel with 30% 
loaded nanocapsules to simulated synovial fluid, 37 °C, 72 h.  
 
It is expected that the release from the fortified HA-fibrin hydrogel might be more 
prolonged due to slower rate of degradation. In this case, FXIII and α2-AP enzyme should 
retard the gel decomposition
45
 at simulated and physiological environments. Even though the 
results of the in vitro release studies cannot be directly extrapolated to the in vivo conditions, 
the fact that a certain amount of DXM (> 35%) remains encapsulated in the NCs after 60 h 
would be highly advantageous for intra-articular drug delivery of small molecule drugs that 
are known to be eliminated from the joints within few hours after administration.
1
 
In summary, we developed an in situ hydrogel for IA delivery that contains HA NCs 
as multireservoirs for anti-inflammatory lipophilic drugs (e.g. DXM, Gal-3i). The 30% of 
NCs are dispersed within the HA-fibrin IPN. On the other hand, the gel is aimed to protect 
NCs from the rapid decomposition in SF, to reduce the elimination from the synovial cavity 
and the cell internalization, allowing at the same time a controlled drug release.  
 
2. A novel Gal-3i as the lead compound for immunotherapeutic drugs for RA treatment 
Taking into account the involvement into pathophysiology of RA, Gal-3 appears a 
novel potential immunotherapeutic target. Currently, only three Gal-3 antagonists among the 








However, none of them was designed or tested for RA treatment so far. The chemical 
structures of a natural poly-saccharide inhibitor (GM-CT-01), a small sugar-derived molecule 
inhibitor bis-3-[(3-fluorophenyl)triazolyl] thiodigalactoside (TD139, approved by FDA) and 





Figure 7. Structures of two commercial Gal-3 inhibitors: GM-CT-01 (DAVANAT
®
), TD139 
and developed oxazoline (compound 16) and Gal-3i (compound 26). 
 
Given that the Gal-3 CRD domain has a canonical structure as other galectin family 
members, all of them bind the same β-galactoside motifs with similar Kd values for these 
ligands.
62–64
 Thus, to design highly selective and affine Gal-3 inhibitor new binding contacts 
with two nonconserved Arg144 and Arg186 residues, adjacent to the binding site of Gal-3 
CRD,
65,66
 were established. For this purpose, type II lactosamine core [Gal(1→4)GlcN], due 
to its higher intrinsic affinity to Gal-3 over type I,
62,67
 was modified with different aromatic 
substituents at 3’-C position of Gal and 2-C position of the GlcN residues, respectively. Such 
modifications allowed to greatly improve the binding affinity of inhibitors to CRD of Gal-3 
helped by cation-π interactions establishment between guanidinium ions of Args and 
arenes.
10,66
 Three different synthetic approaches (A, B, and C), were evaluated to obtain Gal-3i 






deoxy-2-(3-methoxybenzamido)--D glucopyranoside), that was further transformed to a 















































































Scheme 1. A short scheme of derivatives preparation by 3 approaches: iodosulfonamidation 
(A), azidophenylselenation (B) and 1+1 glycosylation (a donor-acceptor coupling approach) 
(C). 
 
The affinity studies were held with the fluorescein-labeled Gal-3i 28 (shown in 
Chapter 2, Section 2.2), an oxazoline (compound 16), Gal-3i (compound 26) and TD139 
(Figure 7) (a positive control) by direct and competitive fluorescence polarization assay 
towards recombinant human Gal-1 C3S, Gal-3 and Gal-7, expressed in E.coli, at two 
different temperatures (Table 3). 
We found that all the tested compounds were selective to Gal-3, what is an evident 
observing lower Kd values compared to Gal-1 or Gal-7 ones. Considering that the fluorescein 
tag contributes to the binding to galectins,
64,69,70
 fluorescein-labelled Gal-3i displayed very 
high affinity to Gal-3 (Kd = 14 nM at 4 °C) and selectivity: or Kd(Gal-1)/Kd(Gal-3) = 1143 
and Kd(Gal-7)/Kd(Gal-3) = 1500 at 4 °C. In turn, its intact analogue Gal-3i has Kd = 590 nM 
at 4 °C and showed selectivity Kd(Gal-1)/Kd(Gal-3) = 46 and Kd(Gal-7)/Kd(Gal-3) = 152. The 
same tendency was observed for oxazoline 16 with Kd = 4.4 µM and selectivity: (Kd(Gal-
1)/Kd(Gal-3) = 25.5 and (Kd(Gal-7)/Kd(Gal-3) = 57 at 4 °C. As expected, compared to the 









aromatic ring of compound 16 greatly facilitate the complexation between the tested inhibitor 
and CRD of Gal-3.
10
 However, larger π-systems as (2-naphtyl)methyl of compound 26 are 
more polarizable and form stronger interactions with Arg144 that is capable to accommodate 
such substituents, resulting to the higher affinity and better selectivity between Gal-3/Gal-
1/Gal-7.
64
 Thus, an inhibitor 26 demonstrated 7.5 and 7.7 times higher affinity towards Gal-3 
than oxazoline 16 at 4 °C and room temperature, correspondingly, designing the derivative 26 
as a lead compound for evaluation of Gal-3 inhibition in vivo. 
 
Table 3. Dissociation constants of FITC-labeled compound 16, compound 26, compound 28 
and TD139 and galectin-1 C3S, galectin-3 and galectin-7. 
 
                             Kd (µM)
[a]  
Compound Galectin-1[b] Galectin-3 Galectin-7 Affinity 
Temperature 4 °C 
LacNAc-β-OMe [c] 65 ± 28 n.d. 550 ± 98 + 
16 112 ± 7 4.4 ± 0.25 249 ± 21 ++ 
26 27 ± 5 0.59 ± 0.11 90 ± 35 +++ 
28 16 ± 1 0.014 ± 0.005 21 ± 1 ++++ 
TD139 2.2 ± 1.4 0.036 ± 0.023 32 ± 17 ++++ 
TD139[e] 0.012 ± 0.003 0.014 ± 0.003 1.9 ± 0.38  ++++ 
RT 
LacNAc-β-OMe [c] n.d. 59 ± 12 n.d. + 
16  n.d. 23 ± 0.31 n.d. ++ 
26  n.d.
[d] 2.99 ± 0.17 n.d. +++ 
28  43 ± 4 0.082 ± 0.014 129 ± 18 ++++ 
TD139  n.d. 0.166 ± 0.091 n.d. ++++ 
TD139 [f] 0.22 ± 0.05 0.068 ± 0.01 38 ± 0.71 ++++ 
[a] Mean values from two assays; [b] Galectin-1: galectin-1 C3S (this study) or native 
galectin-1 (last two rows) [c] Determined by fluorescence polarization (from 
reference64); [d] n.d. = not determined; [e] Measured by fluorescence polarization at RT 
except for Gal-7 (from ref.68); [f] Determined by ITC at 24.8 °C (from ref.59).  
 
3. In vivo anti-inflammatory activity of Gal-3 inhibitor at carrageenan-induced acute 
knee joint synovitis 
The homology between human and rat Gal-3 CRDs is about 96.5%,
62
 which make the 






of the Gal-3i we synthesized we used an acute carrageenan-induced synovitis model. This is a 
short-term model usually used for drug screening and testing of cell therapies. Besides, these 




Before testing the activity of the Gal-3i, a syringeability test was done with one rat 
receiving 100 μL of HA-fibrin in situ gel with 30% blank NCs and without further 
inflammation induction. In order to see the influence of the DDS and the activity of the Gal-
3i, an in vivo experiment was done in rats with induced synovitis. Another animal was 
induced with carrageenan, acting as a disease control. Other rats were distributed between 
three groups according to the received treatment (100 µL, IA): blank NCs used as vehicle 
control (group 1), Gal-3i loaded NCs at dose 200 µg/kg (group 2) and HA-fibrin in situ gel 
with 30% Gal-3i loaded NCs at dose 55 µg/kg (group 3). The drug activity was monitored at 
4 hours after synovitis induction, when the peak of inflammation is reached.
72
 Knee swelling 
measurements, whole blood tests, and histopathological analysis data demonstrated 
pronounced anti-inflammatory activity of Gal-3i. Knee swelling data (Figure 8) exhibited 
reduction of knee diameter in: 1.6 times (group 1), 3.5 times (group 2) and 7 times (group 3) 
compared to carrageenan control. 
 
 
Figure 8. Effect of the treatment with Gal-3 inhibitor on the carrageenan-induced joint 
inflammation model using NCs, and NCs in a gel compared to blank NCs, a gel with blank 
NCs and carrageenan control (n = 5 for groups 1-3, n = 1 for carrageenan control). Δ is the 
difference in knee diameter at different time points before and after injection of carrageenan, 






This becomes more remarkable if we consider that the dose used for group 3 is 
considerably lower than for the group 2 (55 vs 200 µg/kg). Possibly, HA-fibrin hydrogel 
effectively keeps NCs within the articular cavity, modulates the release and by itself has a 
beneficial effect on joints healing even in the short inflammatory rat model. 
The inflammation process is accompanied by rapid inversion of the leukogram ratio: 
decrease of lymphocytes and increase of neutrophils,
72
 which in turn attract macrophages and 
dendritic cells expressed as total monocytes in Figure 9. Considering the obtained results, 
Gal-3i loaded NCs in the hydrogel is able to prevent this tendency, improving the total 






Figure 9. Effect of the treatment with Gal-3 inhibitor on leukocyte levels at the blood plasma 
at different doses administered in NCs, and the gel compared to blank NCs and carrageenan 








Supplementary, after a decalcification process the rat hind paws and knees were 
sliced, stained and analyzed by light microscopy (Figure 10 A-D). The improvement on the 
histological level was gradually observed from carrageenan control to group 3, suggesting 
that Gal-3i in its final DDS (Gel + 30% NCs) has the most detectable impact on the inhibition 
of synovial inflammation and the articular tissues integrity in rat synovitis model. Group 3 
has less synovial membrane changes than other groups, besides, the articular cavity was free 
of neutrophils and no signs of cell infiltration were detected in the surrounding tissues. 
 
               A                                                                 B 
 
            C                                                                 D 
  
 
Figure 10. Microphotographs from rat knee joints stained with haematoxylin and eosin; low 
(40×), medium (100×) and high (400x) magnification (columns 1, 2 and 3 respectively). The 
square areas in the images reveal the amplified regions of the photograph. Groups: control of 
carrageenan (row A), blank NCs + carrageenan (row B), Gal-3i NCs + carrageenan (row C), and 
Gal-3i NCs + gel + carrageenan (row D) (row E). Abbreviations: SM, synovial membranes; JC, 
joint cavity. 
 
Given that articular cartilage has limited ability to self-healing,
76
 fortified HA-fibrin 














models, serving as a temporary matrix for in vivo cells encapsulation.
35
 In vivo gel half-life 
time in rat joint was not evaluated in this study, but might be interesting for further 
exploration of DDS performance. Such a composite might result to a synergistic effect in 




In summary, this work highlights the development of a new nanotechnology-based 
platform for an efficient treatment of joint pathologies (e.g. rheumatoid arthritis). An intra-
articular injectable in situ hydrogel consisting of an IPN of HA and fibrin crosslinked with 
FXIII and α2-AP, containing drug loaded NCs (30%). The system presents well-organized 
structure and rheological behavior typical for stable gel networks, with features of both 
elastic and solid-like materials desired for IA application. HA NCs, dispersed in the gel, serve 
as multireservoirs for lipophilic anti-inflammatory drugs and they control and prolong the 
release of the encapsulated drug. The physicochemical evaluation of the drug delivery system 
was performed for DXM, as a model drug, and later on applied to a synthetized highly affine 
and specific Gal-3i.  
The results obtained in a preliminary in vivo acute knee synovitis rat model showed a 
remarkable suppression of inflammation by Gal-3 inhibitor encapsulated within hydrogel and 
administrated intra-articular at microgram scale doses. Treated rats showed improvement on 
the knee swelling, at the histological and at the white cells levels. These findings present a 
promising strategy for the treatment of inflammatory knee diseases by the inhibition of 
galectin-3 and Gal-3 inhibitor as a lead compound for immunotherapeutic drug candidate in 
particular for RA. Efficiency of Gal-3 inhibitor could be further enhanced by preparation of 
multivalent inhibitors using synthetic scaffolds mimicking lactose units. Apart from joints 
pathologies, Gal-3 mono- or multivalent inhibitors could be applied for the treatment of other 
inflammatory conditions, e.g. cancer, inflammatory bowel disease, etc. increasing the range 
of therapeutic possibilities for these new compounds. At the same time, we showed the 
potential of a new in situ hydrogel as an IA DDS. The developed hydrogel might also have 
self-healing properties, behaving as a viscosupplement and could work as an in situ cell 
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This thesis project comprised the design, development and characterization of a novel 
injectable nanotechnology-based system intended to prolong and control the release of the 
associated drug in the intra-articular (IA) cavity. The system is composed of an in situ 
forming hydrogel loaded with polymeric nanocapsules, which serve as multireservoirs for 
different lipophilic anti-inflammatory drugs, namely i) a model drug – dexamethasone; and 
ii) a novel synthesized drug candidate – galectin-3 (Gal-3) antagonist. The obtained 
experimental results led to following conclusions: 
 
1) A novel highly affine, potent and selective monovalent Gal-3 inhibitor, composed of 
two different moieties assembled to a modified lactosamine core was developed and 
synthetized in this study. Its Kd to Gal-3, measured by direct and competitive 
fluorescence polarization assay, was 0.59 µM at 4 °C (2.99 µM at 25 °C), while 
fluorescein-labelled Gal-3 inhibitor displayed very high affinity to Gal-3, Kd = 14 nM 
at 4 °C (82 nM at 25 °C), certainly higher than a reported commercial Gal-3 inhibitor 
DAVANAT® has. An important feature of this compound is the ability to 
discriminate between Gal-1/Gal-3/Gal-7, while DAVANAT® could hardly 
discriminate between Gal-1 and Gal-3. On the other hand, a first low MW Gal-3 
antagonist TD139, approved by FDA, with modified thio-digalactoside core, 
measured in the same assay, has been experimentally confirmed to have high affinity 
Kd(Gal-3) = 0.036 µM at 4 °C (0.166 µM at 25 °C) and high selectivity among Gal-
1/Gal-3/Gal-7. Considering the success of TD139, the low MW Gal-3 inhibitor that 
we developed might receive future pharmaceutical advancement. 
 
2) Polymeric NCs consisting of an olive oil core and a HA coating were successfully 
prepared using a simple solvent displacement method. The NCs can be loaded with 
dexamethasone (5.6 ± 0.4 mg/mL) or Gal-3 inhibitor (531 ± 5 µg/mL), have 
nanometric size (135 ± 9 nm and 122 ± 11 nm, correspondingly), negative surface 
charge and regular spherical shape. 
 
3) Two injectable in situ forming hydrogel systems were developed. One of them is 
composed of HA and fibrin interpenetrating network, and the other one contains HA 






order to have an increased half-life time. The hydrogels showed an easily adjustable 
gelation time, a well-defined microstructure and adequate mechanical properties. In 
addition, the gels could load 30% (v/v) of NCs during their self-assembly. The initial 
viscosity of the gelling system was significantly lower compared to commercial 
viscosupplementations agents, thus allowing its good syringeability. The rheological 
studies revealed the resistance of the hydrogels to high deformations, and showed 
both, elastic and solid-like behavior, adequate for IA sustainability. Regarding its 
structure, the formulation has well-defined pores with NCs randomly dispersed within 
the gel. This IA drug delivery system (DDS) exhibited a controlled and prolonged in 
vitro drug release profile. 
 
4) Preliminary in vivo studies performed in carrageenan-induced acute knee joint 
synovitis rat model demonstrated a remarkable suppression of inflammation by Gal-3 
inhibitor. Both, the group with drug-loaded NCs and the group with drug-loaded NCs 
in the gel, administrated IA at microgram scale doses (55 and 200 μg/kg), performed 
significantly better compared with the non-treated control. These findings presented 
Gal-3 inhibitor as a lead compound for immunotherapeutic drug candidate for 
inflammatory knee diseases, in particular for rheumatoid arthritis. Noticeably, blank 
NCs also showed a tendency to contribute to joints healing by reducing the synovial 
inflammation. 
 
Overall, the work presented here describes the development and characterization of a 
new biodegradable in situ forming hydrogel adapted for IA administration. The hydrogel 
serves as a depot for drug-loaded NCs, preventing their fast elimination from the joint cavity 
and allowing prolonged drug release profile. The rheological properties of the initial system 
enabled good syringeability and desirable mechanical properties for intra-articular 
application. Preliminary in vivo activity of galectin-3 inhibitor confirmed galectin-3 as a 
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